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SUMMARY 
Type 1 Gaucher's disease (GD), an autossornal recessive disorder, is the most 
common lysosomal storage disease in the Portuguese. The primary metabolic defect 
consists in the deficient activity of glucocerebrosidase, which leads to the accumulation 
of the glycosphingolipid glucosylceramide in lysosomes of macrophages. The 
occurrence of these cells (Gaucher cells) in tissues and organs underlies the most 
common signs of pancytopenia, organomegaly and skeletal deterioration but a striking 
variability in clinical expression and course of type 1 GD can be observed. The 
delineation of the mutations in the glucocerebrosidase locus and the emergence of 
enzyme supplementation therapy required more complete understanding of the 
determinants of genotype/phenotype relationships and the modulation of 
glucocerebrosidase activity. Of the more than 100 disease associated alleles, the 
N370S has significant frequency in various ethnic and demographic groups, being the 
most common causal mutation in the Ashkenazi Jews and in the Portuguese. 
In this thesis, the frequency of the N370S mutated allele in the Portuguese population 
was determined by DNA analysis of 2000 individuals. On the basis of the obtained 
gene frequency (0.0043), an incidence of 1/55000 homozygotes was calculated to 
existe in the Portuguese population and a significant number of these patients were 
predicted to remain undiagnosed, most probably due to a milder clinical presentation. 
To address the question of the origin of this mutation in the Portuguese, the association 
to an intragenic polymorphic marker was investigated. The occurrence of the N370S 
allele on a unique haplotype argued against locus heterogeneity between the 
Ashkenazi Jews and the Portuguese. In order to study Portuguese affected families in 
which a significant number of mutations remain unidentified, an assay for carrier 
detection was developed, based in the measurement of glucocerebrosidase activity per 
amount of cross reacting material. 
The study of glucocerebrosidase activity in peripheral blood total leucocytes of 
genotyped GD patients showed that patients carrying at least one N370S allele 
presented higher residual activity and that glucocerebrosidase was predominantly 
extracted in a complex form containing saposin C and phosphatidylserine. Moreover, 
although plasma glucosylceramide concentration was found to be significantly 
correlated with score of patients clinical seventy, the clinically milder N370S 
homozygotes presented also significantly less abnormal plasma chitotriosidase activity 
(a putative marker of the lipid loaded macrophage activation) and tartrate resistant acid 
phosphatase (TRAP) activity (which probably reflects osteoclastic activity). Importantly, 
XIII 
although this indicates that genotype is implicated in the outcome of a clinical 
phenotype, the study of the peripheral blood T lymphocyte major subsets showed an 
association between clinical signs of bone pathology and statistically significant 
decrease of the CD8+ T lymphocyte subset. This finding suggests thus possible 
regulatory interaction of T lymphocytes in the pathophysiology of GD. 
The results obtained in the study of GD patients receiving enzyme suplementation 
therapy allow to conclude that the lipid-loaded macrophages were indeed involved in 
the release of glucosylceramide, chitotriosidase, p-hexosaminidase and TRAP activity 
and that their plasma levels may constitute quantitative markers for the correction 
and/or prevention of ongoing formation of the glucosylceramide storage cells. 
The advances obtained in the study of the proposed goals may provide useful disease 
markers and contribute to obtain more insights into the complicated pathophysiology of 
the disease in order to finally facilitate appropriate interventive therapy to prevent the 
morbid long-term manifestations of GD. 
xiv 
RESUME 
La maladie de Gaucher du type 1 présente une transmission autossomique et 
récessive et est le plus fréquent défaut de l'accumulation lysosomal chez les 
Portuguais. Le défaut métabolique primaire consiste dans le déficit de l'activitée de la 
glucocérébrosidase, résultant en une accumulation intralysosomal du 
glycosphingolipide glucosylcéramide dans les macrophages. La présence de ces 
cellules (les cellules de Gaucher) dans les tissues et organes est à l'origine des plus 
fréquents syntomes de la pancytopénie, de la viscéromégalie et de la détérioration 
osseuse mais une grande variétée de l'expression clinique et de l'évolution de la MD 
du type 1 peut être observée. L'identification des mutations dans le locus de la 
glucocérébrosidase et l'aparition de la thérapie de suplémentation enzymatique 
requèrent une plus profonde compréhension de la relation entre les déterminants du 
génotype/phénotype et des méchanismes impliqués dans la régulation de l'activitée de 
la glucocérébrosidase. Des plus de 100 alleles mutés associés à la maladie, le N370S 
a une fréquence significative dans de nombreux groupes ètniques et démographiques, 
étant la pluis frequente mutation dans le Juifs Ashkenazi et le portuguaise. 
Dans cette thèse la fréquence de l'allèle muté N370S chez la population portuguaise a 
été déterminée à partir de l'analyse de l'ADN de 2000 nouveaux nés. Ayant comme 
base la fréquence du gene obtenue (0.0043), une incidence de 1/55000 homozygotes 
a été calculée dans le portuguaise et on prévoit um nombre significatif de ces malades 
sans être diagnostiqués, probablement dû à une présentation clinique pluis légère. Afin 
d' étudier l'origine de cette mutation ches le portuguaise, l'association à um marqueur 
polymorphique intragénique à été étudiée.. La présence de l'allèle N370S sur un 
unique haplotype contrarie l'hypothèse de l'hétérogénéité des locus entre les Juifs 
Ashkenazi et les Portuguais. Afin d'étudier les familles portuguaise affectées dans 
lesquelles un nombre significatif de mutations est encore non identifié, un essai, pour 
détecter les portateurs, a été dévelopé à partir de la détermination de l'activité 
enzimatique de la glucocérébrosidase par unitée de matériel immuno reconnu. 
L'étude de l'activitée de la glucocérébrosidase dans les leucocytes totaux du sang 
périphérique des malades génotypes a révélée que les malades portant au moins un 
allele N370S aprésentent une activitée résiduelle plus grande et aussi que la 
glucocérébrosidase est extraie prédominantement sous une forme complexe contenant 
la saposin C et la phosphatidylsérine. De plus, même si cela la concentration 
plasmique de la glucosylcéramide a été significativement corrélationée avec le degré 
de sévérité clinique chez les malades de Gaucher, les homozygotes N370S, 
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cliniquement moins sévères, aprésentent aussi une activitée plasmique de la 
chitotriosidase (un marqueur putatif de l'activation du macrophage par l'accumulation 
lipidic) et une activitée de la phosphatase acide résistante au tartrate (TRAP) 
(probablement traduisant l'activitée ostéoclastique) moins anormaux. Même si cela 
semble indiquer que le génotype est associé à un phénotype clinique, l'étude du 
subgroupe majoritaire des lymphocytes T dans le sang périphérique a permis une 
association entre des signes cliniques de pathologie osseuse et des défauts 
statistiquement significatifs dans le subgroupe des lymphocytes T CD8+. Ces résultats 
sugèrent ainsi une interaction régulatoire possible des lymphocytes T dans la 
pathophysiologie de la MG. 
Les résultats obtenus dans l'étude des malades de la MG suivant une thérapie de 
suplémentation enzymatique ont permis conclure que les macrophages chargés par 
des lipides sont en fait impliqués dans la libération de glucosylcéramide, 
chitotriosidase, p-hexosaminidase et l'activitée de la TRAP et que leur niveaux de 
plasma peuvent constituir des marqueurs quantitatifs pour la correction et/ou 
prévention de la formation des cellules d' accumulation. 
Les progrès obtenus dans l'étude des objectifs propos peuvent fournir des marqueurs 
utils pour cet maladie et contibuent dans l'obtention de plus d'informations sur la 
compliquée pathophysiologie de la maladie afin de finalment faciliter une thérapie 
d'intervention adéquade. 
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RESUMO 
O tipo 1 da doença de Gaucher é uma doença hereditária de transmissão autossómica 
recessiva e constitui a patologia de sobrecarga lisosomal mais frequente na população 
portuguesa. O defeito metabólico primário consiste na deficiente actividade enzimática 
da glucocerebrosidase com a resultante acumulação de glicolipido glucosilceramida 
nos macrófagos. Da ocorrência destas células (designadas células Gaucher) nos 
tecidos e órgãos, resultam os sinais clínicos de pancitopenia, organomegalia e 
envolvimento ósseo; esta patologia é no entanto caracterizada por uma grande 
variabilidade de apresentação e evolução clínica. A identificação de mutações do locus 
da glucocerebrosidase bem como o aparecimento da terapia de suplementação 
enzimática requer um melhor conhecimento dos determinantes da relação 
genótipo/fenótipo bem como da modulação da actividade da glucocerebrosidase. De 
mais de 100 alelos associados á doença, a mutação N370S apresenta uma frequência 
significativa nos vários grupos étnicos e demográficos, e constitui a mutação causal 
mais comum em Judeus Ashkenazi e nos portugueses. 
Neste trabalho, a determinação da frequência do alelo mutado N370S na população 
portuguesa foi determinada pela análise do DNA de 2000 indivíduos. Com base na 
frequência genética obtida (0.0043) foi calculada uma incidência de 1/55000 
homozigotos na população portuguesa. Este valor permitiu prever a existência de um 
elevado número de doentes não diagnosticados provavelmente devido a uma 
apresentação clinica menos severa. No sentido de estudar a origem da mutação 
N370S nos portugueses efectuou-se a análise da associação genética entre esta 
mutação e um polimorfismo intragénico. O ocorrência do alelo N370S no contexto de 
um único haplótipo argumenta contra a hipótese de heterogeneidade do locus entre os 
doentes portugueses e os de ascendência judaica Ashkenazi. O desenvolvimento de 
um ensaio baseado na determinação da actividade da glucocerebrosidase por 
quantidade de proteína imuno-reconhecida permitiu estudar as famílias afectadas nas 
quais um elevado número de alelos mutados permanece por identificar. 
O estudo da actividade da glucocerebrosidase nos leucócitos do sangue periférico 
mostrou que os doentes portadores de pelo menos um alelo mutado N370S 
apresentavam actividade residual superior á dos restantes e que a glucocerebrosidase 
era predominantemente extraída na forma complexa contendo saposina C e 
fosfatidilserina. Apesar de se verificar a existência de correlação significativa entre o 
nível plasmático da glucosilceramida e o grau de severidade clínica, os homozigóticos 
N370S, geralmente afectados com menor severidade, foram também caracterizados 
pela apresentação de uma actividade de quitotriosidase (um putativo marcador da 
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activação do macrófago com acumulação de glucosilceramida) e da fosfatase acida 
resistente ao tartarato, TRAP, (a qual provavelmente reflecte a actividade 
osteoclástica) significativamente menos anormal que os restantes doentes. No 
entanto, embora estes resultados sejam indicadores da implicação de um genótipo 
para um determinado fenótipo, o estudo das subpopulações linfocitárias maioritárias 
do sangue periférico mostrou a existência de uma associação entre a ocorrência de 
sinais clínicos de patologia óssea e uma diminuição estatisticamente significativa da 
subpopulação linfócitária CD8+. Este achado sugere a possibilidade de uma interacção 
reguladora dos linfócitos T na patofísiologia da doença de Gaucher. 
Os resultados obtidos no estudo de doentes de Gaucher submetidos a terapia de 
suplementação enzimática permitiram concluir que células Gaucher estão de facto 
envolvidas na libertação da glucosylceramida, das enzimas quitotriosidase, TRAP e (3-
hexosaminidase, podendo o nível plasmático destas constituir marcadores 
quantitativos da correcção e/ou prevenção da acumulação destas células. 
O avanço obtido no estudo dos objectivos propostos poderão providenciar marcadores 
úteis bem como contribuir para o melhor conhecimento da complexa patofísiologia da 
doença de forma a finalmente facilitar uma intervenção terapêutica adequada á 
prevenção das manifestações a longo prazo lesivas da doença de Gaucher. 
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Chapter 1 
General introduction to Gaucher Disease 
Lysosomes contain a variety of acid hydrolasess responsible for the degradation of 
proteins, lipids and carbohydrates that are internalized via endocytosis. A large number 
of genetically determined defects in lysosomal hydrolases are known, manifested either 
by the absence of a particular hydrolase or by defects in its activity, resulting in 
accumulation of undegraded substracts, a progressive increase in size and number of 
lysosomes, and onset of a lysosomal storage disease with its typical clinical 
manifestations (reviewed in Neufeld, 1991). At the present time more than 30 different 
lysosomal storage disorders have been reported, nearly all of which are inherited in an 
autossomal recessive manner. The incidence at birth of lysosomal disorders varies 
from 1 in 100,000 to 1 in 250,000. The total group of lysosomal storage disorders has 
an incidence of approximately 1:5,000 to 1:10,000 (Galjaard and Reuser, 1984; Reuser 
etal, 1994). 
1.1 Biochemical defect 
The most prevalent lysosomal storage disease, Gaucher disease (Barranger and 
Ginns, 1989; Grabowski et al, 1990; Beutler and Grabowski, 1997), is an autosomal 
recessive disorder of glycosphingolipid metabolism, characterized by accumulation of 
glucocerebroside in reticuloendothelial cells (Aghion, 1934) due to the deficient activity 
of glucocerebrosidase (D-glucosyl-N-acylsphingosine glucohydrolase, E.C.3.2.1.45) 
(Brady et al, 1965; Patrick, 1965). This enzyme cleaves the p-glucosidic linkage of 
glucosylceramide to produce ceramide and glucose (Brady et al, 1966), the latter being 
degraded by lysosomal acid ceramidase to sphingosine and fatty acid (Figure 1-1). The 
fatty acid chain length varies, the most abundant component being stearic acid (C<is) ir< 
brain, and C20to ^24 ^att^ ac 'ds in spleen, liver and blood cells (Mansson et al, 1978). 
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Figure 1-1 
Lysosomal degradation of sphingolipids. Enzimes are 1, sphingomyelinase; 2, glucocerebrosidase; 3 
galactocerebrosidase. 
1.2 Phenotypic presentation and classification by 
characteristic symptoms 
In his medical school thesis in 1882, Philippe C. E. Gaucher described a female patient 
with an enlarged spleen that he believed was an epithelioma. Descriptions of additional 
patients with similar presentations began to appear, and the eponym Gaucher disease 
was ascribed (Gaucher, 1882). 
The clinical manifestations of Gaucher disease are heterogeneous. On the basis of the 
occurrence and age of onset of neurological symptoms three different phenotypic 
variants of GD are generally distinguished: 
-Type 1 (McKusick 230800), is the non-neuronopathic form of GD (the individuals are 
free of primary neurologic involvement; any neurologic symptoms observed in these 
GALACTOCEREBROSII 
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patients are secondary to systemic complications of the illness), and the age of onset 
of clinical symptoms and the severity can differ to a large extent. Symptomatic patients 
exhibit variable splenomegaly (4 to 70 times normal), with accompanying 
haematological abnormalities like anaemia, thrombocytopenia, and ocasionally, 
leukopenia. The spleen is known for it specialised vascular structure: it contains 
lymphocytes and macrophages that serve unique filtering, scavenging and immune 
functions. The enlarged spleen in GD causes cytopenias by haemodilution, 
sequestration and premature destruction of the blood elements in phagocytes that line 
its expanded sinusoids and cords. Increased haematopoiesis may initially compensate 
but continuing enlargement of the spleen and local effects of Gaucher cells in the bone 
marrow ultimately lead to the syndrome of hypersplenism. Severe abdominal pain due 
to infarcts, mechanical interference with adjoining organs, growth retardation (in 
children), or cachexia (in adults) occur; in severely afflicted patients, even high cardiac 
output failure may occur. Easy bruising, epistaxis, and bleeding from gums are 
common. Low haemoglobin levels lead to dyspnea, tachypnea, and fatigue. 
Hepatomegaly (1.5 to 10 times normal) is another common manifestation. Hepatic 
function may be impaired, resulting in elongation of prothrombin time and partial 
thromboplastin time. Skeletal involvement is frequent in patients and can cover the 
spectrum from osteopenia to severe destruction of bone. Erlenmeyer flask-like 
deformities of the distal femur are characteristic of the disorder but occur in about 30% 
of patients. Aseptic necrosis of femoral head is the most common destructive bony 
lesion (reviewed in Beutlerand Grabowski, 1995). 
Besides the very heterogeneous presentation and variable progression of type 1 GD, a 
number of patients have been described with moderately enlarged spleens who were 
otherwise asymptomatic (Brady, 1978), or even symptom-free individuals were 
identified who presented both mutated alleles of the glucocerebrosidase gene and a 
markedly deficient enzymatic activity (Zimran et al, 1991; Sibille et al, 1993; Beutler 
and Grabowski, 1995). Although type 1 is classically devoid of neurological 
symptomatology, association to Parkinsonian symptoms have been reported in adult 
Gaucher patients (Baumann et al, 1995). 
-Type 2 (McKusick 230900), the acute neuronophatic form of GD, is a rare panethnic 
disease presenting a very homogeneous clinical phenotype characterized by 
hepatosplenomegaly, anemia and trombocytopenia noticeable at 3 months of age, and 
universally present by 6 months with severe neurological dysfunction: trismus, 
strabismus, and retroflexion of the head. Seizures may occur, and the infant becomes 
hypotonic and apathetic pre-terminally. Extensive brain-stem involvement leads to 
progressive bulbar palsies with concomitant aspiration pneumonia and feeding 
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difficulties. These problems are compounded by extensive pulmonary infiltrative 
disease. Death usually occurs by about 9 months, but some of these patients live for 2 
years and the examination of the brain show gliosis and cell death (reviewed in Beutler 
and Grabowski, 1995). 
A subset of type 2 Gaucher patients clearly have a different and more severe 
phenotype, namely signs and symptoms presented prenatally or at birth and death 
frequently ensued within hours to days or at the most 2-3 months. Although skin 
involvement in GD had previously been considered uncommon and usually limited to 
pigmentary changes (Goldblatt and Beighton, 1984), this subgroup of type 2 Gaucher 
patients displays ichthyosis (a collodion baby phenotype) (Lui et al, 1988; Lipson et al, 
1991; Sidransky et al, 1992a). 
-Type 3 (McKusick 231000), the sub-acute juvenile neuronopathic form of GD is 
distinguishable of type 2 by a late onset, a heterogeneous presentation and a slowly 
progressive development of neurological symptoms by adolescence, in addition to the 
symptoms found in type 1 of the disease. Death usually occurs in childhood or early 
adolescence from hepatic or pulmonary complications (reviewed in Beutler.and 
Grabowski, 1995) 
Three distinct subtypes of type 3 disease are now recognized: Type 3a describes 
progressive neurological involvement beginning in adolescence but mild systemic 
manifestations; type 3b describes severe systemic disease but mild neurological 
involvement (Brady et al, 1993); type 3c describes corneal clouding, left-sided cardiac 
valvular calcification, and oculomotor apraxia but only mild visceral and skeletal 
manifestations (Abrahamov et al, 1995). 
1.3 Ocurrence and ethnic prevalence 
Like many autosomal recessive disorders, GD shows a prominent ethnic predilection: 
to Ashkenazi Jews in type 1 and to Norbottnian Swedes in type 3. 
Type 1 GD is the most common form, the occurrency is panethnic with an estimated 
incidence of about 1 in 40,000-200,000 births, and is considered to be prevalent among 
the Ashkenazi Jews in which the incidence is 1 in 625-1,500 (Galjaard and Reuser, 
1984; Reuser et al, 1994; Grabowski, 1995), and the carrier frequency is of 1 in 10-20 
(reviewed in Beutler and Grabowski, 1995). 
Type 2 GD, panethnic in incidence, is the least common form of GD with an incidence 
striking fewer than one in 100,000 individuals (Erikson, 1994). 
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Type 3 GD is also relatively rare, affecting less than one in 50,000-100,000 individuals. 
It is panethnic, although there is a cluster of the disease in Norrbotten, the northern 
province of Sweden, and common ancestors have been traced back to the 17th 
century (Erikson, 1994; and also reviewed in Beutler and Grabowski, 1995). 
1.4 Reticuloendothelial cells lipid accumulation 
In lysosomal disorders the substances to be degraded are enclosed within the 
lysosomes and usually there seems to be no feedback regulation or influence of the 
substrate concentration on other biochemical pathways. When the residual activity of 
the degrading enzyme falls below the critical threshold level, substrate influx exceeds 
the degradation rate and the excess substrate accumulates continuously. Since 
undegraded substrates cannot (or only very slowly) leave the lysosomal compartment, 
these organelles are converted into storage granules which steadily increase in size 
and number. When they reach a large volume they interfere with the cell's normal 
function, giving rise to a storage disease (Conzelmann and Sandhoff, 1983/84). 
Although every cell in Gaucher patients is deficient in glucocerebrosidase the 
acumulation of glucocerebroside is most pronounced in macrophages of the 
mononuclear phagocyte system (Parkin and Brunning, 1982). These cells arise from 
the bone marrow, and they are components of the reticuloendothelial system: (alveolar) 
macrophages, histiocytes, Kupffer cells and osteoclasts. By this way, numerous 
enlarged, lipid-laden histiocytes called Gaucher cells are present in the organs of 
patients with Gaucher disease (Gaucher, 1882). Macrophages are not only increased 
in size but also in number. These abnormal macrophages accumulate widely, resulting 
in hepatosplenomegaly, skeletal disease, bone marrow failure, hypermetabolic state 
and pulmonary infiltration. The glucocerebroside that accumulates in these cells arises 
from phagocytosis and degradation of blood group glycosphingolipids, globosides and 
lactosylceramide from respectively senescent erythrocytes and leukocytes (Kattlove et 
ai, 1969), since the main fatty acid of the glucocerebroside that accumulates is 
docosanoic acid (C-22) which is the major fatty acid in the glycolipids of blood cells 
(Mansson et al, 1978). Liver hepatocytes are not involved in the turnover of blood cells 
and appear to avoid accumulation of glucocerebroside by excreting it into the bile 
(Tokoro et al, 1987). However, it can not be excluded that uptake of lipoproteins, the 
carrier of plasma glucocerebroside, by macrophages contributes to the high level of 
storage material in these cells. 
In neurons of patients with type 2 GD the glucosylceramide accumulated probably 
arises from the catabolism of endogenous gangliosides (acidic sphingolipids). 
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Gangliosides undergo rapid turnover via synthesis and catabolism during brain 
development and the formation of neural circuits. This is supported by the finding that 
in the ceramide composition of the accumulated glucosylceramide isolated from 
cerebral and cerebellar cortex, stearic acid (C-18) is the predominant fatty acid, 
(comprising 60-75%), and sphingenine constitutes 66-85% of the long-chain bases, 
which is similar to the ceramide composition that has been found only in brain 
gangliosides (Mansson et al, 1978). In type 3 patients the fatty acid composition of the 
cerebral glucosylceramide shows large differences. Glucosylceramide from cerebellar 
cortex is partially of extracerebral origin, being the proportion of stearic acid invariably 
less than 45%; there is a correlation between a large increase of glucosylceramide and 
a low proportion of stearic acid and high proportions of C-16, C-22 and C-24 fatty acids 
(Nilsson and Svennerholm, 1982). 
Patients with type 1 GD seem to have sufficient residual glucocerebrosidase activity to 
degrade glucocerebroside arising from ganglioside turnover in the brain during 
development. However, the much larger load of glucocerebroside originating from 
leukocytophagy and erythrocytophagy cannot be completely catabolized and 
progressively accumulates in the peripheral organs (reviewed in Brady et al, 1993). 
The age of onset, progression, and severity of the disease should, to a large extent, 
depend on the rate at which the substrate accumulates. A total deficiency of an 
enzyme completely blocks the catabolism of its substrate, which therefore accumulates 
rapidly, giving rise to a severe disease with early onset and rapid progression. In 
contrast, even a low residual activity of the affected enzyme may still be sufficient to 
degrade a large proportion of the incoming substrate and will thus retard the storage 
process considerably, leading to a mild form of the disease with late onset and slow 
progression. Thus the symptomatology of the disorder should mainly depend on the 
influx rates of the substrate in the different organs and cell types. A moderate residual 
activity may still be sufficient to cope with a comparatively slow influx of the respective 
substrate in one organ or cell type, whereas in another organ or cell type, where the 
same substrate is synthesised or acquired at a higher rate, the same residual activity 
may prove to be insufficient (Conzelmann and Sandhoff, 1983/84). 
However, in GD there is no simple relationship between the disease manifestations 
and the extent of Gaucher cell infiltration or tissue glycolipid content. Thus, the 
macrophage response on glucosylceramide loading seems to be a critical factor in 
tissue damage but the mechanisms are unknown. 
Gaucher cells or Gaucher-like cells can also be present in other disorders, including all 
leukemias - most often chronic granulocytic leukemia (Kattlove et al, 1969) - Hodgkin's 
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disease (Lee et al, 1982), thalassemias (Zaino et al, 1971), congenital 
dyserythropoietic anemias (van Dorp et al, 1973), malignancy (e.g. multiple myeloma) 
(Scullin et al, 1979; Papadimitriou et al, 1988), infectious diseases and aquired immune 
deficiency syndrome (AIDS) (Solis et al, 1986; Esplin, 1992). The presence of Gaucher 
cells in patients with chronic myelocytic leukemia is due to the production of 
sphingolipid from granulocytes, which is greatly increased since the total body 
granulocyte pool and the granulocyte turnover rate are markedly increased (Kattlove et 
al, 1969). 
1.5 Ultrastructure of epiderme and permeability barrier 
homeostasis 
The permeability barrier of mammalian epidermis is mediated by a system of highly 
organized lamellar bilayers localized to the intercellular spaces of the stratum corneum 
(SC)-protein enriched corneocytes embedded in a lipid-enriched intercellular matrix 
(reviewed in Elias and Menon, 1991). These bilayer structures are enriched in relatively 
hidrophobic species, i.e., ceramides, cholesterol, and free fatty acids, and depleted in 
the phospholipids associated with bilayer formation in other cellular membranes (Gray 
and Yardley, 1975; Elias et al, 1979; Lampe et al, 1983). These hydrophobic species 
derive, in part, from a mixture of precursors, including phospholipids and 
glucosylceramide, contained in the epidermal lamellar body (Menon et al, 1986; Elias 
et al, 1988), a distinctive secretory organelle that delivers these lipids, along with co-
packaged hydrolytic enzymes (Freinkel and Traczyk, 1985; Grayson et al, 1985), to the 
intercellular spaces at the base of the stratum corneum. After secretion, lamellar body 
contents undergo a series of morphologic transformations leading to the formation of 
intercellular lamellar unit structures characteristic of the stratum corneum of terrestrial 
mammals (Elias and Menon, 1991; Landmann, 1988). These structural alterations are 
accompanied by depletion of glucosylceramides and phospholipids, with an increase in 
ceramides and free fatty acids within the stratum corneum interstices (Gray and 
Yardley, 1975; Elias et al, 1979; Lampe et al, 1983; Nemanic et al, 1983). Epidermal 
processing of glucosylceramide to ceramide by glucocerebrosidase is required for 
barrier homeostasis, and this enzymatic step is regulated by barrier requirements 
(Holleran et al, 1991; Holleran et al, 1994b). Glucocerebrosidase activity accounts for 
over 80% of epidermal p-glucosidase activity, and increases in the outer layers 
(stratum corneum and stratum granulosum) of murine epidermis (Holleran et al, 1992). 
An absence of epidermal glucocerebrosidase activity in knockout mice 
(glucocerebrosidase-deficient transgenic mice, discussed below) leads to abnormal 
barrier function in association with accumulation of glucosylceramides and depletion of 
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ceramides in the stratum corneum. Moreover the failure of conversion of 
glucosylceramide to ceramide results in partially processed "immature" lamellar body-
derived sheets extending throughout the lower and mid to outer SC interstices. This 
altered membrane structures in the SC interstices of transgenic mice display abnormal 
functional integrity, while the epidermal lamellar bodies and their secreted contents at 
the stratum granulosum/stratum corneum interface appeared normal (Holleran et al, 
1994a). The presence of ichthyosiform skin changes in both transgenic mice and some 
neonatal type 2 GD patients suggests that blockade of glucosylceramide hydrolysis, 
with failure to form normal lamellar bilayer unit structures, not only compromises the 
integrity of the epidermal permeability barrier, but also provokes an alteration of normal 
desquamation (Lui et al, 1988; Sidransky et al, 1992a). 
The altered lamellar bilayer structures may result from either steric constraints imposed 
by the additional bulk of the glucose residue and/or the increased hydrogen-bonding 
capacities provided by the hydrophilic hexose residue (Curatolo, 1987; Pascher et al, 
1992). Thus, although increased glucose moieties could result in a loss of barrier 
integrity because of an alteration of lamellar bilayer structures and increased perfusion 
of water, a concomitant increase in the cohesiveness of comeocytes, due to increased 
hydrogen bonding, could lead to the abnormal stratum corneum retention, i.e., the 
excess scale seen in Gaucher mice and in neonatal type 2 patients. A correct molar 
ratio of ceramides, cholesterol, and free fatty acids is important, but the persistence of 
glucosylceramide, rather than diminished ceramide is more likely to be the main cause 
of the membrane abnormalities, based on experimental data with topical application of 
ceramide (Holleran et al, 1994a). 
The lack of skin manifestations in most patients with GD may relate to differences in 
residual enzyme activity, since ichthyotic skin involvement in type 2 Gaucher patients is 
associated with severe disease and very low residual enzyme levels in the 
extracutaneous tissues of these patients (Sidransky et al, 1992a). 
1.6 Involved genes: active glucocerebrosidase gene, 
pseudogene and prosaposin gene 
1.6.1 Glucocerebrosidase gene and pseudogene 
The human glucocerebrosidase gene is located on region q21 of chromosome 1 
(Bameveld et al, 1983a; Ginns et al, 1985; Sorge et al, 1985b). Fifteen other genes 
have been localized to the same band (Collins et al, 1992). The gene comprises 11 
exons and 10 introns, contained within 7604 base pairs. The promoter region is located 
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approximately 150 base pairs upstream to exon 1 (Reiner et ai, 1988; Horowitz et al, 
1989). Two functional ATG initiator codons have been identified (Sorge et al, 1987). 
The downstream ATG was translated more efficiently resulting in a 19-amino acid 
signal polypeptide which contains a hydrophobic core (Reiner et al, 1987). A 95% 
homologous pseudogene is located in the same locus at least 50-100 kb downstream 
from the functional glucocerebrosidase gene (Horowitz et al, 1989; Sorge et al, 1990). 
The pseudogene, contained within 5769 base pairs, shows missense mutations, 
deletions in some introns and various base substitutions throughout the gene (Horowitz 
et al, 1989; Reiner et al, 1988). It is assumed that the glucocerebrosidase pseudogene 
is non-functional in the production of enzyme due to the absence of a long open 
reading frame (Sorge et al, 1990). Since the murine genome (O'Neill et al, 1989) does 
not contain the pseudogene the duplication process must have occurred relatively 
recently in evolution (Horowitz et al, 1989; Sorge et al, 1990). 
The novel metaxin gene is localised within the locus, immediately dowstream to the 
pseudogene in proximity to and transcribed convergently to the glucocerebrosidase 
gene (see Figure 1-3). Mutations and/or rearrangements altering metaxin expression 
may potentially have clinical significance (Bornstein et al, 1995). 
1.6.2 Mutations in glucocerebrosidase gene 
Cloning of the human glucocerebrosidase gene led to the identification more than 100 
mutations, including point mutations (missense mutations), an insertional mutation 
(frame shift mutation), two deletions, a splicing mutations and three combinations of 
multiple mutations (crossovers or gene conversions) (reviewed in Beutler and Gelbart, 
1997) (Figure 1-2). 
Only a limited number of these mutations occur frequently. The four most common 
mutations are those involving amino acid substitutions at position 370 (N370S), 
position 444 (L444P), as well as the 84GG frame shift insertion and the IVS2+1 splice 
junction mutation. These four account for at least 88% of the mutations in Ashkenazic 
Jewish and at least 70% of European populations (Beutler, 1993; Mistry and Cox, 
1993; Horowitz and Zimran, 1994a; Grabowski, 1995). 
The most prevalent mutation underlying GD is the A->G transition at nucleotide 5841 in 
exon 9 of the glucocerebrosidase gene, that leads to the production of an enzyme with 
a substitution of asparagine to serine at position 370 (N370S) (Tsuji et al, 1988). This 
allele was not found in neurophatic forms of the disease as well as in Asian (Japonese) 
patients and represented 70-75% of the mutated alleles in Ashkenazi Jewish type 1 
Gaucher patients (Beutler et al, 1992b; Horowitz et al, 1993) and 38-50% in non-
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Ashkenazi Jewish patients (Levy et al, 1991; Choy et al, 1991; Sidransky et al, 1992b; 
Walley et al, 1993; Tuteja et al, 1993). In the Ashkenazim population the N370S 
mutated allele frequency was found to be 0.032 (Zimran et al, 1991; Beutler et al, 
1993). 
HHHKH 1 2 3 4 
A Exonic missense mutations 
O Splice junction mutation 
■ ■ Complex alleles 
<▲. Deletions 
Point deletion 
Point insertion 
Point termination 
Figure 1-2 
Distribution of the mutations that predispose to the Ghacher's disease phenotypes. There are about 
108 with a clustrering towards the 3' half of the gene. (Adopted from Grabowski and Horowitz, 1997) 
Another relatively frequent mutation, which can be found among the three clinical 
phenotypes is a T->C transition at nucleotide 6433 in exon 10, leading to an enzyme 
with a leucine to proline substitution at amino acid 444 (L444P) (Tsuji et al, 1987). This 
mutation might have been introduced (more than once), either by a point mutation or by 
recombination with the pseudogene (Zimran et al, 1990). It is the most prevalent 
mutation in patients with the neuronopathic form of GD, where it accounts for about 
50% of the mutated alleles; this mutation is also found in 30% of alleles in type 1 non-
Jewish GD patients (only 4% among Ashkenazi Jewish), mostly in a heteroallelic state 
(Horowitz et al, 1993). 
The 84GG mutation is an insertion of an extra G at nucleotide 84 (starting from the first 
ATG) of the cDNA (Beutler et al, 1991). This is the second most common mutation 
among Ashkenazi Jewish patients (13%), where it has been described thus far almost 
exclusively. The frequency of the 84GG allele among Ashkenazi Jews was found to be 
0.00217 (Beutler et al, 1993). In the heteroallelic state this mutation is usually 
associated with type 1 Gaucher disease with severe clinical manifestations (Horowitz 
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and Zimran, 1994a). Patients homozygous for this "null" mutation have not been found. 
Homozygosity for 84GG may therefore be lethal in utero or shortly after birth. 
The splice junction mutation due to a G to A transition of the first nucleotide of the 
second intron destroys the 5'donor splice site (He et al, 1992). This splice junction 
mutation (IVS2+1) accounts for 1-3% of the mutated alleles among Jewish and non-
Jewish Gaucher patients (Horowitz et al, 1993). The mutation is also found in patients 
with both non-neuronopathic and neuropathic GD. Most patients with type 1 GD and 
the genotype N370S/IVS2+1 develop moderate to severe GD (Horowitz et al, 1993; 
Horowitz and Zimran, 1994a). 
Another relatively frequent mutation (3.5%) appears in all types of GD but only among 
non-Jewish patients is a C->T transition at nucleotide 6489 in exon 10, leading to an 
enzyme with an arginine to cystine substitution at amino acid 463 (R463C) (Hong et al, 
1990). This mutation is associated with mild to severe clinical manifestations. 
In addition to these, the two complex alleles, or "rec" for recombinant, have been 
referred to as the "pseudogene-like" sequences, in mutated alleles that probably 
represent rearrangements between the homologous sequences by crossovers or ill-
defined rearrangements. 
Two related complex alleles with several mutations were reported. The recNcil is 
composed of three point mutations, namely the 6433 T->C transition (L444P), 6468 G 
->C transversion (A456P) and 6482 G->C transversion (not associated with any amino 
acid change). This recombinante allele (it contains exon 10 of the pseudogene) is 
present in 0.5% and 8% in respectively Jewish and non-Jewish GD patients alleles and 
is associated with a severe, often neuronopathic phenotype (reviewed in Horowitz and 
Zimran, 1994a). The recTL complex allele (Zimran and Horowitz, 1994b) is composed 
of the three point mutations as in recNcil but with a fourth mutation, 5957 G-»C 
transversion (D409H); at least part of exon 9, intron 9 and exon 10 derived from the 
pseudogene. This recombinant allele has been paradoxically associated with mild 
clinical manifestation and is shows a similar prevalence (about 2%) in both Jewish and 
non Jewish mutated alleles. 
1.6.3 Polymorphisms in giucocerebrosidase gene 
Several neutral (benign) polymorphisms (population allele frequency >1%) in human 
giucocerebrosidase gene that do not appear to be related to GD have been described 
(Beutler et al, 1992a). A restriction fragment length polymorphism for the enzyme Pvull, 
due to a G->A substitution at genomic DNA nucleotide 3931 in intron 6 of the 
giucocerebrosidase gene, is responsible for the presence (Pv1.1+) or absence (Pv1.1-) 
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of a 1.1 kb genomic glucocerebrosidase DNA fragment upon Pvull digestion (Sorge et 
al, 1985a; Zimran et al, 1990). This is the most studied polymorphism in 
glucocerebrosidase gene and since it is in virtually complete linkage disequilibrium with 
the 11 other polymorphic sites on the glucocerebrosidase gene (Beutler et al, 1992a), it 
serves as a surrogate site for all of the other polymorphic sites. 
It was shown that the N370S glucocerebrosidase mutation is invariably associated with 
the Pv1.1- haplotype (Zimran et al, 1990; Beutler et ai, 1991). In contrast, mutation 
L444P was found to be in linkage equilibrium with this Pvull polymorphism (Zimran et 
al, 1990; Beutler et al, 1991). The incidence of this Pvull polymorphism was reported 
as being similar in various racial groups and was proposed to be ancient (Sorge et al, 
1985a). 
1.6.4 Prosaposin gene 
The acid exohydrolases that degrade sphingolipids in the lysosomes work in concert 
with small nonenzymic glycoproteins, called "sphingolipid activator proteins" (SAP's) 
for effective interaction with the substrates (reviewed in Sandhoff et al, 1995). 
Glucocerebrosidase has an activator, designated saposin C. This is a heat-stable small 
molecular weight protein (80 amino acids) that binds to the enzyme and enhances the 
in vivo hydrolysis of glucocerebroside (Ho and O'Brien, 1971). This protein is encoded 
by the prosaposin gene which is located on chromosome 10; this gene directs 
synthesis of a 70 kDa protein, prosaposin, and the posttranslationally protelytic and 
glycosidic processing generates saposin A, B, C and D (reviewed in O'Brien and 
Kishimoto, 1991). Saposin A, B and D stimulate the hydrolysis of gluco and 
galactocerebroside, sulfatides and ceramides respectively (reviewed in Sandhoff et al, 
1995). Prosaposin protein, the precursor of the lysosomal saposin proteins, have 
additional functions as a neurotrophic factor (O'Brien et al, 1994). 
Defects in proteins that influence the activity of a lysosomal enzyme as a result of 
abnormalities of activator proteins (Furst and Sandhoff, 1992) may also result in a 
lysosomal storage disease, and a severe form of GD has been reported (Kleinschmidt 
et al, 1987) as the result of mutations in saposin C and prosaposin gene 
(Christomanou et al, 1989; Harzer et al, 1989; Schnabel et al, 1991). 
1.7 Genotype/phenotype correlation 
Some of the phenotypic heterogeneity of Gaucher disease can be ascribed to the 
heterogeneity in defects in the glucocerebrosidase gene. The homozygosity for N370S 
seems to preclude neuronopathic involvement, and with one exception of a child with 
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oculomotor involvement, there seems to be a relation between the presence of at least 
one allele with the N370S mutation and a non-neuronopathic course of the disease or 
type 1 form (Beutler, 1993). In addition homozygosity for the N370S mutation confers 
the mildest form of the disease and it has been estimated that up to two-thirds of such 
individuals never develop clinical symptoms (Beutler, 1993). However a pair of 
monozygotic twins, homozygous for the N370S mutation, and presenting the same 
markedly deficient residual p-glucosidase activity, were reported to show highly 
divergent phenotypes (Mistry et ai, 1995). The twins were shown to be genetically 
identical by DNA microsatellite fingerprinting. Immunoglobulin gene rearrangement 
studies revealed no differences in B cell clonality. This emphasises that determinants 
other than those in the germline DNA influence the clinical expression of GD (Mistry et 
al, 1995). 
It was also reported that most of the splenectomized patients and those who suffered 
from avascular necrosis of a large joint (as a manifestation of severe skeletal 
involvement) present the "severe" genotypes N370S/84GG or N370S/IVS2+1, 
suggesting that both complications are associated with these genotypes (Zimran, 
1995a). Another genotype/phenotype correlation was described: although cardiac 
manifestations are rare in GD, a sample of Spanish and Arab GD patients of 2-20 
years of age, homozygous for the rare point mutation D409H (1342C), presented 
besides systemic symptoms of GD and signs of oculomotor apraxia, a progressive 
thickening and calcification of the aortic, or mitral apparatus, or both, resulting in 
valvular stenosis or insufficiency before adulthood (Chabas et al, 1995; Abrahamov et 
al, 1995). The D409H mutation is the third most common mutation among Spanish 
Gaucher patients. Arab patients come from an inbred population of Jenin and it is likely 
that the mutation arose on a single ancestral chromosome. The possibility of a 
contiguous gene syndrome causing this particularly clinical picture or the alteration by 
this mutation of the transcript of a convergently transcribed gene was however not 
excluded (Mistry, 1995). 
Yet, other data point to the lack of existence of genotype/phenotype correlation; for 
instance, homozygosity for L444P mutation is associated with either the acute 
neuronopathic (type 2), the subacute neuronopathic (type 3) forms, as well as with no 
development of neurological symptoms at all in Japanese patients (Tsuji et al, 1987; 
Dahl et al, 1990; Masuno et al, 1990). Despite the L444P homozygosity reported for all 
Norbotten type 3 patients, it was also found a wide inter-individual variability in disease 
severity and progression (Dahl et al, 1990). Since this mutation has also been found in 
patients from other origins often affected with a more severe phenotype (type 2), never 
seen in Norrbotten patients, in them this mutation must be linked to another genetic 
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change which causes a milder phenotype. In addition, even within other particular 
genotype group, a wide variability in severity of disease has been described, even 
within sibships and between identical twins (Amaral et al, 1994; Mistry and Cox, 1995). 
In order to study this presence/absence of genotype-phenotype correlation, the 
phenotypic diversity within the genotype, the pathogenesis of the disease and also for 
evaluating therapeutic approaches, an animal model for Gaucher disease was 
generated. This was done by creating a null allele in embryonic stem cells through 
gene targeting and using these genetically modified cells to establish a mouse strain 
carrying this mutation. Mice homozygous for this mutation were found to have <4% of 
normal glucocerebrosidase activity, died within twenty-four hours of birth and stored 
glucocerebroside in lysosomes of cells of the reticuloendothelial system (Tybulewicz et 
al, 1991; Tybulewicz et al, 1992). This transgenic model allowed the recognition of a 
distinct GD phenotype, a neonatal form (Sidransky et al, 1992a), which consists of a 
progressing fatal disease, and associated ichthyotic skin (Lui et al, 1988) and/or 
hydrops fetalis. This specific clinical manifestations have helped in recognising and 
beginning to emphasise a distinct human phenotype of Gaucher disease (Sidransky et 
al, 1992a). 
Other work point to an eventual additional inter-regulation among glucocerebrosidase 
and closely linked genes. In an attempt to establish a mouse model for the described 
mild form of GD (N370S mutated protein), a targeted mutation (A-^G in exon 9) was 
introduced into glucocerebrosidase gene by homologous recombination in embryonic 
stem cells; for this, a phosphoglycerate kinase-neomycin gene cassete was also 
inserted into the 3'-flanking region of glucocerebrosidase gene as a selectable marker, 
disrupting the coding region in the terminal exon of metaxin (Bomstein et al, 1995) and 
presumably interfering with the processing and/or stability of the transcript, since 
metaxin mRNA levels became reduced by 50% in mice hétérozygotes. Mice 
homologous for the combined mutations (in the glucocerebrosidase and metaxin gene) 
die early during gestation (Bomstein et al, 1995). Since the analogous amino acid 
substitution in human glucocerebrosidase gene is generally associated with a mild form 
of GD (Horowitz and Zimran, 1994b) and since mice that lack glucocerebrosidase gene 
do not die until after birth (Tybulewicz et al, 1992), Bomstein and coworkers (1995) 
suggest that metaxin protein may be required for embryonic development. Metaxin 
protein was found to be expressed ubiquitously in tissues of the young adult mouse 
(Bomstein et al, 1995) and preliminary data suggest that metaxin is a component of the 
outer mitochondrial membrane and may function in mitochondrial import (Armstrong et 
al, 1995). The metaxin murine gene, spans the 6-kb interval separating the 
glucocerebrosidase gene from the thrombospondin 3 gene in chromosome 3E3-F1, 
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and was found to be transcribed convergently with glucocerebrosidase gene. 
Thrombospondin 3 protein is a member of a family of five homologous, secreted, 
modular glycoproteins, and in the mouse is present primarily in lung, brain and 
cartilage but its function is essentially unknown. The organisation of the 
metaxin/thrombospondin 3/glucocerebrosidase genes in the mouse is conserved on 
human, with the added complexity that the DNA duplication has led to the creation of a 
direct repeat containing pseudogenes for glucocerebrosidase and metaxin. In the 
human genome, metaxin is interposed between thrombospondin 3 and the 
glucocerebrosidase pseudogene (Figure 1-3). The metaxin and the thrombospondin 3 
gene share a common promoter region and are transcribed divergently. On the other 
hand, metaxin and the glucocerebrosidase pseudogene are transcribed convergently 
and contain very closely apposed polyadenylation sites. The metaxin pseudogene was 
characterised and it was reported that it is not transcribed or is transcribed at only a 
very low level (Long et al, 1996). If coordinate regulation of expression of either two or 
all three genes can be shown, such regulation may reflect metabolic interrelationships 
among glucocerebrosidase, metaxin and thrombospondin 3 genes. 
KSS8-^^-E5>Bg^^a-^5>-
GBA METP GBAP MET THBS3 MUC1 
Figure 1-3 
Diagram of genomic region near the glucocerebrosidade (EBA) locus on chromosome 1. MET, 
THBS3 and MUC1 are the metaxin, thrombospondim 3 and muc 1 oncogene loci, respectively. The METP 
and GBAP are the MET and GBA pseudogenes. The arrows indicate the direction of transcription of 
various genes. The MET and THBS3 genomic loci overlap in the promoter region. The region from GBA to 
THBS3 is about 40 kb in length (Adopted from Grabowski and Horowitz, 1997). 
All human disease may be said to result from an interaction of an individual's genetic 
makeup and the environment (Wachbroit, 1994). Other factos such as genetic 
background or non-genetic factors may also influence the clinical heterogeneity 
observed in patients for a given genotype. 
1.8 The p-Glucosidases 
1.8.1 Isoenzymes and molecular forms 
Five p-Glucosidases isoenzymes have been described in humans: 
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a) Lysosomal giucocerebrosidase (EC 3.2.1.45), the enzyme deficient in Gaucher 
disease, is a membrane-associated glycoprotein present in all cell types. This enzyme 
hydrolyses not only the natural substrate, glucosylceramide, but also artificial (3-
glucosidic substrates and is irreversibly inhibited by conduritol B-epoxide (CBE). The 
optimum pH of the enzyme is dependent on the assay conditions, varying from 4.0 to 
5.5. Glucosylsphingosine is also a substrate for giucocerebrosidase (Vaccaro et al, 
1985; Sarmientos et al, 1986). 
b) The lactase-phlorizin hydrolase (EC 3.2.1.62-108) is an integral membrane 
glycoprotein that catalyses the hydrolysis of p-galactosidic and p-glucosidic substractes 
(Leese and Semenza, 1973; Mantei et al, 1988) and is exclusively present in the 
microvilli of intestinal epithelial cells (Leese and Semenza, 1973). This enzyme is 
active towards glucosylceramide and is irreversibly inhibited by CBE (Mantei et al, 
1988). 
c) The soluble broad-specificity p-glucosidase (EC 3.2.1.21) is not a glycoprotein and is 
most probably located in the cytosol. This enzyme is active towards |3-glucosidic, p-
galactosidic, p-fucosidic, p-xylosidic and p-arabinosidic derivatives of 4-
methylumbelliferone and p-nitrophenol, but not towards glucosylceramide. The 
isoenzyme is not inhibited by CBE and its pH optimum is near neutral. This enzyme is 
present in various tissues, in particular in liver, spleen and kidney, but absent in 
fibroblasts (reviewed in Glew et al, 1988). 
d) A tightly membrane-bound p-glucosidase has been described and referred to as 
membrane-bound non-specific p-glucosidase (Turner et al, 1977). This isoenzyme is 
also not able to hydrolase glucosylceramide, has a pH optimum of 5.4, is very strongly 
and competitively inhibited by D-gluconolactone and is markedly inhibited by 
detergente (Maret et al, 1981; Salvayre et al, 1982). 
e) Finally, a non lysosomal giucocerebrosidase that is not deficient in patients with GD 
but is also active towards glucosylceramide, was recently described in human skin 
fibroblasts, Epstein Barr-virus transformed lymphocytes, a erythroblastoid and 
hepatoma cell lines. This hitherto giucocerebrosidase is located in compartments with a 
considerably lower density than lysosome and differs in several respects from the 
lysosomal giucocerebrosidase. The non-lysosomal isoenzyme proved to be tightly 
membrane-bound, whereas lysosomal giucocerebrosidase is weakly membrane-
associated. The optimum pH of the non-lysosomal isoenzyme (5.5) is less acidic than 
that of lysosomal giucocerebrosidase. The non-lysosomal giucocerebrosidase, in 
contrast to the lysosomal isoenzyme, was not inhibited by low concentrations of 
conduritol B-epoxide, was markedly inhibited by taurocholate, and was not stimulated 
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by the lysosomal activator protein saposin C. This second non-lysosomal 
glucocerebrosidase seems to be able to catabolize some of the endocytosed 
glucosylceramide. The physiological function of this enzyme is yet unknown. However 
it presents the same properties as the membrane-bound non-specific p-glucosidase, 
when measured in the presence of detergent (van Weely et al, 1993a). 
1.8.2 Glucocerebrosidase synthesis, modi f icat ion, t ransport and 
stabil i ty 
The glucocerebrosidase polypeptide (497 amino acids) (Dinur et al, 1986) is only 
proteolytically processed for the removal of the leader sequence and presents three 
disulphide bridges (Martin et al, 1989). The protein has five potential N-glycosylation 
sites (Tsuji et al, 1986; Martin et al, 1989), but studies of normal and mutated cDNA's 
in Sf9 and COS-1 cells showed that one of these sites (Asn-462) is not glycosilated 
(Takasaki et al, 1984). In addition, it was demonstrated that glycosilation of the first 
asparagine residue (Asn-19) is critical for the synthesis of a catalytically active enzyme 
(Berg-Fussman et al, 1993) (Figure 1-4). 
The purification of glucocerebrosidase and the preparation of monospecific antibodies 
against the enzyme enable to discriminate the different molecular forms of the enzyme 
(Ginns et al, 1982; Barneveld et al, 1983b). The enzyme is synthesized in the rough 
endoplasmic reticulum and the signal peptide is cotranslationally cleaved by signal 
peptidase. The asparagine residues are core glycosilated (Erickson et al, 1985). In the 
Golgi apparatus the oligosaccharide chains of glucocerebrosidase are predominantly 
processed to complex-type structures with terminal sialic acid residues, resulting in an 
increase of apparent molecular weight of the 62 kDa precursor form to species of 
approximately 65-68 kDa (van Weely et al, 1990). Glucocerebrosidase membrane 
association probably occurs between exit from the endoplasmic reticulum and arrival in 
the trans-Golgi network (Rijnboutt et al, 1991). These forms are transported to 
lysosomes by a mechanism independent of the mannose-6-phosphate specific 
receptor pathway (Aerts et al, 1988), probably a transport pathway leading directely 
from the trans-Golgi network to the lysosomes (Willemsen et al, 1991). There, 
glucocerebrosidase undergoes further modification of its oligossaccharide chains by 
the action of exoglicosidases, resulting in mature 59 kDa molecular weight species 
(Aerts et al, 1986a; van Weely et al, 1990). According to these study the extent of 
modification does not significantly influence membrane association, half-life or catalytic 
efficiency of glucocerebrosidase. The enzyme does not contain a sufficiently long 
stretch of hidrophobic amino acids to allow membrane spanning (Sorge et al, 1986; 
Beutler and Grabowski, 1995). In particular in the carboxy-terminal part of the enzyme 
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a number of short hydrophobic stretches are present; this may underly the tendency of 
the enzyme to associate with membranes (Furbish et al, 1977; Murray et al, 1985; 
Willemsen et al, 1987). Glucocerebrosidase spends a major part of its life time in 
prelysosomal structures, and has a relatively short life span in lysosomes as compared 
to other acid hydrolases (Aerts, 1988); thus the physiological role of 
glucocerebrosidase may not be restricted to intralysosomal glucosylceramide 
degradation (Aerts, 1995). 
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Figure 1-4 
A function map of the glococerebrosidade protein. The alternating dark and light regions represent 
exons that are numbered below. The dark and light hexagons are the occupied and unccupied N-
glycosylation concensus sequences. Glycosylation of the first site is essential for proper folding of the 
enzime during translation. The Cs are the cysteines with free C129 in bold. All other cysteines participate 
in disulphide bond formation. The hatched and solid arrows bellow represent regions important to enzyme 
stability and catalytic activity, respectively. The tree-dimensional structure of the acid (3-glucosidase has 
not been solved (Adopted from Grabowski and Horowitz, 1997). 
1.9 Diagnosis and residual activity/phenotype correlation 
The diagnosis of the disease can be made by determining p-glucosidase activity in 
leucocytes (Peters et al, 1976; Raghavan et al, 1980; Wenger et al, 1978), platelets 
(Nakagawa et al, 1982), skin fibroblasts cultures (Beutler et al 1971; Ho et al, 1972; 
Mueller and Rosenberg, 1977) or ammonium sulfate-concentrated urine (Aerts et al, 
1986b). The amount of p-glucosidase activity in control leukocytes measured with the 
fluorogenic substrate 4-methylumbelliferyl-p-D-glucopyranoside (if sodium taurocholate 
is added) is very comparable to the p-glucosidase activity measured with the natural 
substrate and all GD patients present 8-18% of control p-glucosidase activity using 
both substrates. Concentrations of pure sodium taurocholate above about 6 mg/ml will 
give the optimum amount of hydrolysis of the substrate. Replacement of the large 
amount of taurocholate with a mixture of 2.5 mg/ml taurocholate and 2 mg/ml Triton X-
100 resulted in equally high values (Wenger et al, 1978). 
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Clinical variability is generally believed to be due to differences in the residual activity 
of the affected enzyme. In GD as well as in other lysosomal storage diseases 
(Conzelmann and Sandhoff, 1983/84), residual enzyme activity, even in very mild 
variants or apparently healthy individuals, can be as low as 1-4% of normal activity 
(Beutler, 1977a). In addition, since it is associated with recessively transmitted 
disorders, hétérozygotes, which usually possess half normal enzyme levels, are 
clinically normal. The great variability in possible residual activities arising from the type 
of molecular defect in a single gene locus (e.g., point mutation, base pair insertion or 
deletion, posttranslational modification) is amplified by the occurrence of heteroailelic 
compounds, i.e., individuals carrying different mutations in the two alleles of the same 
gene. Furthermore, the consequences of a reduced enzyme activity for the turnover 
rate of the substrate in vivo are different from that suggested with in vitro experiments, 
where a linear relationship can be observed between the amount or activity of the 
enzyme and the turnover rate of its substrate. Substrate concentrations in vivo are 
usually far below saturation of the enzyme and may also vary to a great extent. A 
reduction of the amount of enzyme may therefore within wide limits be compensated 
for by an ensuing increase in substrate concentration, restoring normal turnover rate. In 
addition, other factors need to be considered in establishing a correlation between the 
residual activity of a mutated enyme and the severity of the disease, like removal of the 
accumulating substrate by other processes (e.g., alternative metabolic pathways or 
excretion), interaction of enzyme or substrate with other cofactors, and feedback 
regulation mechanisms (Conzelmann and Sandhoff, 1983/84). 
All of the mutated forms of glucocerebrosidase result in a large, but comparable, 
decrease in glucocerebrosidase activity when measured in vitro using a variety of 
synthetic substrates (Dinur et al, 1984; Osiecki-Newman et al, 1987). For instance, no 
correlation is observed in vitro between the V m a x towards 4-methylumbelliferyl p-D-
glucopiranoside of glucocerebrosidase produced from different GD mutated alleles 
(Horowitz and Zimran, 1994a). Other authors reported a correlation between levels of 
residual lysosomal glucocerebrosidase activity, measured in situ in fibroblast cells, and 
the type of Gaucher disease, by making use of lissamine rhodamine 
sulphonylamidosphingosyl derivatives. Long incubations revealed differences in the 
ratio of fluorescent ceramide to fluorescent glucosylceramide between type 1 and type 
2 or 3 Gaucher fibroblasts (Agmon et al, 1993); similar differences were reported in 
another study by using a radioactive short-acyl-chain analogue of glucosylceramide, N-
(1-[14C]hexanoyl)-D-erythro-glucosylsphingosine (Meivar-Levy et al, 1994). Moreover, 
these authors claimed that cells with similar mutations had similar specific activities in 
situ. Although in these studies a consistent correlation between enzyme activity and 
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Gaucher type has been observed, it should be noticed that reticuloendothelial cells are 
affected to a greater extent in Gaucher disease than skin fibroblasts; in fact, these cells 
may be an unattractive cell model, since the level of glucocerebrosidase is about 30-
fold higher than that in blood cells and most tissues, and thus, even in fibroblasts from 
type 2 and 3 GD patients that are severely deficient in glucocerebrosidase protein, 
more enzyme is present per unit of total cellular protein. 
However, no strict correlation was noted between GD phenotype and parameters like: 
specific activity of the enzyme in extracts towards radioactively labelled natural lipid 
and artificial substrate in the presence of different activators; the enzymatic activity per 
unit of glucocerebrosidase protein; the rate of synthesis of the enzyme and its stability; 
and the post-translational processing of the enzyme (van Weely et al, 1991). In 
subsequent studies, the activity in situ of glucocerebrosidase, i.e. the lysosomal activity 
in the intact cell (fibroblasts and cultured macrophages obtained by isolating 
monocytes from peripheral blood), was assessed towards exogenous analogue 6-[N-7-
nitrobenz-2-oxa-1,3-diazol-4-yl-aminocaproyl] sphingosyl-p-glucoside, (Cg-NBD-
glucosylceramide). Again no clear relationship was found between the clinical 
phenotype, the genotype and the activity in situ (van Weely et al, 1991, van Weely et 
al, 1995) and the authors suggest that the properties of glucocerebrosidase in tissue 
macrophages are different from those in cultured cells or, alternatively, that other 
factors besides endogeneous glucocerebrosidase determine the ability of tissue 
macrophages to manage the influx of glucosylceramide substrate. 
Still according to the theoretical model (Leinekugel et al, 1992; Conzelmann and 
Sandhoff, 1983/84), the correlation between residual activity and clinical variability 
should exist since small changes in residual enzyme activity below a critical threshold 
value would significantly affect the rate of degradation of lysosomal substrates; 
changes in levels of enzyme activity above the threshold would have no effect, since 
the enzyme is present at higher levels than that required to hydrolyse all the substrate. 
1.10 Therapeutics 
Among inherited metabolic disorders, the lysosomal storage diseases are the most 
susceptible to therapeutic attempts through enzymatic correction (de Duve, 1964). 
Exogenous enzymes may diffuse from circulation to tissues and be transported to 
lysosomes after passive pinocytosis (Loyd and Griffiths, 1979) or receptor mediated 
endocytosis (Kornfeld, 1987). Several ways of administering exogenous enzymes have 
been reported, such as infusion of plasma, leukocytes, or purified enzymes, and 
transplantation of fibroblasts, organs, or bone marrow (Di Ferrante et al, 1971; 
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Knudson et al, 1971; Daloze et al, 1977; Dean et al, 1979; Brady et al, 1974; Groth, 
1982; Hobbs et al, 1982; Vellodi et al, 1987). 
1.10.1 Cell transplantation 
Repeated implantations of amniotic epithelial cells, freed from other stromal cells of the 
amniotic membrane, and maintained in culture some time before the implantation was 
described in the treatment of several lysosomal diseases includind type 3 GD 
(Scaggiante et al, 1987; Bembi et al, 1992, Sakuragawa et al, 1992). Although not 
providing a lifelong source of the deficient enzyme, amniotic epithelial cells 
implantations can be carried out easily also in outpatient clinics without requiring 
immunosuppression (Adinolfi et al, 1982; Scaggiante et al, 1988). Under normal 
conditions epithelial cells of the amniotic membrane lack HLA-A,B,C antigens and B2-
microglobulin on their surface and do not undergo malignant transformation in culture 
(Adinolfi et al, 1982). 
Bone marrow transplantation (BMT) from a normal donor has also been used as a 
continuous source of enzyme, by replacement of enzyme deficient cells with normal 
cells of hematopoietic origin. Type 1 GD had been a good candidate for BMT since this 
type of GD primarily results in the accumulation of glucocerebroside in bone marrow-
derived macrophages. Type 3 GD patients revealed a stable neurological status 
although giucocerebrosidase activity in brain did not increase (Tsai et al, 1992). 
Curative BMT has however the disadvantages of the limited number of donors (about 
25% of the patients will have a compatible donor) and the risk of fatality that is 
estimated to be between 10-25%. 
1.10.2 Enzyme supplementat ion 
Type 1 Gaucher disease is the first inheritable disease of lysosomal storage to be 
treated successfully by supplementation of the deficient enzyme, giucocerebrosidase 
(Barton et al, 1991a; Brady and Barton 1994a; Brady and Barton 1994b). 
Attempts at enzyme therapy for Gaucher disease began with the development of 
purification techniques for giucocerebrosidase from human placenta (Pentchev et al, 
1973). The initial trials using human placental giucocerebrosidase showed encouraging 
biochemical results, but the subsequent experience was disappointing (Brady et al, 
1974; Brady RO, 1977; Brady et al, 1980; Beutler and Dale, 1982), since uptake 
studies in rat liver showed that the purified human placental enzyme was 
predominantly targeted to parenchymal cells instead of nonparenchymal cells (Furbish 
et al, 1978). However a sequential exoglycosidase digestion of native placental 
giucocerebrosidase exposes internal mannose residues (Murray et al, 1985; Brady et 
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al, 1994) and directs enzyme to the targeted mannose-specific lectin receptors on the 
surface of cells (Achord et al, 1978). 
The therapeutic efficacy of the preparation of human glucocerebrosidase, alglucerase 
(Ceradase®; Genzyme Corporation, Cambridge, MA), was clearly demonstrated, even 
for the 13% patients who developed antibodies against the enzyme (Richards et al, 
1993). 
Pharmacokinetic and pharmacodynamic data as tissue, cellular, subcellular 
distribution, as well as the half-life of alglucerase in Gaucher cells after infusion, is 
being studied in order to establish the optimum dosage regimen for the better efficiency 
of the treatment. In vitro studies have shown that endothelial cells are more effective in 
uptake of alglucerase than macrophages (Sato and Beutler, 1993). In addition, some 
beneficial response to alglucerase therapy has been attributed to the clearance of the 
storage material from blood circulation (Sidransky et al, 1993). Electromicroscopic 
studies in mice and rats following intravenously administered alglucerase demonstrated 
that alglucerase is targeted to the endosomal/lysosomal system of both Kupffer cells 
and endothelial cells (Willemsen et al, 1995; Bijsterbosch et al, 1996). The uptake and 
metabolism of mannose-terminated glucocerebrosidase was also studied in vivo by 
123|_ anc j 125|_|abelled placental and recombinant enzymes (Mistry et al, 1995). In this 
work, the metabolism of the enzyme admnistered by bolus injection to patients with 
type 1 GD, was followed by analysis of blood, urine and feces; the tissue distribution 
was followed by y-scintiscanning. The disappearance of labeled enzyme could be 
resolved into 4 exponential: 56-66% was removed rapidly with t-|/2 of 3-6 minutes; the 
t-|/2 of the other 3 exponential ranged from 0.25 to 27 hours. There was rapid uptake 
by the liver (29-37% of the injected dose) and the spleen (8-23% of the injected dose). 
Bone marrow uptake was demonstrated but reliable quantification was not possible. 
Serial scintigraphy was performed over 48 hours to estimate t-|/2 of the tracer in 
different organs. In the liver and spleen, 40-55% of the tracer in the viscera 
disappeared with t-|/2 1-2 hours; the remainder persisted with a t^/2 49-60 hours. The 
t-|/2 in the bone marrow was 17 hours. Analysis of urine over 48 hours revealed that 
6.1-8.5% of the injected dose was excreted in trichloroacetic acid-precipitable form and 
31-34% of the injected dose in the non-iodide form. Thus 73-78% of the excreted label 
was bound to proteins or peptide fragments. Cumulative urinary excretions of tracer (% 
of injected dose) was at 10 hours, 32-38%; 20 hours, 42-46%; 30 hours, 47-49%; 40 
hours, 52-53% and 48 hours, 52-54%. Fecal excretion was negligible. 
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1.10.2.1 Clinical results obtained with different dose/regimen 
Several aspects of enzyme replacement therapy remain unresolved and require further 
investigation, namely, if the disease progression occur when therapy is initiated with 
low-dose regimens, if highly frequent infusions confer any additional benefits beyond 
those of dose alone, the minimum dose of enzyme required to produce skeletal 
improvement, and finally under what circumstances should prophylatic treatments be 
considered (Barton, 1995). It has been claimed that enzyme supplementation therapy 
reverse the signs and symptoms of GD if sufficient doses are administered, and that 
clinical responses are dose dependent and organ system specific. The dosage range 
administered for most patients has been 10-60U per Kg of body weight, every 2 weeks. 
Reversal of skeletal pathology occurs slowly compared with the hematologic and 
visceral responses to enzyme replacement therapy (Rosenthal et ai, 1995). After 6 
months of high-dose infusions (60 U/kg every 2 weeks), biochemical improvement in 
the bone marrow was demonstrable in paired marrow biopsy specimens obtained from 
two patients; a twofold increase in triglyceride and a fivefold reduction in 
glucocerebroside content were observed. Noninvasive imaging studies were not 
informative at this time. However, after 42 months of treatment, dramatic normalization 
of the marrow fat content, as assessed by quantitative chemical shift imaging, was 
observed in all 11 patients who participated in the trial. Furthermore, the histologic 
appearance of the marrow reverted to normal in a single child who was treated in a 
similar fashion (Parker et al, 1991). In addition to the marrow response, net increases 
in either cortical or trabecular bone mass, as assessed by combined cortical thickness 
measurements and dual-energy quantitative computed tomography, respectively, were 
observed in 10 patients. The latter responses to treatment are particularly important for 
children, because a normal peak bone mass is achieved by early adulthood if they are 
adequately treated before fusion of the epiphyseal growth plates. Conversely, although 
several patients with a previous history of chronic bone pain/avascular necrosis of large 
joints, noticed an amelioration in intensity/frequency of pain, radiological evidence of 
bone improvement was not seen within 6-36 months of treatment (Zimran et al, 1995b). 
The enzyme replacement therapy in the treatment of four patients with the neutrophil 
chemotactic defect and suffering from either severe pyogenic infections or recurrent 
urinary tract infections, allowed the reduction of neutrophil chemotaxis and of incidence 
of bacterial infections (Zimran et al, 1993). 
Eight patients with the type 3 GD (from the Norrbottnian region) aged 4-42 years, and 
five of them splenectomized, were treated with high dosage at start of enzyme 
infusions. In the 13 to 29 months follow-up of treatment all patients responded well, 
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with decreased liver and spleen volumes, normalized hematological parameters, 
growth in children, and no further neurological deteoration (Erikson and Mansson, 
1995). 
With respect to the establishment of the minimum dose, once a stable reversal of 
disease had been achieved in patients, the dose of enzyme has been empirically 
reduced by 50% every 9 months to determine the minimum amount required for 
biochemical control of the illness (Barton et al, 1991a; Brady and Barton, 1994a). All 
patients remained clinically and biochemically stable for 9 months at an enzyme dose 
of 30 U/kg every 2 weeks. However, 9 months after the dose was reduced to 15 U/kg 
every 2 weeks, 3 of 11 patients developed recurrent signs and symptoms of the illness. 
These included a gradually decreasing platelet count, slowly increasing splenic volume, 
and recurrent dull pain in the distal femurs. Modest increases in enzyme dose to 20-25 
U/kg every 2 weeks provided adequate long-term maintenance therapy in the latter 
patients. 
Altered dosage was accompanied by change in the glucosylceramide concentration. 
After single enzyme infusions, the level of circulating glucosylceramide was determined 
during 12 days in two patients. A slight reduction was observed during the first 24 
hours and thereafter the concentrations slowly returned to the levels before infusion 
(Mansson and Erikson, 1995). 
A different dosing regimen have been proposed, consisting of frequently administered 
low doses of alglucerase, either 30U/kg/month (Zimran et al, 1994b) or even 
15U/kg/month (Hollak et al, 1995a,b) administered three times a week, which the 
respective authors claimed to be as effective as the high dose/low frequency, given 
every two weeks (120U/kg/month). The rationale of frequent administration is that the 
continuous presence of the enzyme in the macrophages is promoted, since the half-life 
of endogeneous glucocerebrosidase is approximately 24 hours (and the lysosomal 
turnover of endogenous glucocerebrosidase seems not to be determined by the glycan 
composition of the enzyme) (Van Weely et al, 1990). No sub-set of patients responded 
in a unique way, implying that there is apparently no correlation with age, sex, prior 
splenectomy, genotype or general phenotypic expression on the extent of response to 
therapy (Zimran et al, 1995b), and emphasizing the need for individual dosing (Hollak 
et al, 1995a,b). The high frequency of this administration causes however a burden for 
the patients, which is partly overcome by the more convenient method of home 
treatment. 
Although therapy with alglucerase is effective, the purification from pooled human 
placental tissue cannot absolutely guarantee against the risks such as of viral 
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contamination, or the agent of the Creutzfeldt-Jakob disease. The preparation of 
human glucocerebrosidase expressed as the recombinant product in engineered 
Chinese hamster ovary cells, imiglucerase (Cerezyme^M; Genzyme Corporation) is 
becoming available and is as effective as alglucerase (Grabowski et al, 1995; Zimran et 
al, 1995c). Imiglucerase is a monomeric glycoprotein of 497 amino acids, which differs 
from placental alglucerase by one aminoacid at position 495 where histidine is 
substituted for arginine. Kinetics of the labeled recombinant enzyme was also 
indistinguishable from those of the placental one (Mistry et al, 1995). 
1.10.3 Somatic gene therapy 
The transfer of genes for somatic gene therapy has been attempted by in vivo transfer 
of the gene (by either viral or nonviral methods) directly into the affected cell or tissue, 
or by ex vivo delivery of the gene to targeted host cells followed by autologous cell 
transplantation. For several disorders allogenic bone marrow transplantation (ABMT) 
has reversed the visceral complications of the disease. In Hurler disease and 
adrenoleukodystrophy, clinical results suggest that the complications in the nervous 
system can be halted, if not reversed, by ABMT (Krivit and Shapiro, 1991; Aubourg et 
al, 1990). The mechanism of this effect is probably the consequence of the gradual 
replacement of brain macrophages and microglia that are derived from the allograft. 
Bone marrow transplantation studies in the mannosidosis cat show that bone marrow-
derived cells gain acess to the brain and result in improvement in the neurologic 
manifestation of the disease (Walkely et al, 1994). 
In the development of gene therapy for Gaucher disease, it was demonstrated that 
ABMT restores hematopoietic stem cells and results in the repopulation of tissues with 
bone marrow-derived cells (Ginns et al, 1984; Ringden et al, 1988). Since in Gaucher 
disease the macrophage is the major cell involved in storage of glucosylceramide, 
bone marrow is, therefore, an appropriate target cell for gene transfer. Furthermore, 
since the gene product (glucocerebrosidase) is therapeutic when targeted to 
reticuloendothelial cells and macrophages, gene therapy will be efficient for Gaucher 
disease, provided that sufficient transfer and expression of the transgene can be 
achieved. 
Several groups have reported protein expression in macrophages differentiated from 
mouse hematopoietic stem cells that were infected with a retroviral vector containing 
the human glucocerebrosidase gene (Weinthal et al, 1991; Ohashi et al, 1992; Correi 
et al, 1992; Krall et al, 1994). Imunohistochemical analysis of tissues of transplanted 
mice revealed that expression of human glucocerebrosidase was not only restricted to 
macrophages in visceral tissues, but also in brain (Mowery-Rushton et al, 1993). In the 
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central nervous system of these mice, human glucocerebrosidase-positive 
macrophages were observed, predominantly in perivascular spaces, but surprisingly 
also in microglia in close proximity with blood vessels. These findings suggest that 
circulating monocytes can enter the brain as perivascular cells and subsequently 
traverse the basement membrane and enter the brain parenchyma. The reconstitution 
with mouse glucocerebrosidase-positive macrophages is however only partial i.e. on 
the average in 20% of Kupffer cells, splenic macrophages and microglia cells by 8 
months after transplantation (Krall et al, 1994). 
Long-term bone-marrow cultures of hematopoietic cells of Gaucher patients were also 
successfully transduced with a retroviral vector encoding normal glucocerebrosidase 
cDNA (Nolta et al, 1992; Xu et al, 1994). Gene therapy is under study for all types of 
Gaucher disease (Barranger, 1994; Correi and Karlsson, 1994). Allogenic bone marrow 
transplantation may however have a role, possibly supported by enzyme replacement 
therapy, in very early stages of type 2 and type 3 GD. However none of the somatic 
gene therapy attempts till now have led to a permanent correction of the protein 
deficiencies (Correll and Karlsson, 1994). In addition, the clinical response was slow 
and required 10-12 months for measurable improvement to be evident. 
1.10.4 Splenectomy and partial splenectomy as a therapeutic 
procedure 
Prior to the era of enzyme replacement therapy, full or partial splenectomy was a 
commonly performed therapeutic procedure since generally it corrects the 
haematological abnormalities (neutropenia, thrombocytopenia and anaemia), relieves 
the symptoms of mechanical compression, engenders a compensatory growth spur in 
children, and improves the nutritional status in adults (Fleshner et al, 1991; Cohen et 
al, 1992). 
However mental deterioration in patients with the type 3 of GD was reported to 
accelerate after splenectomy (Herrlin and Hillborg 1962; Dreborg et al, 1980). A 
deposition of circulating glucosylceramide in the adventitial cells of small blood vessels 
of cerebellum was found, which could be responsible for the accelerated mental 
retardation before death. The storage of glucosylceramide increased in other organs, 
e.g. the liver, and the level of circulating glucosylceramide raised (Nilsson and 
Svennerholm, 1982). Since there have been also reports of significant progression in 
liver and bone involvement following splenectomy (Ashkenazi et al, 1986), and the 
increase of risk of serious microbial infection particularly in infants, splenectomy is no 
longer a treatment of choice in GD. Given the ability of even low-dose enzyme 
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replacement therapy to relieve splenomegaly and ameliorate cytopenias, splenectomy 
has been reserved for patients with life-threatening hémorragie diathesis. 
1.11 Unresolved questions of GD 
Many questions remain unsolved with respect to either the epidemology and the 
pathophysiology of GD. In the Ashkenazi Jewish population the most commonly 
encountered mutation is the N370S glucocerebrosidase, which in the homo and 
heteroallelic form is associated with a non-neuronopathic clinical course. However, it 
remains to be established the N370S gene frequency which would allow to ascertain 
the incidence of the homozygosity, and its association with actual disease 
manifestation. With respect to the pathophysiology of GD, the mechanisms responsible 
for the variability of the clinical manifestations, especially in type 1 GD, are unclear. 
Although some authors claimed to obtain differences in glucocerebroside catabolism 
between the different types of GD (type 1,2 and 3), no correlation was established 
between the properties of the mutant enzymes and the residual activity in cells of type 
1 GD patients, who present the most heterogeneous phenotype of the disease. In 
addition, the presence of a large number of storage cells can not explain all 
phenomena observed in GD patients. The storage macrophages are viable cells and it 
seems likely that chronic, excessive secretion of factors by these cells mediates a 
number of pathological processes that remain to be established and that probably 
contribute to the large clinical evolution of the disease. Finally, other factors besides 
the basic deficiency remain unidentified and may have a role in the clinical presentation 
of the disease; cellular glucocerebroside and ceramide concentrations may have an 
effect on key cellular events and by this way determine the involvement of other 
physiological systems. 
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Aims of the experimental work and background 
information 
2.1 Outline of this thesis 
The studies described in this thesis were aimed to obtain further insight into the 
epidemology of Gaucher disease (GD) in Portugal as well as into the 
pathophysiological aspects of the disease. The nature and aims of the present 
investigations were the following: 
i. To determine the frequency of the N370S mutation in the Portuguese population 
and selected areas (Chapter 3). 
ii. To study the possibility of a common origin of the N370S mutated allele in 
Portuguese and Ashkenazi Jewish patients (Chapter 3). 
iii. To establish an enzyme binding assay for the detection of carriers with unknown 
mutated glucocerebrosidase alleles (Chapter 3). 
iv. To evaluate the predictive value of genotype for the glucocerebrosidase residual 
activity and the seventy of clinical manifestation of GD (Chapter 4). 
v. To analyze secondary abnormalities of GD patients and their relation with 
glucocerebrosidase genotype and/or specific clinical phenotype (Chapter 5). 
vi. To study the effect of enzyme supplementation therapy on secondary 
abnormalities in order to get insights in the pathophysiology of GD (Chapter 5). 
2.2 Purposes, approaches and new contributions 
For these purposes different approaches were used and the experimental work of this 
thesis revealed the following new contributions for the study of GD: 
Chapter 2 
(i) Gaucher disease (GD) revealed to be the most frequent inherited sphingolipid 
lysosomal storage disorder in the Portuguese population, and that when studied at the 
gene level, the Portuguese GD patients resembled the Ashkenazi Jewish Gaucher 
patients with respect to the high incidence of the N370S mutated allele. The general 
Portuguese population was characterized with respect to the frequency of N370S 
mutated allele: 
-The frequency of the N370S mutated allele in the Portuguese population was found to 
be of 0.0043 (with 95% confidence limits between 0.0023 and 0.0063) (Chapter 3). 
-On the basis of the frequency value, the incidence of N370S homozygotes can be 
calculated to be about 1/55 000 in the total Portuguese population (Chapter 3). 
This result pointed to a mild or sub-clinical presentation of this genotype since 
apparently about 90% of the Portuguese N370S homozygous patients remain 
undiagnosed. 
(ii) On the basis of the occurrence of the N370S mutation in the context of one 
haplotype of an intragenic polymorphism, the N370S mutation has been claimed to 
arisen recently and only once. The possibility of a common origin for the N370S 
mutated allele in the Portuguese and in the Ashkenazim populations was studied by 
linkage analysis: 
-In the Portuguese population the frequency of each intragenic Pvull polymorphic form 
was found to be of 0.836 and 0.164 (for respectively Pv1.1- and Pv1.1+), which differs 
from the 0.647 and 0.353 values described as being the average of different racial 
groups (Chapter 3). 
-The N370S mutated allele was always invariably associated with the Pv1.1- form of 
the intragenic polymorphism (Chapter 3). 
Like GD patients of Ashkenazi Jewish ancestry, Portuguese GD patients 
presented linkage disequilibrium between the N370S mutated allele and the 
intragenic Pv1.1- haplotype, and thus a common origin for this mutated allele in 
both populations can not be excluded. 
(iii) Due to the relatively high percentage of unknown mutations in the remaining 
mutated alleles, an enzyme-based assay was applied in the study of affected families 
presenting non-identified mutated alleles: 
-The enzyme based screening assay allowed the detection of carriers for the two most 
frequent mutated alleles in Portuguese GD patients (N370S and L444P) as well as the 
identification of obligate carriers of unknown mutated allele(s) (Chapter 3). 
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Increased frequencies of N370S carriers were demonstrated within the 
population originated from certain Portuguese geographical areas with incidence 
ofGD. 
(iv) Compound hétérozygotes for the N370S mutated enzyme were free from 
neurological symptoms. The clinical presentation of the Portuguese GD patients is 
however very heterogeneous, which may be related to combinations (at least 12) of 
different glucocerebrosidase mutated alleles. Yet no genotype/phenotype correlation 
could be established even among sibs. Glucocerebrosidase residual activity was 
determined in cells of patients presenting different genotypes: 
-The proportion of glucocerebrosidase extracted in aggregated form 
(enzyme+lipids+activator protein) was found to contribute predominantly to the total 
glucocerebrosidase activity in leukocytes of patients presenting at least one N370S 
mutated allele (Chapter 4). 
-The dependence of the N370S glucocerebrosidase activity on the aggregated form 
was reflected by the marked effect of the physiological activators (phosphatidylserine 
and saposin C) on the specific activity of the monomeric form at pH 4.5 (Chapter 4). 
The reactivation ability of the N370S mutated enzyme probably contributes to a 
higher residual activity in cells of patients carrying at least one N370S mutated 
allele. The variable percentage of this mutated glucocerebrosidase in the 
activated state (aggregated form) probably determine the residual activity. 
(v) GD patients present increased plasma chitotriosidase activity (which may reflect the 
overall Gaucher cell accumulation in the body) and tartrate resistant acid phosphatase 
(TRAP) activity (which may constitute a marker of osteoclastic activity). Plasma 
glucosylceramide, the peripheral blood T lymphocyte major subsets, serum ferritin and 
known abnormalities associated with GD were studied as indicators of disease 
manifestation in order to find any correlation with either genotype or clinical severity: 
-A genotype/marker correlation was obtained where N370S homozygous patients were 
characterized by the absence of significant abnormalities in CD47CD8+ T lymphocyte 
ratio, significantly less abnormal TRAP and chitotriosidase activity (Chapter 5). 
-A phenotype/marker correlation was observed where plasma glucosylceramide 
concentration was significantly correlated with the clinical severity score. In non-
splenectomised GD patients it was observed an association between bone pathology 
and statistically significant abnormalities in the CD8+ T lymphocyte subset, further 
substantiated by the existence of a significant correlation between the number of these 
cells in peripheral blood and plasma TRAP activity (Chapter 5). 
31 
Chapter 2 
The clinically milder phenotype of the N370S homozygotes was characterized by 
relatively less abnormal secondary markers. The obtained findings on T 
lymphocyte major subsets suggest the involvement of the immune system in the 
pathophysiology of GD, providing a useful disease marker. 
(vi) Since enzyme supplementation therapy aims the correction and/or prevention of 
ongoing formation of the glucosylceramide-loaded macrophages, secondary 
abnormalities were studied in patients submitted to the alglucerase supplementation 
therapy, as quantitative markers of the amount of storage cells and macrophage 
activation: 
-Chitotriosidase activity decreased in a dose dependent manner and preceding the 
reduction of glucosylceramide concentration which occurred after 12 months of therapy 
(Chapter 5). 
-No effect was observed in the %CD4+ and %CD8+ T lymphocytes. With respect to the 
CD4+ and CD8+ T lymphocytes statistically significant changes occurred only after 12 
months of treatment (Chapter 5). 
-The evolution of TRAP activity agrees with the observed unclear and/or slower 
reversion of bone pathology in GD patients (Chapter 5). 
Chitotriosidase activity seems to reflect the overall Gaucher cells accumulation 
in the body, whereas glucosylceramide decreased probably reflects the lysed 
lipid loaded macrophages. The less clear reduction of TRAP activity seems to 
indicate that the release of this enzyme is probably more restricted to a specific 
location of slower correction and/or prevention of ongoing formation of the lipid 
laden GD cells. 
2.3 Background information 
2.3.1 Genotype and cl inical presentation of studied GD patients 
All Gaucher disease (GD) patients described in this work were identified during the last 
12 years in the Enzymology Department from the Instituto de Genética Médica Jacinto 
de Magalhães. Biochemical diagnosis was done by demonstration of severely reduced 
glucocerebrosidase activity in leukocytes, as measured with 4-methylumbelliferyl-(3-
glucoside artificial substrate in the presence of taurocholate. A total of 40 GD patients 
were clinically classified as being type 1 (37 patients), type 2 (2 patients) and type 3 (1 
patients). Up to the present time none of the type 1 patients investigated has shown 
pathological involvement of the central nervous system. 
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At the beginning of this work detection of mutant glucocerebrosidase alleles by DNA 
analysis was restricted to two mutations. Consequently the initial research focused 
largely on the frequency and origin of the commonest in Portugal. Identification of more 
rare glucocerebrosidase mutations in the Portuguese GD patients was the topic of 
another work presently undertaken at the same Institute. The screening of mutations 
allowed the identification of about 87% of the mutant alleles among unrelated 
individuals. The remaining 13% of patients mutant alleles are still unidentified, even 
when tested for a total of 19 previously described mutations (Amaral et al, 1996). 
The patients present age ranges from 10 to 59 years, 11 of them being male and 20 
women. In general all non-splenectomized patients suffered from enlargement of the 
liver and spleen with subsequent pancytopenia and abdominal pain. Ten patients had 
had total splenectomy which, with the exception of one patient, resulted in the 
correction of anemia and thrombocytopenia. The accumulation of Gaucher cells in 
bone marrow is associated with varying degrees of necrosis, fibrous proliferation and 
resorption of the bony trabeculae, followed by erosion of the endosteal surface of the 
cortex and modeling deformities. Bone pathology was evaluated by treating physicians, 
using several methods, e.g. X-ray, magnetic resonance imaging (MRI) and bone 
tomodensitometry. The lesions detected ranged from diffuse osteoporosis (stage 1), to 
medullary expansion (stage 2), osteolysis (stage 3), necrosis/sclerosis (stage 4), 
destruction and collapse (stage 5) (Hermann et al, 1986). Among the earliest signs is 
the Erlenmeyer flask deformity of the distal femur and the proximal tibia (stage 2) which 
although not pathognomonic of the disease, is seen in most patients at presentation. 
For each patient, the clinical severity was calculated on the basis of the Zimran's 
severity score index (SSI) (Zimran et al, 1989). This index takes into account the age of 
onset, the degree of organomegaly, liver function tests, clinical signs of liver disease, 
cytopenia, bone involvement and other organ involvement (Table 2-1). 
The severity score index of each type 1 GD patient was evaluated by Ana Maria 
Fortuna, M.D. (from the Instituto de Genética Médica Jacinto de Magalhães). Patients' 
characteristics including age, sex, genotype, clinical presentation with respect to 
splenectomy, bone involvement, and the overall disease severity, presented as severity 
score (SSI) on the basis of the respective clinician assessment, are shown in 
Table 2-2. 
As shown in Figure 2-1, a large variability in the severity score seems to exist in the 
seven most frequent genotype groups (N370S/N370S, N370S/L444P, N370S/IVS2+1, 
N370S/Rec TL, N370S/? and G377S/G377S); since only one patient was identified in 
each of the remaining genotype groups (N370S/R463C, N370S/X, X/X, 
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N370S/RecNcil, L444P/L444P and L444P/?), nothing can be stated in this respect. In 
relation to three of these genotypes the clinical variability could also be observed 
between sibs. The intra-familial heterogeneity is particularly remarkable in the unique 
family with the N370S/IVS2+1 genotype, SSI varying from 5 to 14. 
Table 2-1 
Parameters used in the calculation of the severity score index (SSI) (Zimran et ai, 1988). Mild, was 
used when spleen/liver tip does not extend below level of umbilicus; moderate, was used when tip is 
palpable between level of umbilicus and pelvic rim, and for the spleen, without extension to right side of 
abdomen; massive, was considered to be when the organ extends to below pelvic rim, and virtually 
occupies whole abdomen. 
Feature Score Feature Score 
Age at diagnosis(yr) Liver function tests 
<50 0 Normal 0 
26-50 1 Minor abnormalities 1 
11-25 
6-10 
1-5 
2 
3 
4 
Severe abnormalities 2 
Clinical signs of liver disease 4 
Cytopenia 
<1 6 Unsplenectomised 
Splenectomised 
1 
Splenectomy 3 3 
Splenomegaly 
None 0 
Other organ involvement 4 
Bone involvement 
Mild 1 No signs/symptoms 0 
Moderate 2 Radiograph or scan signs 1 
Massive 3 Mild pain 
Chronic pain 
2 
Hepatomegaly 3 
None 0 Fractures 
Mild 1 Pathological 4 
Moderate 2 Post-traumatic 1 
Massive 3 Joint replacement 
Severe disability 
5 
2 
When analyzed by genotype, a lower number of N370S/N370S homozygous patients 
were found to present bone involvement (Table 2-2). As can be observed in Figure 2-1, 
this is reflected in a comparatively milder overall clinical presentation of the N370S 
homozygotes, as assessed by the Zimran severity score index (SSI). 
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Figure 2-1 
Clinical severity (SSI) of genotyped type 1 GD patient. 
2.3.2 Gaucher disease patients submit ted to the enzyme 
supplementat ion therapy 
From the 46 studied patients 24 started intravenously administered enzyme 
supplementation therapy, the large majority with alglucerase (human 
glucocerebrosidase purified from human placenta and enzymatically deglycosylated to 
reveal terminal mannose residues, which are recognized by the macrophages 
membrane mannose-specific receptors, allowing the targeting and intracellular 
trafficking (Furbish et al, 1981)). Presently all treated patients are receiving the recently 
available imiglucerase (human glucocerebrosidase expressed as the recombinant 
product in engineered Chinese hamster ovary cells and enzymatically deglycosylated). 
With respect to the dosage and frequency of administration, 21 patients started with 
high dose (60 U/per kg body weight) given every two weeks (60U/kg/2w). Three 
patients (patients 23, 31 and 34) started with frequently administered low doses 
(7U/per kg body weight)), given either weekly or three times a week (30U/kg/4w). 
Treatment regimens were changed according to the patient's clinical response. 
Patients 29 and 39 interrupted therapy after 9 and 6 months, respectively. 
GD patients submitted to enzyme supplementation therapy presented different 
genotype and clinical severity (SSI) aged at start ranged from 9 to 53 years, being 10 
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of them man and 9 women. In addition to skeletal complications, all non-
splenectomized patients suffered from excessive enlarged liver and/or spleen with 
subsequent pancytopenia and abdominal pain. Six patients were submitted to total 
splenectomy in the past which, with the exception of one patient (patient 41), resulted 
in the correction of anemia and thrombocytopenia (Table 2-2). 
2.3.3 Clinical fol low-up of GD patients submit ted to enzyme 
supplementation therapy 
With respect to the clinical follow-up, in accordance to the highly heterogeneous clinical 
presentation of GD, the response to therapy is also variable and organ system-specific 
(reviewed in Beutler and Grabowski 1995). Sustained clinical improvement was 
observed in all patients, with the high dose regimen (60U/kg/2w). In contrast patients 
receiving the low dose regimen (30U/kg/4w) showed a delayed clinical response and 
for that reason were changed to the high dose regimen. 
Objective clinical improvement was obtained as well as a clear increase in the quality 
of life, with respect to personal performance and well being. After 12 months a 
significant reduction in the size of the spleen (20-54%) could be observed in 4 patients 
that presented splenomegaly. In 3 of these patients as well as in other non-
splenectomized patient, the resulting reductions in liver size obtained after a 12 month 
period were between 17-44%. Patients presenting mild organomegaly at baseline, 
showed completely regress to normal after 12 months of treatment; with respect to the 
remaining patients in general the excessively large spleens became markedly smaller, 
but did not completely regress after 12-36 months of treatment. 
The bone painful symptoms were drastically reduced in all patients and specially in the 
patient who required hip replacement during treatment. One patient that presented 
growth retardation at baseline, increased 14cm in height after 36 months of therapy. 
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Chapter 3 
N370S glucocerebrosidase gene mutation in the 
Portuguese 
3.1 Introduction 
3.1.1 Occurrence of rare genetic disorders in smal l populat ions; The 
incidence of lysosomal storage diseases in the Ashkenazi 
Jewish communi ty 
The occurrence of one or more rare genetic disorders -in particular autosomal 
recessive ones- in relatively high frequency, have been reported in isolated 
communities or small populations, like for instance, the Old Order Amish people, the 
Ashkenazi Jews, the Finns or the French Canadians. These communities were isolated 
because of geographical conditions, religion, or by preference. In some cases, the 
genealogical studies demonstrated a common origin of the carriers, and a founder 
effect together with genetic drift was proposed to explain the high frequency of the 
disorders (Diamond and Rotter, 1987). 
In the Ashkenazi Jews, who represent the largest Jewish community, several genetic 
diseases have been reported to occur in relatively high incidence, including Tay Sachs 
(GM2 gangliosidosis type B), Gaucher type 1, Niemann-Pick type A (1:40 000 and 1:80 
000 of type B), familial dysautonomia, Canavan, Bloom, mucolipidosis (ML) type IV, 
hereditary dystonia, and factor XI deficiency (reviewed in Bonné-Tamir and Adam, 
1992; Diamond, 1994). Four of these disorders -Tay Sachs, Gaucher, Niemann-Pick A, 
B and ML IV- are lysosomal storage disorders. The incidence of lysosomal storage 
diseases in the general population is very low, similar to those of other autosomal 
recessive genetic disorders, and thus the existence in high frequency of four of these 
diseases among the Ashkenazi Jews is unexpected and intriguing, particularly since it 
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involves the storage of substances of a common nature - the GM2 ganglioside in Tay-
Sachs, the glucocerebroside in Gaucher, the sphingomyelin in Niemann-Pick, and the 
gangliosides in ML IV, all share the ceramide-lipid backbone (Zlotogora et al, 1988; 
Diamond, 1994). Also in the analysis of patients with lysosomal storage disorders a 
similar tendency was observed that is, more than one lysosomal storage disorder in 
certain large families or communities and despite the different enzymes involved the 
stored substances are usually of similar or common nature (Zlotogora et al, 1988). 
According to the analysis of haplotypes and/or mutations, it may be possible to 
distinguish 3 groups of disorders frequent in isolated populations. In the first group, all 
the affected patients have only one frequent mutation, suggesting a founder effect with 
genetic drift. In the second group, more than one mutation is found among the patients, 
however, most of the patients are homozygous for one frequent mutation which most 
probably originated from a common founder; the other patients are compound 
heterozygous for the common mutation and a rare mutation. In the third group, more 
than one frequent mutation is found responsible for each disease. This may be due to a 
selective advantage which allows the expansion of each new mutation in the particular 
population or to multiple founder effect with genetic drift in smaller communities which 
thereafter mixed to form the larger population (Zlotogora, 1994). 
Using mathematical analysis Jorde (1992) concluded that at any reasonable rate of 
mutation or migration, and at any effective population size, drift alone is unlikely to 
account for the elevated frequency of either of the major Tay-Sachs mutations in the 
Ashkenazi population. In considering elevated frequencies of recessive disease genes, 
a selective advantage is often invoked for the hétérozygote. This can take the form of 
either increased resistance to a selective agent or an intrinsic fertility advantage (Jorde, 
1992). A selective advantage for the carriers of lysosomal storage diseases has been 
suggested (Zlotogora et al, 1988). It may be that even though carriers of lysosomal 
diseases are healthy, the partial enzyme deficiency leads to a subtle storage of similar 
type of substances in the lysosome. This storage may be advantageous to the cell in 
some particular environmental conditions. For instance, it may confer resistance to 
some infectious agents to the cell. In a population such as the Ashkenazim, such a 
selective advantage may explain that not only one disease is caused by more than one 
frequent mutation, but also that more than one lysosomal storage disease is found in 
high frequency. It has been suggested that the advantage may have been resistance to 
pulmonary diseases, in particularly tuberculosis, which were more prevalent in the 
urban ghettos where the Eastern European Ashkenazi Jews lived, than in their 
predominantly rural Gentile neighbours (Rotter and Diamond, 1987). So, the selection 
forces might be environmental (e.g., lung disorders) which would be a situation similar 
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to that seen in both the resistance to the malaria parasite in heterozygous for the sickle 
cell-anaemia gene and G6PD deficiency in Africa, or alternatively, the selection could 
occur at the gamete level; the later hypothesis is however unlike since these disorders 
are rare in the general population (Zlotogora et al, 1988). 
3.1.2 Frequency of Gaucher disease mutated alleles in the Ashkenazi 
Jewish and the Portuguese populat ions 
The prevalence of the GD mutations has been reported as being different between 
patients of Ashkenazi Jewish and non- Ashkenazi Jewish origin (Horowitz et al, 1993). 
The N370S mutation was reported as the most frequent among Ashkenazi Jewish 
patients, whereas L444P was described as the most prevalent among non-Jewish 
patients (Beutler et al, 1993). More specifically, the N370S mutation is present in 77% 
of the mutated alleles in the Ashkenazi Jewish type 1 Gaucher patients (Beutler et al, 
1992), where in the few studies that have been performed on non-Jewish of diverse 
ethnic or non-specific origin patients, the N370S mutated allele accounted to 22-46% of 
mutated alleles (Beutler et al, 1991 ; Levy et al, 1991 ; Choy et al, 1991 ; Sidransky et al, 
1992b). 
However DNA analysis of the Portuguese type 1 Gaucher patients showed that the 
N370S mutation was the most prevalent mutation, accounting for 63% of mutated 
alleles (being L444P the second most frequent one) (Amaral et al, 1993). The high 
prevalence of the N370S allele was thus closer to that described for Ashkenazi Jewish 
patients than the remaining non-Jewish Gaucher patients. Two mutations alone 
(N370S and L444P) account for as much as 84% of all the mutated alleles in the 
Portuguese patients. 
In the Ashkenazim patients five common mutations collectively were reported as 
accounting for about 97 per cent of Ashkenazi Jewish GD alleles (Beutler et al, 1992b). 
The two most frequent mutant alleles had a measured hétérozygote frequency of 
0.0022-0.032 -far higher than could be sustained at equilibrium (in the face of deaths or 
debilitation from Gaucher) by recurrent mutations in the absence of any compensating 
selective advantage. Since three of the mutant alleles occurred in Jews in the context 
of only a single haplotype, the mutations must havearose in Jews recently, and only 
once, and have within a short time been pumped up to high frequencies by selection 
(Diamond, 1994). Another possible explanation for the finding of more than one 
frequent mutation in a population where a disease is frequent, may be that while 
nowadays the population seems to be homogeneous, however it is composed of 
smaller communities which, in the past, were isolated one from the other. In fact, the 
Eastern European Jewry were dispersed in small communities since the Middle Ages, 
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and only recently are considered as the Ashkenazim ethnic group (Goodman and 
Motulsky, 1979). The occurrence of mutations in some of the smaller communities may 
have been followed later by the spread of each mutation within the community. The 
spread may have been because of a selective advantage or a founder effect (which is 
essentially a form of genetic drift) in each of the smaller communities (Zlotogora, 1994). 
The noted high frequency of the N370S mutated allele in the Portuguese population 
raise the question that this could be due to the historical major influx of Sephardic 
Jewish genes in the Portuguese country. 
3.1.3 Cultural and genetic roots of Jewish communi t ies - Sephardic 
Jewish ancestry of the Portuguese 
During the process of their formation and settlement in a given territory, human 
populations are subjected to the influences of various evolutionary factors, such as 
migration, admixture with people from other populations, random differentiation, and 
specific selective process. Despite the complicated interactions of these factors in the 
ethnic groups populating modern Europe, evidence of the effects of single processes, 
such as directional patterns caused by migration, as well as of stochastic 
differentiation, may be demonstrated (Sokal et al, 1989). 
Jewish communities trace back both culturally and genetically to some extent to a 
population occupying a small geographic area in Eastern Mediterranean, the land of 
Israel, several thousand years ago (Dellapergola, 1992). Jewish populations were 
dispersed from there in the main between 600 B.C. and the Second Diaspora 
(dispersion of Jews from the land of Israel after the destruction of the Second Temple 
by the Romans in 70 A.D.). The history of their subsequent residence in and 
movements between various countries in Europe, North Africa, and the Middle East 
has resulted in a nearly unique pattern of genetic relationships among Jewish 
populations and between them and the non-Jewish peoples among whom they live. 
Modern Jewish population includes: The Sephardic Jews who live in and around the 
Mediterranean basin; the Oriental Jews which came from Asia; the Eastern European 
Jewry, whose story began probably after the Crusades (1200 A.D.) with the arrival of a 
modest number of Jewish immigrants (most probably Sephardic Jews from Western 
Europe) to Middle (corresponding to Austria, Hungary, Czech and Eslovakia Republic) 
and then Eastern Europe (Poland and Russia) (Petersen et al, 1983) where they have 
lived for centuries, and only recently are considered as the Ashkenazim ethnic group 
(Goodman and Motulsky, 1979). Nowadays they comprise about 40% of the Jewish 
population. 
42 
N37QS glucocerebrosidase gene mutation in the Portuguese 
The Sephardic Jews may be described briefly as the descendants of that group of 
Jews who lived in Spain during the Middle Ages. It is not known when Jews first 
entered Spain, but the expressed intention of the Apostle Paul (Romans 15: 24) to visit 
that country almost certainly implies the presence there of Jewish communities in the 
first century of the Christian era. However, long before the Muslim invasion in 711 A.D., 
the Christianised Visigoths, who had succeeded the Romans in power, had completely 
suppressed the open practice of the Jewish religion (reviewed in Mourant et al, 1978). 
The Jews who entered Spain in large numbers immediately after the original Muslim 
invasion came from North Africa. The Jews of this region, while including many who 
were of Berber descendent, were mostly the descendants of Palestinian Jews who had 
entered through Egypt. The descendants of these Egyptian Jews had in turn been 
driven further west by persecution, especially by the Romans, first pagan and then 
Christian, as long as they controlled north Africa. The freedom of the Jews in Spain 
(during the Muslim control) and their growing intellectual and religious status attracted 
Jews from communities of the eastern Mediterranean and especially from Babylon, 
which finally, in the eleventh century, yielded the religious and cultural leadership of the 
Jewish world to Spain. The reconquest of Spain by the Catholic forces of Ferdinand 
and Isabel resulted at first in intolerance and for a short time in conciliating position to 
Judaism, but in 1492 under papal influence Jews were expelled by decree (unless they 
accepted Christianity they were forced to leave the country). Those who reached the 
Portuguese frontier achieved a short rest but, one of the conditions for the marriage of 
the Portuguese king with the daughter of the Spanish Catholic sovereigns was that all 
Jews should be expelled. Repressive laws and massacres began to cause Jews in 
Portugal to conversion to Christianity, but large numbers of those who did so became 
"Marranos", publicly professing conversion but continuing to practise the Jewish 
religion in secret. While, however, these "New Christians" (as converted Jews were 
called) continued to occupy positions which they had held as Jews, many even married 
into "Old Christian" families and any suspicion that their conversion was not genuine 
exposed them to the heresy-hunting Inquisition (reviewed in Mourant et al, 1978). To 
this day, however, it also remains, among the Catholics of Portugal the Belmonte 
community who, hardly knowing the reason why, continue to perform some of the 
superficial rites of the Jewish religion (Prinz, 1974; Garcia, 1993). 
In the XVIII century important groups of Portuguese Sephardic Jews were settle down 
in the USA (reviewed in Sequeiros, 1989), most of them coming from Holland to where 
they had emigrated due to the Inquisition persecutions. In fact American Jewish 
communities of New Amsterdam (actually New York) were founded by Portuguese 
Jews (Silveira Cardozo, 1976; San-Payo, 1985). In 1677 a new group of Portuguese 
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Jews coming from Barbados were established in Newport (San-Payo, 1985); several 
other groups joined them later on coming from Curaçao, Holland, Brazil and Portugal 
(Silveira Cardozo, 1976). In 1734 David Mendes Machado, born in Lisbon, was rabbi of 
the New York Jewish community (Silveira Cardozo, 1976), and the most ancient 
synagogue in the USA, which was builded in 1759 and located in Newport, was 
founded by the Portuguese Jew Aaron Lopes. 
The Azores islands are constituted by 9 islands in the North Atlantic which were 
discovered in 1432 and colonised 7 years later. The first colons were in the great 
majority from Southern Portugal (in particular the Algarve region), and included both 
"new" Christians (Jewish and Muslim) and "old" Christians; the remaining population 
was originated from Britain, Scotland, Ireland and Italy (Guill, 1972). Nowadays the 
Azores population is constituted by about 250 thousands inhabitants, and in the USA 
live about 1,5-3 millions of people with Portuguese ascendance and most of them from 
Azores Islands (Guill, 1972). They are distributed mostly in the New England and 
California states, special in the South of Massachusetts, Rhode Island, as well as in the 
North of California and San Francisco bay (U.S. Department of Commerce, 1983). 
3.1.4 Genetic affinities of Jewish populat ions to each other and to 
their non-Jewish neighbours 
Whereas the factors molding the genetic structure of the typical European population 
are spatial differentiation, migration, and amalgamation of native gene pools (Sokal et 
al, 1989), Jewish populations have the potential for exhibiting a more dendritic or 
hierarchic structure due to their migration and branching history. Spatial differentiation 
based on isolation by distance is possible for them only in situations where they were 
numerous and widespread enough and resident for a sufficient period to permit the 
effects to become manifest (Livshits et al, 1991). Computer simulation studies have 
shown that the percentage of shared polymorphic alleles declines very rapidly in 
groups of populations after their splitting, even when daughter populations are of as 
large an effective size as 10,000 individuals (Li and Nei, 1977; Fuerst, 1985). Because 
the sizes of Jewish populations frequently were small, there is evidence (Carmelli and 
Cavalli-Sforza 1979; Morton et al, 1982) of the additional significant effects of chance 
sampling of the gene pool (genetic drift, bottleneck effects). Finally, although religious 
law and custom proscribed intermarriage with the surrounding non-Jewish populations, 
there is little doubt that some genetic admixture took place (Livshits et al, 1991). 
With respect to the genetic affinities of Jewish populations to each other and to their 
non-Jewish neighbours, Mourant et al (1978) maintained that each major Jewish 
community as a whole bears some resemblance to indigenous peoples of the region 
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where it first developed, while Morton et al (1982) using the modified kinship function of 
Malécot, concluded that there was substantial intermixture between Jewish and 
neighbouring non-Jewish populations. Other studies (e.g., Karlin et al, 1979; 
Kobyliansky et al, 1982; Bonne-Tamir, 1985) reported a considerably greater genetic 
similarity for most pairs of Jewish populations than between Jewish and non-Jewish 
communities. It has also been shown by blood groups ABO and typing that inbreeding 
within Jewish populations as measured by FjS is higher than in non-Jewish populations, 
whereas Wright's standardised genetic variance (Fst) among Jewish groups is lower 
than among non-Jewish communities (Kobyliansky and Livshits, 1983). Other studies 
concluded that European Jews and non-Jews form two distinct and closely knit 
clusters, and that North African and Iraqi Jews are closer to the European Jews than to 
the corresponding non-Jews (Rao and Boudreau, 1984). In other studies (Wijsman, 
1984) it was found that Ashkenazi Jews have a low to moderate non-Jewish genetic 
component, consistent with both the low estimates suggested by Karlin et al (1979) and 
higher estimates suggested by others (Carmelli and Cavalli-Sforza, 1979; Morton et al, 
1982). Computing the level of admixture separately for the different loci, no admixture 
was found in HLA-A and HLA-B loci, but various amounts of admixture for other loci 
(Cavalli-Sforza and Carmelli, 1979). Similar variability across loci was reported 
(Motulsky, 1980). 
By assembling the largest combination of gene frequencies based on independent loci 
for matched Jewish and non-Jewish populations reported to date, and the largest 
number of loci for individual Jewish populations, and also by introducing a new 
analytical distance by means of Mantel tests against design matrices, the results of the 
study of Livshits et al (1991) consistently showed lower distances among Jewish 
populations than with their non-Jewish neighbours, most simply explained by the 
common origin of the former. This findings are easiest to explain by deriving the 
modern Jewish populations from a common original gene pool which underwent 
relatively few changes during the dispersion of the Jewish people. Unless differential 
evolutionary rates are postulated, the common origin of the Jewish populations must be 
more recent than that of the non-Jews (Livshits et al, 1991). Yet, there was evidence 
also of genetic similarity between Jewish and corresponding non-Jewish populations, 
suggesting reciprocal gene flow between these populations or convergent selection in 
a common environment. The study also indicated that stochastic factors are likely to 
have played a role in masking the descent relationships of the Jewish populations 
(Livshits et al, 1991). 
Modern genetic structure of Jewish populations do not reflect the history of dispersal, 
placing all but two of the Jewish populations in a common cluster, and the fine structure 
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of this cluster does not mirror the known history of these populations (Livshits et al, 
1991). Starting out as a single entity (comparable to other ethnic groups of that time), 
the Jewish people at the beginning of the Diaspora were subdivided into numerous 
populations which became dispersed in the course of dozens of generations to various 
parts of the world. Within each country in which they came to reside the Jews usually 
became nonintermarrying subpopulations. Consequently, a significant contribution of 
stochastic differentiation between populations and inbreeding within populations could 
be expected. The reduction of effective population size in such a set of populations 
may lead to a rapid increase of genetic distances between them, primarily due to the 
decrease of heterozygosity in each of these populations (Chakraborty and Nei, 1977). 
The effect of a bottleneck on average heterozygosity may last for hundreds or even 
thousands of generations after the recovery of population size (Nei, 1987). Thus 
estimates of the descent and branching relationships of populations may be seriously 
distorted by bottlenecks. One way to study this problem is to examine the relationship 
between genetic distance and the average heterozygosity over pairs of populations 
(Livshits and Nei, 1990). The negative correlation between genetic distance and 
heterozygosity of pairs of populations would be expected on condition that the 
populations were derived from the same ancestral stock and at the same historical 
time. But it is also necessary to assume absence of migration, as well as of selection 
after separation (Livshits et al, 1991). Despite the fact that human populations can 
hardly satisfy the above conditions, especially regarding the total absence of migration, 
genetic distance values are strongly negatively correlated with heterozygosity 
estimates. Statistically significant negative correlations between genetic distance and 
heterozygosity were found in separate studies of Caucasoid, Amerindian, and Far 
Eastern Mongoloid populations (Livshits and Nei, 1990). Therefore stochastic factors 
are likely to have played a role in masking the descent relationships of the Jewish 
populations. However, when populations representative of different major races were 
combined, an almost negligible correlation was found, implying that the time after 
splitting of the human species into the major races was long enough to restore equal 
heterozygosity in each stock (Livshits and Nei, 1990). So, the complex structure of the 
cluster of Jewish populations must also be due to the differences in the amount of 
admixture with neighbouring non-Jewish populations, because of both different lengths 
of contact and different rates of admixture. 
3.1.5 Aims and approaches of the study 
Molecular studies of haplotypes and mutations are useful to try to understand the 
mechanisms which lead to the high frequency of genetic disorders in some 
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populations. However, it is difficult in some cases to determine whether the principal 
cause is related to genetic drift or selection. The analysis of mutations and their 
diffusion in isolated populations will help to understand what were the mechanisms 
which lead to the high frequencies of genetic diseases in isolated populations. This 
knowledge should be useful for understanding the cause of the high frequency of 
diseases in larger populations (Zlotogora, 1994). 
Gaucher disease is the most frequent inherited sphingolipid lysosomal storage disorder 
in the Portuguese population. DNA analysis of Portuguese type 1 Gaucher patients 
showed that the N370S mutation accounted for 63% of the glucocerebrosidase 
mutated alleles (Amaral et al, 1993), which was more similar to the described in 
Ashkenazi Jewish type 1 Gaucher patients (72-75%) (Levy et al, 1991; Beutler et al, 
1991), than in the remaining non-Jewish type 1 Gaucher patients, where it accounted 
for 46% (Levy et al, 1991), 39% (Walley et al, 1993) or 25% (Beutler et al, 1991) of the 
mutated glucocerebrosidase alleles. The estimation of the N370S gene frequency in 
the Portuguese population, based on the prevalence of the mutation in patients, would 
be misleading since homozygous for this mutation can present a mild or asymptomatic 
clinical phenotype and escape detection (Beutler et al, 1993). 
• In order to accurately determine the N370S frequency, for the first time in a non-
Ashkenazi population, the DNA of 2000 individuals randomly sampled from the 
Portuguese new-born PKU screening program were genotyped. 
• In order to find hot spots in the Portuguese population, the N370S gene frequency 
was also determined in two restricted populations, Azores Islands and Belmonte 
village. 
It was previously shown that the N370S glucocerebrosidase mutation was invariably 
associated with one haplotype of the intragenic Pvull polymorphism (Zimran et al, 
1990; Beutler et al, 1991). In contrast, mutation L444P (Tsuji et al, 1987), was found to 
be in linkage equilibrium with both forms of this polymorphism (Zimran et al, 1990; 
Beutler et al, 1991). 
• The frequency of each Pvull polymorphic form was first determined in the general 
Portuguese population (where a Sephardic but not an Ashkenazi Jewish 
background is probable) by studying an ethnically homogeneous sample of 
unrelated individuals. Portuguese type 1 Gaucher patients and carriers where then 
studied with regard to linkage between mutations and Pvull polymorphism. 
DNA analysis of Portuguese type 1 Gaucher patients showed that L444P was the 
second most frequent mutation in the Portuguese patients, accounting for 22% of the 
glucocerebrosidase mutated alleles (Amaral et al, 1993). Moreover, although some of 
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the most frequent mutations described in type 1 Gaucher patients had been tested, 
15% of Portuguese patients mutated alleles remained unidentified (Amaral et al, 1993), 
contrasting with the 4% described in Ashkenazi Jewish patients (Beutler, 1992). 
• An enzyme based assay, in which the enzymatic activity was determined per unit of 
cross-reactive glucocerebrosidase protein bounded to a monoclonal antibody 
(Aerts et al, 1991), was applied in the study of Portuguese affected families, 
including the ones carrying known mutations. The reliability of this assay in the 
detection of N370S and L444P mutated proteins was confirmed by DNA analysis. 
3.2 Materials and methods 
3.2.1 Materials 
3.2.1.1 Samples 
Subject population studied for the N370S frequency determination: The Portuguese 
Neonatal Screening Program covers 95% of all the new-borns in Portugal, and all the 
analysis are done at the Instituto de Genética Médica Jacinto de Magalhães. In this 
program blood spots are collected on Guthrie cards and for the present research work 
they were used as a source of DNA. 
For ethical reasons the sampled individuals were not identified. 
Subjects studied with respect to the Pvull polymorphism: DNA was extracted from 
white blood cells or from cultured cells (skin fibroblasts or lymphoblasts) according to 
standard methods (Maniatis et al, 1982; Miller et al, 1988), from the following subjects. 
Type 1 Gaucher patients: Fifteen patients presenting five different genotypes, namely 
N370S/N370S (n=4). N370S/L444P (n=5), N370S/? (n=4), L444P/? (n=1) (Amaral et 
al, 1993), as well as N370S/R463C (n=1). 
Members of Gaucher families: Thirty-eight obligate or possible carriers, being 27 
carriers of the N370S mutation, 4 carriers of the L444P mutation and 7 obligate carriers 
in which the mutated allele remained unidentified. 
Controls: Sixty-four healthy individuals unrelated to Gaucher families, none presenting 
the N370S glucocerebrosidase mutation. 
Subject population studied with the immunobindinq assay: Urine was collected from 15 
patients (2 males and 13 females with ages ranging from 7 to 74 years), 41 family 
members of Gaucher patient's families of both sexes (including 22 obligate carriers and 
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19 relatives designated as "putative carriers") with ages ranging from 6 to 82, and 81 
healthy control subjects of both sexes with ages ranging from 4 to 62 years. 
3.2.1.2 Reagents 
The 4-methylumbelliferyl-p-D-glucoside substrate was purchased from Koch Light 
(Colnbrook, UK) and sodium taurocholate (grade A) was purchased from Calbiochem 
(San Diego, CA). 
Monoclonal anti-placental glucocerebrosidase antibodies were a kind gift from Prof. J. 
Aerts. 
[y.32P]ATP was purchased from Amersham, T4 polynucleotide kinase was purchased 
from New England Biolabs, and Zeta probe membrane was from Bio-Rad. The 
oligonucleotide primers used for DNA amplification where chosen on the basis of the 
published gene and pseudogene sequence (Horowitz et al, 1989), and were 
synthesized by Centro de Citologia Experimental, Porto. Taq polymerase and PCR 
buffer were from Clontech. Xhol and Pvull restriction enzymes and buffer used in the 
digestion reaction were from Pharmacia. Electrophoresis agarose gel NuSieve 3:1 from 
FMC BioProducts was used. All other reagents were of pure grade quality. 
3.2.2 Methods 
3.2.2.1 Portuguese population sampling for the N370S frequency 
determination 
The whole Portuguese population comprised 9.6 in 1993 million persons; a Sephardic 
Jewish ancestry is known (Schmelz, 1970), but not an Ashkenazi one. 
To accurately determine the N370S mutated frequency in the Portuguese population, 
DNA was obtained from dried blood spots randomly collected from the Portuguese 
Neonatal Screening Program. The information on each card is kept in a database, and 
from a total of about 75000 cards, corresponding to 79000 new-boms in the whole 
country for a period of 8 months, a simple random sample of 2000 cards was selected 
through a random number generator. The frequency of individuals selected from the 
different regions in Portugal was compared with the population distribution through a 
chi-squared test. This sampling was executed by Prof. Pedro Oliveira, from the 
Department of Production and Systems Engineering, of Minho University. 
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3.2.2.2 Portuguese Azores islands population sampling 
The Azores islands comprise about 250 thousands inhabitants and are relatively free 
from admixture population. 
To determine the frequency of the N370S mutation in the Azores islands population, 
DNA was obtained from dried blood spots randomly collected from the Portuguese 
Neonatal Screening Program. The information on each card is kept in a database, and 
from a total of 2148 cards, corresponding to about 2285 newborns in this region for a 
period of 8 months, a simple random sample of 279 cards was selected through a 
random number generator. The frequency of individuals selected from the different 
islands was compared with the population distribution through a chi-squared test. 
3.2.2.3 Belmonte population sampling 
Belmonte village comprises 2008 individuals, 95 of them claiming to be part of an 
ancient closed Sephardic Jewish community (Garcia, 1993). 
To determine the frequency of the N370S mutation in Belmonte population, DNA was 
obtained from dried blood spots collected from the Portuguese Neonatal Screening 
Program. The information on each card is kept in a database, and a total of 219 
newborns in a period of 3 years were genotype, corresponding to all the newborns in 
that period. 
3.2.2.4 DNA analysis for the N370S mutation 
The genomic DNA amplification was performed directly from autoclaved dried blood 
specimens on filter paper (reviewed in McCabe 1991). The detection of the N370S 
mutation was done using primers chosen on the basis of gene versus pseudogene 
sequence (Horowitz et al, 1989), the 5'-primer being mismatched at one nucleotide so 
as to create a Xhol restriction site (Beutler et al, 1990, with minor modification) (Figure 
3-1). 
A 4 mm2 piece of dried blood spot on Guthrie cards was cut from each filter and added 
to a 100 \x\ reaction mixture containing 100 pmol of each oligonucleotide primer, 10 
mmol/l Tris-HCI (pH 8.8 at 25°C), 50 mmol/l KCI, 1.5 mmol/l MgCL2, 0.1% Triton X-
100, 5% DMSO (dimethyl sulfoxide) and 0.2 mmol/l of each deoxynucleotide 
triphosphate (Saiki et al, 1988). The contents of the reaction tube were denatured at 96 
°C for 15 minutes in a Bio-Med Thermocycler 60. Two units of Taq polymerase were 
then added to each tube, and 30 cycles of PCR amplification consisting of 94°C for 1 
min, 55°C for 2 min and 72°C for 3 min were done. The products were cooled and next, 
38.9p.l aliquots of each reaction mixture were digested by 16.5 units of Xhol restriction 
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enzyme in a 50u.l reaction mixture containing 20 mmol/i Tris-acetate (pH 7.5), 20 
mmol/l magnesium acetate, and 100mmol/l potassium acetate. The digested fragments 
were then subjected to electroforeses in 3% NuSieve 3:1 agarose gels in 1 x TBE (Tris-
Borate-EDTA, pH 8.0) for 3 hours at 60 V. The PCR products were then visualised by 
ethidium bromide staining and exposure to U.V. light. 
Amplified fragment of 118 base pairs from the genomic nucleotide 5820 to 5938: 
5820^Upstream primer^-5840 _____^^^2Í!ÍÍ!Í^J^I^!^^^ 
intron 8 " exon 9 
Oligonucleotide antisense primer (20):  
5GATGGGACTGTCGACAAAGT3' Downstream 5919-5938 (exon 9) fragment 
Oligonucleotide sense primer (21 mer):  
5TGCCTTTGTCCTTACCCTCGA3' Upstream 5820-5840 (intron 8) fragment 
A to C mismatch PCR 
Wild sequence 5TGCCTTTGTCCTTACCCTAGA3, 
Amplified sequence by mismatched PCR STGCCTTTGTCCTTACCCTCGAS' 
Restriction digestion: 
Xhol cut 
It 
C TCGAG Xhol recognised sequence 
* 
A to G substitution in mutated alleles 
Figure 3-1 
DNA analysis of the N370S mutation. Amplified fragment, oligonucleotide primers and Xhol restriction 
digestion. 
3.2.2.5 DNA analysis for the Pvull polymorphism 
The genomic DNA was amplified in the region between nucleotides 3003 and 4086 
with genomic sense primer 3003-3026 and antisense primer 4068-4086. The amplified 
sequence contains two Pvull restriction sites as well as the polymorphic site at position 
3931 (Zimran et al, 1990) (Figure 3-2). 
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Amplified fragment of 1083 base pairs from the genomic nucleotide 3003 to 4086: 
3003->L)pstream primer<-3026 4068^D^wstneamprimer^40^6 
intron 4 intron 6 
Oligonucleotide antisense primer (19 mer): 
5TCCACTTTCTTGGCCGGAT3N Downstream 4068-4086 (exon 4) fragment 
Oligonucleotide sense primer (23 mer): 
OXTCGGACTACCATATCTTGATCAS' Upstream 3003-3026 (intron 6) fragment 
Restriction digestion: 
Pvull cut 
(I 
CAG CTG Pvull recognised sequence 
* 
G to A substitution in polymorphic 3931 nucleotide 
Figure 3-2 
DNA analysis of the Pvull polymorphysm. Amplified fragment, oligonucleotyde primers and Pvull 
restriction digestion. 
Genomic DNA (1 u.g) was added to 100 u,l of reaction mixture containing 100 pmol of 
each oligonucleotide primer, 10 mmol/l Tris-HCI (pH 8.8 at 25°C), 50 mmol/l KCI, 1.5 
mmol/l MgCl_2, and 0.2 mmol/l of each deoxynucleotide triphosphate (Saiki et al, 
1988). The contents of the reaction tube were denatured at 94°C for 6 minutes in a Bio-
Med Thermocycler 60. Three units of Taq polymerase were then added to each tube, 
and 30 cycles of PCR amplification consisting of 94°C for 45sec and 66°C for 6 min 
were done. The products were cooled and next, 2000ng of amplified DNA of each 
reaction mixture were digested by 5 units of Pvull restriction endonuclease enzyme in a 
30u.l reaction mixture containing 20 mmol/l Tris-acetate (pH 7.5), 20 mmol/l magnesium 
acetate, and 100mmol/l potassium acetate. The digested fragments were then 
subjected to electroforeses in 3% NuSieve 3:1 agarose gels in 1 x TAE (Tris-Acetate-
EDTA, pH 8.0) for 3.5 hours at 2 V/cm. The PCR products were then visualized by 
ethidium bromide staining and exposure to U.V. light. 
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3.2.2.6 Statistical analysis 
In order to estimate the overall prevalence of N370S allele in each of these restricted 
areas, it was weighted the observed prevalence in each area by the population of the 
area based on the census. 
3.2.2.7 Concentration of urine samples 
Freshly voided urine from healthy individuals and patients with type 1 Gaucher disease 
was collected in the morning, cooled to 0 CC and concentrated 20-fold by ammonium 
sulfate precipitation, as follows. To the urine, solid ( N H ^ S G ^ was added to 70% 
saturation. After stirring for 0.5 hours, the suspension was centrifuged at 50,000xg 
during 0.5 hours at 4°C, and the precipitate was taken up in distilled water and dialyzed 
overnight against distilled water. Any precipitate formed was removed by centrifugation 
at 10,000xg for 0.5 hours (Aerts, 1988). 
3.2.2.8 Measurement of glucocerebrosidase activity per amount of antigen 
The relative enzymatic activity of glucocerebrosidase, defined as the enzymatic activity 
per unit of antigen, was determined according to the following: 
An identical amount of rabbit anti-(mouse IgG) prepared in PBS (phosphate buffered 
saline ) was coated to each well (0.45u.g/well) of a microtitre plate by incubation for 1 h 
at 37°C. Next, an identical amount of anti-glucocerebrosidase monoclonal antibody 
8E4 (Barneveld et al, 1983) prepared in PBS was coated on each well (62.5 ng/well) by 
incubation for 16 hours at 4°C. Unbound antibody was removed by washing in PBS 
containing 0.05% (v/v) Tween-20. Concentrated urine containing excess amount of 
glucocerebrosidase protein was previously diluted in 50/100 mmol/l citric acid/sodium 
phosphate buffer (pH 5.2) containing 10g/l ovalbumin and 0.25% (v/v) Triton X-100, to 
a a-glucosidase activity of 300 nmol/h/ml. The enzyme binding assay was made by 
incubation overnight at 4°C and for 2 hours at room temperature the antibody with 
serial dilutions of the excess amount of glucocerebrosidase added to the first wells. 
After washing the unbound material, the maximal bound glucocerebrosidase activity for 
each extract was measured by incubating the wells for 2 hours at 37°C with 4-MU-p-
glucoside (3.7 mmol/l), at pH 4.5 and 5.2 (100/200 mM citric acid/sodium phosphate 
buffer), in the presence of 0.2% (w/v) sodium taurocholate and 0.1% Triton X-100 
(Aerts et al, 1990a). The reaction was stopped by addition of excess glycine/NaOH (pH 
10.0) and the 4-methylumbelliferone formed was measured fluorimetrically. The 
released fluorescence was compared with that of standards, being measured with a 
excitation and emission wavelength of respectively 365 and 445nm (fluorescence read 
on a Titertek plate spectrofluorometer). Standards used for the calibration curve were 
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prepared from a solution of 10mmol/l 4-MU in cloroform/methanol (2:1). For each 
sample the bound activity was determined as the mean of triplicate assays. Results of 
each serious of measurements were algebrically calculated by using the linear 
regression parameters corresponding to the calibration curve. 
Since the affinity of N370S mutant and control glucocerebrosidase for binding to 8E4 is 
similar (as checked by mixing experiments) (Aerts et al, 1990a) the activity that is 
bound to identical amounts of antibody is directly proportional to the enzymatic activity 
per identical amount of antigen. 
3.3 Results 
3.3.1 Frequency of the N370S mutated glucocerebrosidase gene in 
the general Portuguese populat ion 
In order to accurately determine the N370S frequency, for the first time in a non-
Ashkenazi population, the DNA of 2000 individuals randomly sampled from the 
Portuguese newborn PKU screening program were genotype by direct PCR 
amplification of DNA obtained from dried blood spots on Guthrie cards. The digestion 
of the 118 bp PCR amplified fragment encompassing an A to G substitution in exon 9, 
yields 101 bp and 17 bp fragments (Table 3-1). 
Table 3-1 
DNA analysis of the N370S mutation: Expected fragments upon Xhol digestion. 
Undigested Digested 
Wild type Homozygous 
mutant 
Heterozygous 
mutant 
Expected 
fragments 
118bp 118bp 
101bp 
17bp 
118bp 
101bp 
17bp 
In Figure 3-3 the detection of this mutation is exemplified. Non-carriers present the 
non-digested 118 bp band and carriers display the 118 bp band corresponding to the 
normal allele and the products of the cleaved band (101 and 17 bp fragments). Each 
set of 40 PCR amplifications and digestion reactions included a double hétérozygote 
patient; PCR amplification was done using master mix reaction mixture. 
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Figure 3-3 
Ethidium bromide-staining patterns of DNA fragments obtained by PCR amplification genomic DNA 
blood spots. Master mixture without DNA and the double hétérozygote patient DNA amplifications are 
also included in each experiment. Fragment sizes are shown on right. DNA samples from normal 
individuals show only the uncut 118bp fragment. Heterozygous for the N370S mutated allele shows both 
the 118bp and 101 bp fragments. M, molecular weight markers; H, hétérozygote for the N370S mutated 
allele. 
Seventeen heterozygous and no homozygous for the N370S mutation were identified 
(Table 3-2). The frequency of this allele was found to be 0.0043 with 95% confidence 
limits between 0.0023 and 0.0063. On the basis of the obtained gene frequency the 
number of homozygous predicted by the Hardy-Weinberg (Emery, 1976) equation 
should be 1 in 55000, i.e. about two hundred homozygous when considering a total 
Portuguese population of 107 individuals. 
Table 3-2 
Frequency of N370S mutated allele in the Portuguese population 
Observed Expected* 
Total individuals 2000 2000 
Heterozygous 17 16.9 
Homozygous 0 0.036 
Gene frequency 0.0043 
* Calculated by the Hardy-Weinberg equation for 0.0043 gene frequency. 
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3.3.2 Frequency of the N370S mutated allele in relatively c losed 
populat ions: Azores islands and Belmonte 
To test whether major differences of the N370S allele frequency in Portuguese sub-
populations exist, the incidence of this mutated allele in individuals from two selected 
areas was examined: the Azores islands and the Belmonte village (which have an 
ancient Sephardic Jewish community). 
Among 379 randomly sampled Azores islands new-borns, 4 heterozygous and no 
homozygous for the N370S mutated allele were identified (Table 3-3). The frequency of 
this mutated allele was found to be 0.0053, with 95% confidence limits between 0.0001 
and 0.0104. Due to the overlapping of confidence intervals this frequency is not 
statistically significantly different from the frequency of the general population. 
Table 3-3 
Frequency of the N370S mutated allele in the Azores islands. 
Studied individuals Mutated alleles/ 
total alleles 
Frequency 
Azores islands 379 4/758 0.0053 
Total Portuguese 2000 17/4000 0.0043 
All newborns from Belmonte were genotyped for this mutated allele during a period of 3 
years and 4 non-related heterozygous were found. As it can be observed in the Table 
3-4, in the second studied year it was observed a relative high number of N370S 
mutated alleles. If assumed that in this population the N370S frequency is the same as 
that in the general Portuguese population, this number is significantly different, since 
the probability of observing a value equal or higher is 4.9%. However, this value must 
be taken with caution due to the variation over the other studied years. 
Table 3-4 
Frequency of the N370S mutated allele in the newborns of Belmonte . 
Total newborns Mutated alleles/total alleles Frequency 
1 s t year 83 0/166 0 
2nd year 93 3/186 0.0161 
3rd year 43 1/86 0.0116 
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3.3.3 Linkage analysis between the N370S mutated allele and the 
intragenic Pvull polymorphism 
A restriction fragment length polymorphism for the enzyme Pvull, due to a G-»A 
substitution at genomic DNA nucleotide 3931 in intron 6 of the glucocerebrosidase 
gene, is responsible for the presence (Pv1.1+) or absence (Pv1.1") of a 1.1 kb genomic 
glucocerebrosidase DNA fragment upon Pvull digestion (Sorge et al, 1985a; Zimran et 
al, 1990). 
In order to determine the Pvull haplotype of the Portuguese GD mutated alleles, 
genomic DNA was genotyped by PCR amplification and restriction enzyme analysis. 
The digestion of the 1083 bp PCR amplified fragment yields a 983, a 72 and a 28 bp 
fragments (designated in literature as Pv1.1" haplotype); samples encompassing an 
G->A substitution in intron 6 (the Pvull polymorphic site) yields the 857 bp and 126 bp 
digestion fragments instead of the 983 bp band (here designated as Pv1.1+ haplotype) 
(Table 3-5). 
Table 3-5 
DNA analysis of the Pvull polymorphism: Expected fragments upon Pvull digestion 
Undigested Digested 
Pvi.i7Pvi/r Pv1.17Pv1.1+ Pv1.1+/Pv1.1+ 
1083bp 983 983 
Expected 857 857 
fragments 126 126 
72 72 72 
28 28 28 
In Figure 3-4 it is exemplified the detection of this mutation. Pv1.1" samples present the 
non-digested 983 bp band; in Pv1.1+ samples it can be observed the products of this 
cleaved band (857 and 126 bp fragments). 
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Figure 3-4 
Ethidium bromide-staining patterns of DNA fragments obtained by PCR amplification genomic DNA 
samples. Master mixture without DNA and the double Pv1.1-/Pv1.1+ genotype amplification are also 
included in each experiment. Fragment sizes are shown on right. DNA from Pv1.1- haplotypes show only 
the uncut 983 bp fragment. Pv1.1-/Pv1.1+ haplotypes show both the 983 bp and the 857 bp fragments. M, 
molecular weight markers; U, undigested 1083 bp fragment. 
Table 3-6 presents the Pvull genotype of 15 type 1 Gaucher patients and 38 carriers. 
The frequency of the Pv1.1" and Pv1.1 + alleles in individuals carrying the N370S or the 
L444P mutation in one allele is compared with the frequency determined in the 
Portuguese control. As can be observed in the table, the four homozygous for the 
N370S mutation presented a Pv1.17Pv1.1" genotype; all the heterozygous patients 
(n=10) for this same mutation presented at least one Pv1.1" allele. The R463C mutation 
present in a compound hétérozygote is therefore presumably associated with the 
Pv1.1+ haplotype. The L444P mutation found to be present in six of the patients studied 
appeared either in Pv1.1+ (n=1) or Pv1.1" (n=5) alleles. Mutated alleles with as yet 
unidentified glucocerebrosidase mutations were either Pv1.1+ or Pv1.1". The results 
obtained with the Pvull polymorphism study in the Portuguese controls (64 Caucasian 
individuals, not carrying the N370S mutation) showed 0.836 and 0.164 frequencies for 
the Pv1.1' or Pv1.1+ alleles, respectively, in contrast to the corresponding 0.647 and 
0.353 allele frequencies previously described as an average of different racial groups 
(Sorge et al, 1985a). Frequencies of 0.92 and 0.080 for the Pv1.1" or Pv1.1+ alleles, 
respectively, were obtained in the 37 individuals carrying the N370S mutation in one 
allele (10 double heterozygous and 7 carriers) (Table 3-6). 
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Table 3-6 
Pvull haplotype of genotype of type 1 Gaucher patients, carriers and controls. 
Pvull genotype Gene frequency 
-/- +/- +/+ Pyl.1" Pv1.1+ 
Patients per genotype 
4 N370S/N370S 
5 N370S/L444P 
4 N370S/? 
1 L444P/? 
1 N370S/R463C 
4 0 0 1.00 0.00 
5 0 0 1.00 0.00 
2 2 0 0.75 0.25 
0 0 1 0.00 1.00 
0 1 0 0.50 0.50 
Carriers per genotype 
27 N370S 
4 L444P 
7 ? 
24 3 0 0.94 0.06 
2 2 0 0.75 0.25 
3 3 1 0.64 0.36 
N370S heterozygous per genotype 
37 N370S/X 31 6 0 0.92 0.08 
L444P heterozygous per genotype 
5 L444P/Y 2 2 1 0.60 0.40 
Unrelated individuals 
64 Controls 
Expected <b) 
43 21 0 0.836 0.164 
44.7 17.6 1.7 
"?" indicates that none of the tested mutations were present. 
"X" indicates normal or mutated alleles with the exception of L444P. 
"Y" indicates normal or mutated alleles with exception of N370S. 
(t>) The expected number of cases based on Hardy-Weinberg equilibrium. 
3.3.4 Identif ication of Gaucher disease carriers in affected famil ies 
and control populat ion of the same geographic area: 
glucocerebrosidase antigen and DNA analysis 
The activity of hydrolases in urine samples, like those in blood cells and tissues, differ 
between individual control subjects, but the pattern of hydrolase activities was very 
constant in morning urine (Aerts et al, 1986b). Urinary glucocerebrosidase was found 
to originate almost entirely from turnover of proximal tube epithelial cells rather than 
being directly secreted in a precursor form into urine (Aerts et al, 1986c). 
Serial dilutions of a concentrated urine sample were added to wells containing identical 
amounts of immobilised anti-glucocerebrosidase monoclonal antibody 8E4. After 
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washing, the activity of the bound glucocerebrosidase was measured. In Figure 3-5 the 
bound glucocerebrosidase activity is related to the input of urine sample expressed as 
equivalents of acid a-glucosidase activities in the incubations. Curve 1 represents a 
urine sample of a control subject and curve 2 that of a carrier for N370S 
glucocerebrosidase. It can be seen that at similar input of a-glucosidase activity a 
maximum is reached for glucocerebrosidase binding in both samples. This indicates 
that a similar amount of glucocerebrosidase antigen is present in both preparations. In 
the case of the carrier sample the maximal bound activity is about half of that obtained 
for the control subject. This difference is due to the fact that about half the 
glucocerebrosidase antigen of the carrier sample represents enzyme with very low 
specific activity. Curve 3 represents a sample of a carrier for the L444P mutation which 
leads to a rapidly degraded enzyme. It can be seen that a higher input of urine (a-
glucosidase equivalents) is required to reach maximal binding, indicating that indeed 
less glucocerebrosidase antigen is present in the sample of the L444P 
glucocerebrosidase carrier. The maximal bound activity can be, however, near normal 
due to the fact that the sample contains only glucocerebrosidase molecules with 
normal specific activity. 
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Figure 3-5 
Glucocerebrosidase activity per amount of antigen of controls and carriers for the N370S and 
L444P mutations. Urines were concentrated equally by volume and the different lines represent serial 
dilutions of a control (curve 1), a N370S carrier (curve 2) and a L444P carrier (curve 3). a-Glucosidase 
activity corresponding to each dilution is marked along the X axis. 
By investigating enzyme binding curves from a large number of obligate carriers, we 
established that when an input of urine equivalent to 300 nmol/h of a-glucosidase 
activity is used, the discrimination between control subjects and carriers for the two 
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mutations is optimal. However it must be noticed that the ranges of fixed 
glucocerebrosidase activity values for both carriers and controls, may depend on the 
described (Aerts et al, 1991) individual heterogeneity in the amount of a-glucosidase 
secreted into urine. This was overcome by using serial dilutions of each sample. 
Urine samples from 15 type 1 Gaucher disease patients, 41 relatives (22 obligate 
carriers and 19 putative carriers), and 83 controls were tested with the enzyme binding 
assay (EBA) procedure. In Figure 3-6 the frequency distribution of the results is 
depicted. It can be seen that the data distribution is non-Gaussian. This phenomenon 
has been observed earlier (Aerts et al, 1991) and is most likely due to the 
heterogeneous a-glucosidase secretion. All patients are clearly distinguishable from 
the healthy controls. An overlapping zone can be observed between control and type 1 
Gaucher families (obligate and putative carriers) EBA values. 
14 -i 1 
Class number 
D patients H obligate and putative carriers ■ controls 
Figure 3-6 
Histogram of glucocerebrosidase activity per amount of antigen of urine from controls, GD 
patients, obligate and putative carries. Every class has a range of 50 units of glucocerebrosidase 
activity, which is within 2x the mean range of the triplicate readings. 
Obligate and putative carriers as well as controls presenting low EBA values were 
screening for the N370S and L444P glucocerebrosidase mutations. The DNA analysis 
results are presented in Figure 3-7 and Figure 3-8. With the exception of one obligate 
carrier for an unidentified mutation (class 16) all the others ranged between classes 4 
and 13 (Figure 3-7). 
Four of the nine healthy controls presenting EBA values within and below class 13 
proved to be carriers for the N370S mutation (marked with green in Figure 3-8). The 
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remainder did not present either of the two mutations. On the basis of these results the 
overlapping range was considered to comprise EBA frequency classes 11-13. 
Figure 3-8 also shows the DNA results of 19 putative carriers. From the 14 cases 
presenting EBA values in the obligate carrier range (below class 11), 9 carried the 
N370S glucocerebrosidase mutation. The remainder (all from families where an 
unknown allele was present) had neither of the tested mutations. 
Obligate carriers 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
Class number 
QN370S carrier DL444P carrier ■neither mutation present 
Figure 3-7 
Comparison of genotype results obtained by DNA analysis of the N370S and L444P mutations and 
the results obtained with the enzyme binding assay of obligate carriers. 
Putative carr iers and cont ro ls 
HN370S carrier DN370S carrier "control" subject ■ neither mutation present 
Figure 3-8 
Comparison of genotype results obtained by DNA analysis of the N370S and L444P mutations and 
the results obtained with the enzyme binding assay of GD putative carriers and control subjects. 
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Healthy individuals sampled in the general population, but in which the N370S mutation was found to be 
present, are also indicated. 
The results obtained with carrier identification using EBA procedure and DNA analysis 
showed that when considering an EBA cut-off value corresponding to class 13 (Figure 
3-7 and Figure 3-8), all carriers for N370S and the L444P mutations were detected. 
Five controls can be considered to be misclassify as carriers on the basis of the two 
glucocerebrosidase gene mutations analysed. No definitive statement can be made 
when unknown glucocerebrosidase gene mutations are also considered. Nevertheless, 
one can say that by using class 13 as cut-off value, five obligate carriers for unknown 
mutation(s) were detected and only one was lost. Therefore, it can be expected that a 
significant proportion of the 9 putative carriers for these mutations are also "true" 
carriers. Considering the probability density functions corresponding to confirmed 
carriers (carriers of either N370S or L444P and obligate carriers for unidentified 
mutations) and controls, a probability below 1% of misclassifying a control as a carrier 
can be calculated for results below class 11, and so these individuals should be 
considered as carriers; a probability below 2% of misclassifying a carrier as a control 
can be calculated for results above class 13. Eleven individuals presented results 
between classes 11 and 13 - one obligate and one putative carriers for unidentified 
mutation(s), four N370S carriers, and five controls not carrying either N370S or L444P 
mutations. In this class range the probability of misclassifying a control as a carrier 
varies from 1% (class 11) to 8% (class 13) and the probability of misclassifying a 
carrier as a control varies from 18% (class 11 ) to 2% (class 13). 
3.4 Conclusions 
Glucocerebrosidase activity per amount of cross-reacting activity recognised by a 
monoclonal antibody, was determined in urine samples from type 1 Gaucher disease 
patients, obligate carriers, putative carriers and controls. The reliability of this enzyme 
binding assay (EBA) for the detection of carriers, in a population where 15% of mutated 
alleles remain unidentified, was tested by DNA analysis for two most frequent mutated 
alleles in Portuguese patients (N370S and L444P). All N370S and L444P carriers were 
distinguished from healthy controls but an overlapping zone was observed between 
values of controls, obligate carriers and putative carriers for unknown mutations. Of the 
six obligate carriers for an unknown mutant allele, only one was not identified. So, this 
EBA assay may be used in the identification of carriers for most unidentified mutant 
alleles, since it should detect carriers for any mutation affecting the glucocerebrosidase 
enzymatic activity or the amount of protein (cross reacting material). Individuals 
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presenting a result in the overlapping range comprising classes 11-13 must however 
be extensively studied at the DNA level (tested for other mutations, SSCP analysis, 
sequencing) to exclude the presence of a mutated glucocerebrosidase allele. 
The frequency of the causual type 1 GD most common mutated allele (N370S) was 
determined in the Portuguese population. On the basis of the obtained gene frequency 
of 0.0043, the number of homozygotes calculated by the Hardy-Weinberg equation 
should be about 1 in 55 000 individuals, although only 15 N370S homozygous patients 
have been identified till now. The obtained value for the N370S frequency in the 
general Portuguese population was also found to be about 7-fold lower than that 
described in the Ashkenazim, but the survey of the general Portuguese population 
could not detect "hot spots" with a high frequency of carriers. The EBA screening of 
control individuals from areas with known incidence of GD revealed however a 
remarkably high local frequency of the N370S mutated allele (0.024, value which is 
close to the 0.032 described in the Ashkenazi Jewish population. However the number 
of tested individuals (n=83) was small. By this reason, the hypothesis was tested that, 
like in Ashkenazi Jews, in the Portuguese population within restricted areas, a high 
frequency of the N370S mutation could have been maintained due to a certain degree 
of inbreeding. The results obtained in DNA analysis of the restricted area of Azores 
islands population, showed however that although the obtained frequency value is 
slightly higher than is the one observed for the general Portuguese population, there 
were no significant differences (respectively 0.0053 and 0.0043). Regarding the 
Belmonte population study (which included the closed small community of individuals 
claiming a Sephardic Jewish ancestry) the determined N370S allele frequency was 
found to be higher than that in the general population, but still not statistically significant 
(0.0091). No conclusion can however be drawn with respect to the Jewish ancestry to 
the newborns presenting a mutated allele, since for ethical reasons this study 
employed only coded samples. 
The incidence of the N370S mutation is also interesting in the light of the origins of the 
Portuguese population, where a Sephardic rather than an Ashkenazi background has 
been ascribed. In this study, the N370S glucocerebrosidase mutated allele in the 
Portuguese type 1 Gaucher patients was found to be invariably associated with the 
Pv1.1" form of the intragenic Pvull polymorphism, as it was reported for other patients. 
A common Jewish origin for the N370S glucocerebrosidase allele in Ashkenazi Jews 
and in Portuguese can, theoretically, be advanced although the possibility that this 
mutation occurred by an independent event cannot be excluded since the Pv1.1" 
haplotype was found to be the most common in the Portuguese population. 
64 
Chapter 4 
Activity of glucocerebrosidase extract from cells 
of type 1 Gaucher disease patients with different 
genotypes 
4.1 Introduction 
4.1.1 The glucocerebrosidase protein 
Heterologous expression in eukaryotic cells of human cDNAs encoding normal and 
mutant glucocerebrosidases was performed to characterize these enzymes with 
respect to catalytic properties, stability, inhibitor binding and modifier interactions 
(Ohashi et al, 1991; Grace et al, 1994). Kinetic studies have indicated effector binding 
sites on the enzyme for negatively charged lipids and protein activators. These 
effectors induce conformational changes and enhance catalytic activity. Based on the 
effects of the mentioned modifiers of glucocerebrosidase activity it was proposed that 
the active site of glucocerebrosidase consists of three subsites: the hydrophilic glycon-
binding site; the aglycon-binding site for interaction with the fatty acid-acyl chain of 
glucosylceramide; and a site for interaction with the sphingosyl moiety of 
glucosyiceramide (Osiecki-Newman et al, 1987) (Figure 4-1). G lu 3 4 0 was identified as 
the catalytic nucleophile in the active site of glucocerebrosidase (Miao et al, 1994). The 
critical importance of the catalytic nucleophile and the surrounding structure for enzyme 
activity is also reflected in the fact that G lu 3 4 0 is located in the sequence within the 
longest stretch of 100% amino acid identity (315-375) between the human and murine 
enzymes (O'Neil et al, 1989). 
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Figure 4-1 
Proposed schematic for the active site of acid (3-glucosidase containing the major natural 
substrate, glucosylceramide. The designated amino acids may function as the proton donor (Asp358, 
putative) and the Br-conduritol B epoxide binding site (Asp443). Asn370 is important for determining the 
specificity of interaction at the active site and N370S is the most frequent substitution in Gaucher disease 
genes. The sphingosyl moiety is usually an octadecene but chain lengths vary from 16 to 22. The fatty acid 
acyl moiety chain length varies from 16 to 24 carbons and is dependent on the tissue source. Cleavage of 
the bond at the anomeric carbon releases glucose with retained [3 configuration. (Adopted from Beutler and 
Grabowski, 1997). 
Mutations in genes encoding lysosomal hydrolases like glucocerebrosidase gene may 
result in the reduction of the in vivo enzyme activity in a number of ways. Missense 
mutations in the structural gene may affect substrate binding (Km variants) or the 
turnover rate of the substrate (V m a x mutations) or both. Base pair insertions or 
deletions in the DNA may lead to frame shift mutations that potentially result in the 
formation of an incomplete protein devoid of any catalytic activity. Other mutations may 
result in enhanced degradation of newly synthesized protein in the rough endoplasmic 
reticulum or in lysosomes. Some other mutations may alter the solubility properties of a 
polypeptide (Praia and Neufeld, 1982) or may result in impaired post-translational 
modification leading to incorrect compartmentalization or secretion, enhanced 
degradation, or impaired function in the lysosomes (Ginns et al, 1982). Disturbances of 
posttranslational modification may, of course, also result from an abnormality of one of 
the enzymes required for this process (Conzelmann and Sandhoff, 1983/84). Mutations 
may also result in an altered transcription rate, splicing or stability of the mRNA. 
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4.1.2 Properties of the mutated glucocerebrosidases presented by the 
Portuguese Gaucher disease patients 
4.1.2.1 The N370S mutated glucocerebrosidade 
The properties of the N370S mutated glucocerebrosidase have been investigated by 
site-directed mutagenesis of human cDNA followed by transfection in insect or murine 
cells (Grace et al, 1990; Ohashi et al, 1991; Grace et al, 1994). It was shown that this 
mutant enzyme is synthesised in near normal amounts, is efficiently transported to 
lysosomes, shows a normal intralysosomal stability, and is as stable to heating as the 
normal enzyme. However, the kinetic properties are altered, presenting low activity 
toward an artificial or natural substrate (Grace et al, 1990) and abnormal interaction 
with active site-directed inhibitors (which localizes this residue to the glycon binding 
region of the active site) (Grace et al, 1994). The concentration of inhibitor which 
results in a 50% decrease of initial enzyme activity is increased 2.5-7 fold. In studies 
where the expression of this mutant cDNA was performed in human HeLa cells using a 
vaccinia virus derived expression system, the Km of the enzyme towards the artificial 
substrate 4-MU-|3-D-glucopyranoside was shown to be close to that of the normal 
enzyme (0.35 versus 0.67mmol/l, respectively). However, V m a x of the mutant enzyme 
was 0.029 compared to 0.4 mmol/h/mg of protein of the normal enzyme (Horowitz and 
Zimran, 1994a) and the glucocerebrosidase activity against the artificial substrate was 
13-25% of the normal activity (Pasmanik-Chor et al, 1995). Furthermore, when 
compared to the normal enzyme this mutant enzyme was shown to be poorly 
stimulated by the physiological activators saposin C while being stimulated to a greater 
extent by phosphatidylserine (Ohashi et al, 1991). However other authors reported that 
the catalytic efficiency was highly dependent on the association with a combination of 
saposin C and phosphatidylserine. In these conditions and provided this mutated 
glucocerebrosidase is able to operate at a sufficiently acid pH, it can be reactivated in 
vitro to near-normal activity (Aerts et ai, 1990b; van Weely et al, 1993b). 
4.1.2.2 The L444P mutated glucocerebrosidade 
Analysis of the human glucocerebrosidase with the L444P mutation expressed in 
murine fibroblasts has revealed that the mutant enzyme is synthesised in normal 
amounts, but is unstable (Ohashi et al, 1991) being the most part degraded 
prelysosomally (Willemsen et al, 1987). Overexpression of the mutant gene in Sf9 
insect cells resulted in the synthesis of enzyme in amounts comparable to normal; the 
observation of several additional smaller bands was interpreted as degradation 
products and the enzyme was described as unstable. In addition the authors reported 
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very low catalytic activity and poor stimulation by saposin C and phosphatidylserine, 
which was considered to indicate that the enzyme sites for interaction with these 
activators were within the carboxyl terminal of the protein (Grace et al, 1994). In 
contrast, expression of this mutated enzyme cDNA in human HeLa cells using a 
vaccinia virus derived expression system, resulted on a stable mutant protein 
presenting an enzyme activity against the artificial substrate with 13-25% of normal 
activity (Pasmanik-Chor et al, 1995). Its Km toward the artificial substrate was found to 
be close to that of normal enzyme (0.35 and 0.67 mmol/l, respectively), the Vmax being 
however much lower for the mutant enzyme (0.03 versus 0.4 mmol/h/mg of protein for 
the normal). 
4.1.2.3 The IVS2+1 mutated glucocerebrosidade 
The IVS2+1 mutation is a splice site mutation. Due to a G to A transition of the first 
nucleotide of the second intron of the active glucocerebrosidase gene, the 5'donor 
splice site is destroyed. This mutant allele directs synthesis of low levels of aberrant 
mRNAs. One of these mRNAs lacks exon 2 while the other lacks exon 2 and 115 
bases of the third exon. These mRNAs do not direct synthesis of active enzyme (He 
and Grabowski, 1992). 
4.1.2.4 The R463C mutated glucocerebrosidade 
The R463C mutant protein is less thermostable but presents an active site with similar 
behavior to that observed for the normal glucocerebrosidase (as indicated by Ki for 
glucosphingosine and the concentration of the irreversible inhibitor conduritol B 
epoxide (CBE) required to achieve 50% inhibition of enzyme activity). Being the 
specific activity of this mutant protein about 40% of normal, and since the activity is 
poorly stimulated by saposin C and phosphatidylserine, this was considered to be the 
first example of a refractory response to saposin stimulation as a cause for GD (Ohashi 
et al, 1991). 
4.1.2.5 The RecNcil and RecTL mutated glucocerebrosidades 
The expression of the complex alleles recNcil (L444P, A456P and V460V) and recTL 
(D409H, L444P, A456P and V460V) mutated cDNAs in human HeLa cells using the 
vaccinia virus derived expression system, produced enzymes with very low enzymatic 
activity against an artificial substrate (4.3% of normal activity) (Pasmanik-Chor et al, 
1995). Since the D409H, L444P and A456P mutations are very unfavorable aminoacid 
substitutions, this may lead to the observed decrease in proteolytic stability which 
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results in transient presence or rapid degradation of the expressed mutant enzymes 
(Grace et al, 1994). 
The properties of the above mentioned mutated enzymes are summarised in Table 4-1. 
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4.1.3 Enzymatic activity: physiological , nonphysiological activators 
and inhibitors 
Glucocerebrosidase is optimally active at pH values below 6.0; however the exact pH 
optimum strongly depends on the nature of activators and detergents present (Aerts et 
al, 1990b; Sá Miranda, 1992). Glucocerebrosidase is reversibly inactivated by 
extraction with neutral detergents (e.g. Triton X-100); negatively charged detergents 
such as bile salts (e.g. taurocholate, a potent stimulator of many enzymes that 
hydrolise glycosphingolipids) (Wenger et al, 1978) or anionic lipids (e.g. 
phosphatidylserine) are required for its reactivation in vitro (Aerts et al, 1990b; Sá 
Miranda, 1992). 
The small heat-stable glycoprotein saposin C (Radin and Berent, 1982) is abundant in 
GD patients spleen and immunoelectronmicroscopic studies on the subcellular 
localization demonstrated association of the this activator protein with the lysosomal 
membrane (Paton et al, 1990). This protein has been shown to activate purified 
glucocerebrosidase in vitro provided that acidic phospholipids such as 
phosphatidylserine are also present in the assay; evidence exists that this protein does 
not facilitate enzymatic activity of glucocerebrosidase by dispersion of substrates or 
products, but functions via direct interaction with the hydrolase (Radin and Berent, 
1982; Aerts et al, 1990; Sá Miranda et al, 1990; Sá Miranda, 1992). Acidic lipids are 
also capable of inducing aggregation and activation of glucocerebrosidase, although to 
a lesser extent than saposin C. Using phosphatidylserine-containing vesicles it has 
been found that saposin C is also capable of destabilizing and fusing phospholipid-
containing bilayers, thereby creating a situation by which glucocerebrosidase can insert 
into the membranes and subsequently be enzymatically active towards its substrate 
(Vaccaro et al, 1994) 
Conduritol B-epoxide (CBE) is an effective and irreversible inhibitor of lysosomal 
glucocerebrosidase that bind via an ester bond with aspartate residues in the active 
site and can be used to inactivate the enzyme both in vitro and in the intact cell 
(Grabowski et al, 1985) (Figure 4-2 and Figure 4-1). This inhibitor is analogous in 
structure to the transition state of gluconolactone formed during hydrolysis of 
glucocerebroside and binds with 1:1 stoichiometry (Dinur et al, 1986). The use of this 
inhibitor allows the discrimination between the degradation of substrate by lysosomal 
and nonlysosomal glucocerebrosidase. 
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Figure 4-2 
Model for the transition state of the first step of p-glucoside hydrolysis by p-glucosidases. 
(Adopted from Legler, 1988). 
Figure 4-3 
Reaction of conduritol B epoxide with (l-glucocidase. (Adopted from Legler, 1988). 
4.1.4 Aims and approaches of the study 
No correlation has been found between the clinical manifestation of type 1 Gaucher 
disease and the residual activity of glucocerebrosidase in extracts from various cell 
types and tissues, when measured in the presence of the activator sodium taurocholate 
(method currently used in diagnosis) (Peters et al, 1976; Daniels et al, 1981). 
Complexes of glucocerebrosidase and SAP-2 have previously been detected in 
extracts from cells and tissues (Aerts et al, 1985; Aerts et al, 1987; Sá Miranda et ai, 
1988). In extracts from spleen from control subjects the major part of 
glucocerebrosidase activity is due to the monomeric state of the enzyme (called form I) 
and a minor part to the enzyme present in aggregated form associated with SAP-2 
(form II) (Aerts et al, 1987; Sá Miranda et al, 1988). Monomeric (form I) enzyme was 
found to be poorly active and strongly stimulated by the activator taurocholate, whilst 
form II glucocerebrosidase was present in an activated state and was hardly stimulated 
further by taurocholate. Forms I and II differed also in mobility on cellulose acetate gel 
electrophoresis (Sá Miranda et al, 1988) and reaction with anti-(glucocerebrosidase) 
antibodies (Aerts et al, 1985; Aerts et al, 1986d). Sá Miranda and coworkers (1988) 
were able to show a complete conversion of this enzyme into an aggregate which 
presented identical electrophoretic mobility to that of form II (band 2) B-glucosidase of 
tissue extracts. Finally, it was observed that the proportion of form II 
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glucocerebrosidase was tissue-specific and that it was clearly less reduced in spleens 
from type 1 Gaucher disease patients (Aerts et al, 1985; Aerts et al, 1987; Sá Miranda 
et al 1990). 
Since form II glucocerebrosidase activity may contribute significantly to the total 
glucocerebrosidase activity in vivo, further information about the occurrence of 
glucocerebrosidase-activator protein complexes seems essential in order to be able to 
assess the actual residual glucocerebrosidase activity in genotyped GD patients. For 
this purpose, in the present study the following experiments were performed: 
• The amount of glucocerebrosidase protein as well as the presence of the different 
molecular weight species in cultured skin fibroblasts extracts from patients 
presenting different genotypes was analyzed by Western blotting. 
• Glucocerebrosidase residual activity was measured in peripheral blood total 
leukocytes and fibroblasts from genotyped GD patients. 
• Glucocerebrosidase residual activity of peripheral blood total leukocytes and 
fibroblasts from genotyped GD patients.was determined under conditions favoring 
the existence of the form II. 
• Extracts of leukocytes and fibroblasts from individual GD patients presenting 
different genotypes were studied with respect to the aggregation state of the 
glucocerebrosidase form II. 
• The modulation of the enzymatic activity per unit of cross-reactive 
glucocerebrosidase (form I) by of taurocholate, SAP and phosphatidylserine 
activators, was studied. 
4.2 Materials and methods 
4.2.1 Materials 
4.2.1.1 Samples 
Blood and skin biopsies were obtained from Portuguese patients and control subjects. 
Spleens from Portuguese type 1 GD patients were collected after therapeutic 
splenectomy. All tissues were kept frozen at -70°C. Tissues requiring transportation 
were shipped in solid carbon dioxide. 
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4.2.1.2 Reagents 
Polyclonal antiserum against homogeneous glucocerebrosidase that was raised in a 
rabbit (Ginns et al, 1982) as well as monoclonal antibodies (8E4 and 2C7) that were 
obtained from the culture medium of hybridoma cells (Barneveld et al, 1983b), were 
provided by Dr. J Aerts. 
Ceil culture reagents were from Gibco BRL. CNBr-activated Sepharose 4B-beads were 
from Pharmacia. 
4-Methylumbelliferyl-p-D-glucoside substrate and bovine serum albumin (BSA) was 
purchased from Sigma. Sodium taurocholate (grade A) was obtained from Calbiochem 
and conduritoi B epoxide from Biomol. 
Acrylamide and N,N'-methylenebisacrilamide was purchased from Sigma. 
Nitrocellulose membrane was from Schleicher and Schuell. The alkaline phosphatase 
substrate was the ImunoPure NBT/BCIP Substrate Kit from Pierce. 
All other reagents were from Merck (proanalysis grade). 
4.2.2 Methods 
4.2.2.1 Preparation of cells 
Leukocytes were isolated from heparinised peripheral blood by differential 
sedimentation in dense isotonic dextran (Skoog and Beck, 1956; Magalhães et al, 
1984b). Contaminating erythrocytes were removed by hypotonic lysis and leucocytes 
were washed with 0.9% (w/v) sodium chloride. Pellets were stored at -70°C until used. 
Human skin fibroblasts were obtained by skin biopsy and cultured in Dulbecco's 
modified Eagle's medium supplemented with 20% foetal-calf serum, 10 unit/ml 
penicillin, 10 ng/ml streptomycin and 20 mM glutamine. Cells were grown at 37°C 
under 5% (v/v) CO2 in the gas atmosphere. Until 5 days after confluence cells were 
cultured with HEPES buffered Dulbecco's modified Eagle's medium. Cells were 
harvested by trypsinization and using a rubber policeman and then washed with 
phosphate-buffered saline (PBS) at pH 7.2. 
4.2.2.2 Extraction of cells 
Cell pellets, (leukocytes and fibroblasts), were suspended in 4 volumes of 10mM Tris-
HCI buffer pH 7.0 containing 0.1% (v/v) Triton X-100, 1mM EDTA, 0.287 mM PMSF 
and 0.004 mM leupeptine. Cells were extracted by sonication with 30 cicies of 0.6 
second, 50 watts, with pauses of 0.4 second (Weat Systems W 375). The homogenate 
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was centrifuged for 30 min at 15 OOOxg and the supernatant (referred to as extract) was 
collected. All these procedures were done at 4°C. 
For SDS-PAGE and in order to desaggregate form II glucocerebrosidase, the 
extraction buffer contained 0.25% instead of 0.1% (v/v) Triton X-100. Under that 
conditions all form II is converted into form I as juged by acetate cellulose 
electrophoresis as well as by imunoprecipitation studies using a monoclonal antibody. 
4.2.2.3 Isolation of activator protein SAP-2 preparation 
Activator protein SAP-2 was isolated from the spleen of a Gaucher disease patient. 
The spleen tissue (25g) was homogenised in 4 volumes of 50 mmol/l potassium 
phosphate buffer (pH 6.5) containing 0.25% (v/v) Triton X-100 by 6 cycles of 30 
seconds at 4000 rpm (Polytron homogenizer). Cells were disrupted by sonication with 
30 cycles of 0.6 seconds, 50 watts, with pauses of 0.4 seconds (Weat Systems W375). 
The homogenate was then centrifuged at 40 OOOxg for 0.5 hours (Sorvai centrifuge). 
The supernatant was boiled for 4 minutes and again centrifuged at 18 OOOxg for 0.5 
hours. The supernatant was adjusted to pH 4.4 with 1 mol/l acetic acid and a similar 
centrifugation was performed. After addition of 5 volumes of ice-cold absolute ethanol 
to the supernatant the preparation was centrifuged at 100 OOOxg for 1 hour and the 
pellet was dissolved in 2% trichloroacetic acid (TCA). The procedure was repeated and 
the obtained precipitate was dissolved in distilled water. This preparation is usually 
referred to as crude activator protein preparation (Peters et al, 1977). 
4.2.2.4 The (i-GIucosidase activity: Glucocerebrosidase and cytosolic 
broad-specific (3-glucosidase activity 
The fluorometric assay was performed using the 4-methylumbelliferyl (4-MU) 
derivatized artificial substrate basically according to Galjaard (1980). The reaction was 
stopped by the addition of 1 mol/l sodium glycinate buffer, pH 10.0. The released 
fluorescence was compared with that of standards, using an excitation and emission 
wavelenght of 365 and 445nm, respectively (fluorescences read on an Aminco SPR 
spectrofluorometer). Standards used for the calibration curve were prepared from a 
solution of 10mmol/l 4-MU in chloroform/methanol (2:1). Results of each series of 
measurements were algebrically calculated by using the linear regression parameters 
corresponding to the calibration curve. 
B-qlucosidase activity: The assay was carried out by incubating during 120 minutes at 
37°C the cell extract with 3.7 mmol/l 4-MU-p-D-glucopyranoside substrate prepared in 
0.1/0.2 mol/l citrate/phosphate buffer (pH 5.2) and 0.02% (v/v) Triton X-100. Sodium 
taurocholate (0.6% (w/v)) was included where indicated. 
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Glucocerebrosidase activity: The cell extract was pre-incubated during 0.5 hours in 
parallel with and without 1 mmol/l conduritol B-epoxide (CBE). This pre-incubation 
results in maximal irreversible inhibition. Glucocerebrosidase activity was calculated as 
being the CBE-inhibitable p-glucosidase activity: 
Cvtosoiic broad-specificitv p-olucosidase: Calculated as the p-glucosidase activity non-
inhibited by CBE. 
4.2.2.5 Measurement of protein 
Protein was measured according to a modification (Herbert et al, 1974) of the Lowry's 
method (Lowry et al, 1951). Bovine serum albumin was used as a standard. 
4.2.2.6 Activity of glucocerebrosidase monomeric and aggregated forms: 
Enzymatic activity per amount of antigen 
Form I glucocerebrosidase is precipitated by the monoclonal antibodies 8E4 and 2C7, 
whereas form II is not. Kinetic parameters, such as Km values for artificial substrates 
and stimulation by activators, were identical for the enzyme in solution and 
immobilized. Since the affinity of the mutant and control glucocerebrosidase for binding 
to the antibodies 8E4/2C7 is similar (as checked by mixing experiments) bounded 
activity to identical amounts of antibody is directly proportional to the enzymatic activity 
per identical amount of antigen. 
An identical amount of rabbit anti-(mouse IgG) prepared in PBS (phosphate buffered 
saline ) was coated to each well (0.45|ig/well) of a microtitre plate by incubation for 1 h 
at 37°C. Next, an identical amount of anti-glucocerebrosidase monoclonal antibodies 
8E4/2C7 prepared in PBS were coated on each well (62.5 ng/well) by incubation for 16 
hours at 4°C. Unbound antibody was removed by washing in PBS containing 0.05% 
(v/v) Tween-20. The enzyme binding assay was made by incubation overnight at 4°C 
and for 2 hours at room temperature an excess amount of antibody with cell extracts. 
Form II glucocerebrosidase activity: The supernatant was removed from wells and the 
unbounded form II glucocerebrosidase activity was measured as the CBE inhibitable p-
glucosidase activity. 
Form I glucocerebrosidase activity: Bounded glucocerebrosidase activity (form I) was 
measured by 
-incubating the wells for 2 hours at 37°C with 3.7 mmol/l 4-MU-p-glucoside, prepared in 
100/200 mM citric acid/sodium phosphate buffer (at the indicated pH), with 0.2% (w/v) 
sodium taurocholate and 0.1% Triton X-100. 
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-incubating the wells for 2 hours at 37°C with 3.7 mmol/l 4-MU-p-glucoside prepared in 
50mmol/l acetate buffer (at the indicated pH), with 0.04 ug/ul phosphatidylserine (PS) 
and 0.138 \ig/\x\ activator protein (Aerts et al, 1990a). 
The reaction was stopped by addition of excess glycine/NaOH (pH 10.0) and the 4-
methylumbelliferone formed was measured fluorimethcally. The released fluorescence 
was compared with that of standards, being measured with a excitation and emission 
wavelength of respectively 365 and 445nm (fluorescence read on a Titertek plate 
spectrofluorometer). Standards used for the calibration curve were prepared from a 
solution of 10mmol/l 4-MU in chloroform/methanol (2:1). For each sample the bound 
activity was determined as the mean of triplicate assays. Results of each serious of 
measurements were algebrically calculated by using the linear regression parameters 
corresponding to the calibration curve. 
4.2.2.7 SDS-PAGE and immunoblotting of glucocerebrosidase 
The glucocerebrosidase present in extracts was immunoprecipitated by incubating 
extracts overnight at 4°C with monoclonal antibodies 8E4 and 2C7 anti-
glucocerebrosidase immobilized to CNBr-activated Sepharose 4B-beads. p-
Glucosidase activity was measured in the supematants to ascertain that all activity was 
imunoprecipitated. Subsequently, beads were washed by 2 cycles with PBS, one cycle 
with 30% ethylenoglycol in PBS, followed by another cycle with PBS. After 
centrifugation for 5 minutes at 10 OOOxg samples were ressuspended in 2x 
concentrated SDS-PAGE sample buffer (125mmol/l Tris/HCI, pH6.8, containing 2.3% 
glicerol, 3.8% SDS, 0.0048% bromophenol blue), and heated at 95°C for 2 minutes. 
After pelleting the beads, supematants containing glucocerebrosidase were removed 
and p-mercaptoethanol was added to the final concentration of 2%. Samples were then 
subjected to SDS-PAGE performed on vertical slab gels. The ratio of acrylamide to 
N.N'-methylenebisacrilamide was 29.2:0.8. Total monomer concentrations were 10% 
and 5% in the separating and stacking gels, respectively. Electrophoresis was stopped 
1cm before the bromophenol blue dye marker reached the bottom of the gel. 
Afterwards protein was transferred electrophoretically into nitrocellulose filters using a 
semi-dry blotting apparatus at 0.8mA/cm2 for 2.5 hours, and with 48 mmol/l Tris/HCI 
(pH 8.3) containing 39mmol/l glicine and 20% (v/v) methanol. After electroblot, 
nitrocellulose filters were washed 2x with PBS containing 0.05% Tween 20 and 0.5% 
BSA during 30 minutes. Next, nitrocelulose filters were incubated overnight with rabbit 
anti-glucocerebrosidase polyclonal antibody diluted 1:2000 in PBS with 0.05% Tween 
and 0.5% BSA. Filters were next washed 3 times with 0.05% Tween in PBS during 10 
minutes, and afterwards incubated during 1 hour with the alkaline phosphatase-second 
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antibody conjugate. Next, nitrocellulose filters were washed 1 hour with 0.05% Tween 
in PBS, followed by another washing with PBS and revealed by adding the alkaline 
phosphatase substrate. 
4.3 Results 
4.3.1 Molecular weight forms and amount of glucocerebrosidase 
protein in patients presenting different genotypes 
Molecular weight determinations of glucocerebrosidase protein from control fibroblasts 
revealed processing forms ranging from 58 to 68 Kda, with three major forms with 
appearant Mr of 66, 63 and 59 kDa (lane p). The observed heterogeneity in the relative 
proportion of the different glucocerebrosidase processing forms is due to the highly 
dependency of subcellular distribution (and thus, molecular mass species patterns) on 
the external pH of culture medium, in physiological range of 7.0-7.4 (Aerts, 1988). 
Minor differences in the amount of glucocerebrosidase protein were observed in 
patients that present both or at least one N370S mutated allele. In the G377S and X 
homozygotes (respectively patients 29 and 37 in Figure 4-4) no differences from 
controls were observed in the presence of processing forms and stability of 
glucocerebrosidase. Thee L444P homozygote patient is the only one presenting a 
markedly reduced amount of protein (patient 41 in Figure 4-4). In the lane 
corresponding to patient 16, the L444P/? compound hétérozygote, a relatively higher 
amount of protein is detectable, presenting apparently normal processing forms, which 
points to the presence of protein codified by the unknown mutated allele. 
78 
Activity of glucocerebrosidase extract from cells of type 1 Gaucher disease patients with different genotypes 
66 kDa-> 
63 kDa-> 
59 kDa-> 
IgG (H chain) -> 
Patient 4 5 10 28 33 3 12 7 8 36 1 29 20  
Controls C C C 
66 kDa-> 
63 kDa-» 
59 kDa-> 
IgG (H chain) -» 
Patient 37 29 16 41 31 30 22 2 14 40 
Controls C C 
Figure 4-4 
Pattern of molecular mass species of glucocerebrosidase protein extracted from cultured skin 
fibroblasts genotyped type 1 GD patients. Prior to SDS-PAGE and immunoblotting, glucocerebrosidase 
was purified by immunoprecipitation from an aliquot of extracts containing 150 pig of total protein. Patients 
4 and 5 are N370S homozygotes; patients 10, 28 and 33 are N370S/L444P compound hétérozygotes; 
patients 3 and 12 are N370S/rec TL compound hétérozygotes; patients 7 and 8 are N370S/IVS2+1 
compound hétérozygotes; patient 36 is a N370S/recNcil compound hétérozygote; patient 1 is a 
N370S/R463C compound hétérozygote; patient 29 is a G377S homozygote; patient 29 is a X homozygote; 
patient 37 is a X homozygote; patient 16 is a L444P/? compound hétérozygote; patient 41 is a L444P 
homozygote; patients 31, 30 and 22 are N370S/? compound hétérozygotes; patient 14 is a N370S/IVS2+1 
compound hétérozygote; patient 40 is a N370S/L444P compound hétérozygote. 
4.3.2 Glucocerebrosidase residual activity in peripheral blood total 
leukocytes and cultured skin fibroblasts of GD patients and 
controls 
The mean glucocerebrosidase activity measured in the presence of taurocholate was 
significantly reduced in extracts of peripheral blood total leukocytes and cultured skin 
fibroblasts from GD patients being less than 11 % of control mean (Table 4-2). The 
activity of the non-specific p-glucosidase was however not significantly different from 
controls in any cell type studied (Table 4-2). 
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Table 4-2 
Glucocerebrosidase and non-specific B-glucosidase activity (nmol/h/mg protein) extracted from 
peripheral blood total leukocytes and cultured skin fibroblasts type 1 GD patients. 
Glucocerebrosidase activity was determined with taurocholate. 
ENZYME CELL-TYPE 
Glucocerebrosidase 
Leukocytes 
Fibroblasts 
Leukocytes 
Fibroblasts 
Activity in controls 
Mean+std Range n 
9.5±3.8 
232±135 
2.8-19 
103-552 
18 
11 
Activity in patients 
Mean+std Range n %contr 
ol 
P 
0.77+0.65 
13+15 
0.00-2.8 
1.46-74 
33 
22 
8.1 
5.6 
<0.01 
<0.01 
Non-specif ic p-
glucosidase 
Leukocytes 
Fibroblasts 
Leukocytes 
Fibroblasts 
Activity in controls 
Mean+std Range n 
0.99±1.0 
6.110.61 
Activity 
0.08-3.6 
0.10-18 
in patients 
18 
5 
Mean+std Range n %contr 
ol 
p 
0.7510.65 
5.315.0 
0.09-2.7 
0.33-20 
32 
23 
76 
90 
n.s. 
n.s. 
Figure 4-5 shows that no significant correlation was observed between the leukocytes 
glucocerebrosidase activity, determined in the presence of taurocholate (T+) and 
clinical severity (SSI) of GD patients. 
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Figure 4-5 
Peripheral blood total leukocytes glucocerebrosidase activity (nmol/h/mg of protein), measured in 
the presence of taurocholate (T+) and clinical severity (SSI) of type 1 GD patients. 
In order to have a first insight on the amount of the residual activity corresponding to 
the aggregated form of glucocerebrosidase (form II), the activity in extracts of 
leukocytes and fibroblasts was measured in the absence of taurocholate. Table 4-3 
shows that in leukocytes, the glucocerebrosidase activity determined in the absence of 
taurocholate was not significantly different from controls (78% of control activity). 
In this table it is also shown the cell type specific effect of taurocholate on the extracted 
glucocerebrosidase activity. Taurocholate stimulated glucocerebrosidase activity 
extracted from fibroblasts of controls and GD patients. In contrast, the 
glucocerebrosidase activity extracted from total leucocytes of GD patients was clearly 
inhibited by the bile salt. 
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Table 4-3 
Comparison between the glucocerebrosidase activity (nmol/h/mg protein) determined in the 
absence (T-) and in the presence (T+) of sodium taurocholate of peripheral blood total leukocytes 
and cultured skin fibroblasts from type 1 GD patients. 
Activity (nmol/h/mg protein) 
Leukocytes Fibroblasts 
T- T+ T- T+ 
Controls n 
mean+std 
range 
T+/T-
n=18 n=18 n=11 n=11 
1.8+0.73 9.5+3.8 36.1+33.0 232+135 
1.1-4.3 2.8-19 8.87-124 103-552 
5.3 6.4 
Patients n 
mean+std 
range 
T+/T-
N=37 n=37 n=26 n=26 
1.4+1.1 0.77+0.65 4.67+5.32 13.1+14.7 
0.0-4.0 0.0-2.8 0.0-19 1.5-74 
0.88 2.8 
P n.s. <0.01 <0.01 <0.01 
Patients % of control 78% 8.1% 13% 5.6% 
4.3.3 Glucocerebrosidase residual activity in peripheral b lood total 
leukocytes and cultured skin f ibroblasts of genotyped GD 
patients 
Glucocerebrosidase activity measured in the absence (T-) of taurocholate was 
compared with that measured in the presence of taurocholate (T+), in both extracts of 
total leukocytes and fibroblast from individual GD patients presenting different 
genotypes. Table 4-4 presents the mean, standard deviation and range of 
glucocerebrosidase activity (measured in the presence and in the absence of 
taurocholate) for each genotype group of GD patients. 
The median and range for each genotype group is also graphically depicted in Figure 
4-6 for total leukocytes and in Figure 4-7 for skin fibroblasts. As shown in Figure 4-6, in 
total leukocytes of patients presenting at least one N370S mutated allele, the 
glucocerebrosidase activity is higher when measured in the absence of the effector 
taurocholate (with the exception of patient 36, N370S/RecNcil). This effect is not 
observed the activity of skin fibroblasts (Figure 4-7). On the contrary, the 
glucocerebrosidase activity of patients without the N370S mutated allele is higher when 
determined in the presence of taurocholate; the glucocerebrosidase residual activity of 
the patient presenting the X/X genotype is not affected by this effector. 
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Table 4-4 
Comparison between the glucocerebrosidase activity (nmol/h/mg of protein) determined in the 
absence (T-) and in the presence (T+) of sodium taurocholate of peripheral blood total leucocytes 
and cultured skin fibroblasts from type 1 GD patients with different genotypes. 
Activity (nmol/h/mg protein) at pH 5.2 
Leukocytes Fibroblasts 
T- T+ T- T+ 
N370S/N370S Patients n=10 n=10 n=6 n=6 
Mean±std 1.3±1.3 0.60±0.47 7.116.1 1819.5 
Range 0-3.8 0-1.6 2.2-19 6.4-34.0 
N370S/L444P Patients n=7 n=7 n=5 n=5 
mean±std 1.6+1.2 0.57±0.60 1.710.89 1317.9 
Range 0.69-4.0 0-1.80 0.49-2.7 4.2-25 
N370S/IVS2+1 Patients n=4 n=4 n=2 n=3 
mean±std 1.7±1.6 0.70±0.47 1.310.70 4.413.0 
Range 0.0-3.2 0.03-1.1 0.81-1.8 1.5-7.4 
N370S/R463C Patient 1 2.0 0.75 2.5 10 
N370S/Rec TL Patients n=2 n=2 n=2 n=2 
mean+std 2.7±0.57 1.3±1.7 1.812.1 5.715.0 
Range 2.3-3.1 0.1-2.5 0.26-3.3 2.2-9.3 
N370S/X Patient 20 NA NA 1.5 6.5 
N370S/RecNcil Patient36 0.56 0.19 3.7 5.05 
N370S/? Patients n=6 n=7 n=3 n=3 
Mean+std 1.2±0.95 0.77±0.36 0.9610.95 3.611.13 
Range 0.07-2.5 0.22-1.3 0-1.9 2.4-4.66 
L444P/L444P Patient 41 0.59 2.8 7.0 13 
L444P/? Patient 16 0.53 0.83 17 74 
G377S/G377S Patients n=2 n=2 n=1 n=1 
meantstd 0.7010.28 1.4510.35 15.9 14.9 
Range 0.50-0.89 1.2-1.7 
X/X Patient 37 0.29 0.28 9.3 7.5 
Controls n n=18 n=18 N=11 n=11 
mean+std 1.79±0.73 9.5313.77 36.1133.0 2321135 
Range 1.10-4.28 2.80-19.1 8.87-124 103-552 
NA means that samples are not available. 
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Figure 4-6 
Genotype median and range values of glucocerebrosidase activity (nmol/h/mg of protein) 
measured in the presence (T+) or in the absence (T-) of taurocholate from peripheral blood total 
leucocytes of type 1 GD patients. 
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Figure 4-7 
Genotype median and range values of glucocerebrosidase activity (nmol/h/mg of protein) 
measured in the presence (T+) or in the absence (T-) of taurocholate, from cultured skin fibroblasts 
type 1 GD patients. 
The glucocerebrosidase mean activity corresponding to each genotype group 
expressed as percentage of the control mean is graphically depicted in Figure 4-8 for 
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total leukocytes. As it can be observed, the residual glucocerebrosidase activity, 
determined in the absence of taurocholate (T-), was almost normal in total leukocytes 
(ranging from 69-151% of control mean), in patients presenting at least one N370S 
mutated allele (being an exception the N370S/RecNcil patient, whose activity 
represents 31% of control mean), in genotypes were the N370S mutation was not 
present, the glucocerebrosidase residual activity in leukocytes, determined in the 
absence of additional activators was lower and ranged from 16-39% of mean control 
value. For all genotype groups, the mean glucocerebrosidase activity measured in the 
presence of taurocholate is always lower than about 30 % of the control mean activity. 
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Figure 4-8 
Percentage of control mean glucocerebrosidase activity of each genotype group, measured in the 
presence (T+) or in the absence (T-) of sodium taurocholate, from peripheral blood total leucocytes 
of type 1 GD patients. 
4.3.4 Quantif ication of the aggregated form of glucocerebrosidase in 
total leukocytes and f ibroblasts extracts 
Form I glucocerebrosidase (monomeric) and form II (aggregate of enzyme+activator 
protein+phospholipids) were separated by immunotitration with monoclonal anti-
glucocerebrosidase antibodies. Table 4-5 shows the contribution of non-
immunoprecipitable (form II) glucocerebrosidase to total glucocerebrosidase activity, 
measured in the presence and in the absence of taurocholate, in extracts of total 
leukocytes and fibroblasts from patients and controls. 
86 
Activity of glucocerebrosidase extract from cells of type 1 Gaucher disease patients with different genotypes 
In fibroblasts, for both patients and controls, the percentage of form II 
glucocerebrosidase related to total glucocerebrosidase activity is similar either when 
measured with or without taurocholate, being in general respectively 12% and 16% of 
the corresponding total glucocerebrosidase. In contrast, in total leukocytes, the 
percentage of form II glucocerebrosidase related to total glucocerebrosidase activity is 
significantly higher than in fibroblasts, specially when measured in the absence of 
taurocholate: 
In controls and when measured in the absence of taurocholate, the percentage of form 
II glucocerebrosidase accounts for about 75% of total glucocerebrosidase activity. In 
patients presenting at least one N370S mutated allele, in the absence of taurocholate, 
the percentage of form II activity is highly variable, ranging from 21-100%, even 
ranging within the same genotype from 21 to 77% (e.g. the results found in patients 
presenting the N370S/L444P genotype). 
With respect to patients that do not have the N370S mutated allele the following was 
observed: 
Although the G377S homozygote presents also an high percentage of agregated form 
activity (76% of total glucocerebrosidase), the remaining genotypes showed a 
comparatively lower amount of form II; patient 37, the X homozygote, presents a low 
percentage of aggregated form activity (27% of total glucocerebrosidase activity) and 
the L444P homozygote shows a very low percentage of form II activity (6.5%). 
The effect of taurocholate on the aggregated form II activity can be also seen in Table 
4-5. With the exception of patient 36 (the N370S/RecNcil), the activity of form II from all 
compound hétérozygotes for the N370S mutated enzyme is dramatically reduced by 
taurocholate. With respect to the taurocholate effect on form II activity of the other 
mutated enzymes, it can be observed that form II activity is slightly decreased, not 
affected and markedly increased for respectively the G377S, X and L444P mutated 
enzymes. 
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Table 4-5 
Percentage of aggregate glucocerebrosidase activity (form II) from total glucocerebrosidase 
activity of peripheral blood total leucocytes and cultured skin fibroblasts of genotyped type 1 GD 
patients. 
% of form II glucocerebrosidase activity 
Total leukocytes Fibroblasts 
Genotype Patients T- T+ T- T+ 
N370S/N370S 21 100 10 0 3.4 
42 87 7.1 15 1.7 
N370S/L444P 10 29 0 1.55 5.0 
23 21 7.4 9.7 6.0 
28 77 29 16.3 5.2 
N370S/IVS2+1 8 100 9 6.4 7.3 
14 100 11 16 36 
N370S/R463C 1 73 6.5 5.7 12 
N370S/Rec TL 3 100 12 35 12 
N370S/RecNcil 36 23 20 2.2 2.0 
L444P/L444P 41 6.4 20 0.95 1.3 
G377S/G377S 29 76 57 2.2 2.0 
X/X 37 27 27 2.4 0 
Controls range 50-75 10-13 8-15 5-6 
n 3 3 4 4 
No correlation was obtained between the glucocerebrosidase residual activity 
measured in conditions that do not lead to the destruction of the aggregated form 
(determined in the absence (T-) of taurocholate) and clinical severity (SSI) of GD 
patients (Figure 4-9). 
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Figure 4-9 
Glucocerebrosidase activity measured without taurocholate (T-) (nmol/h/mg of protein) of 
peripheral blood total leukocytes and clinical severity (SSI) of type 1 GD patients. 
4.3.5 Modulation of glucocerebrosidase monomer ic form specif ic 
activity 
The effect of taurocholate (T+), saposin C (SAP+) and phosphatidylserine (PS+) was 
studied on the enzymatic activity of bounded glucocerebrosidase monomeric 
form.extracted from fibroblasts of GD patients and controls was determined at ph 4.5 
and 5.2 (Table 4-6). 
In the presence of taurocholate, the activity from patients presenting at least one 
N370S mutated allele was in general lower than 25% of control mean value, when 
measured at pH 4.5 or 5.2. Similar findings were observed for the G377S and X 
mutated enzymes. The specific activity of the L444P mutated enzyme was however 
42% and 54% of control mean value, at pH 4.5 and 5.2 respectively. The specific 
activity might be however underestimated due to the fact that little amount of protein 
was available in the extracts, and it can not be excluded that no complete saturation of 
the antibody was accomplished (which is required for obtaining the correct specific 
activity value). 
In the presence of phosphatydilserine and activator protein saposin C the properties of 
form I mutanted enzyme were quite different. In contrast to the L444P and X mutant 
enzymes, the specific activity of the N370S and G377S mutated enzymes became 
close to normal in the presence of the physiological activators. 
89 
Chapter 4 
It is of interest to note the effect of pH on specific activity of the mutant enzymes when 
measured with the physiological activators. In compound heterozygoptes of the N370S 
mutated enzyme the pH dependence was inter individually different: in some cases the 
specific activity is higher at lower pH and in some other cases it is lower. In the case of 
the G377S mutant enzyme the specific activity is clearly higher at pH 4.5 than at pH 5.2 
(Table 4-6). The (PS+SAP+)/T+ ratio showed that the reactivation effect of the 
PS+SAP (related to the activity measured with taurocholate) is clearly higher at pH 4.5, 
for the genotypes presenting at least one N370S mutant allele. 
Table 4-6 
Saposin C, phosphatidylserine and taurocholate modulation effect on form I glucocerebrosidase 
activity (nmol/h/amount of antigen). Glucocerebrosidase was extracted from cultured skin fibroblasts of 
type 1 GD patients and the activity of monomeric (form I) glucocerebrosidase bounded to the monoclonal 
antibodies 8E4/2C7 was measured in the presence of taurocholate (T+) or phosphatidylserine (PS+) and 
activator protein saposin C (SAP+). 
Glucocerebrosidase specific activity (nmol/h/CRIM molecule) 
T+ PS+SAP+ (PS+SAP+)/T+ 
Patient Genotype PH4.5 pH5.2 PH4.5 PH5.2 pH4.5 pH5.2 
4 N370S/N370S 0.07 0.17 1.1 1.9 16 11 
21 0.12 0.16 2.0 0.23 18 1.4 
10 N370S/L444P 0.18 0.29 3.9 1.5 22 5.2 
13 0.18 0.31 1.2 2.0 6.7 6.4 
23 0.23 0.32 0.55 0.64 2.4 2.0 
28 0.19 0.19 1.5 0.21 7.9 1.1 
7 N370S/IVS2+1 0.05 0.15 1.1 1.9 21 13 
8 0.23 0.45 3.5 3.2 15 7.1 
14 0.28 0.38 3.1 3.4 11 8.9 
1 N370S/R463C 0.21 0.55 4.0 4.6 19 8.4 
3 N370S/RecTL 0.06 0.41 2.5 0.47 42 1.1 
36 N370S/RecNcil 0.10 0.16 2.2 0.71 22 4.4 
2 N370S/? 0.05 0.11 0.83 1.3 18 12 
41 L444P/L444P 0.59 1.3 1.1 0.66 1.9 0.51 
16 L444P/? 0.40 0.88 1.4 2.1 3.5 2.4 
29 G377S/G377S 0.32 0.69 3.0 1.7 9.4 2.5 
37 X/X 0.14 0.35 0.62 0.76 4.4 2.2 
Control mean ± std (n=6) 1.4±0.14 2.4+0.18 3.3±0.22 4.2±0.26 2.3±0.17 1.8±0.08 
4.4 Conclusions 
In Portuguese type 1 GD patients, glucocerebrosidase processing forms ranging from 
58 to 68 kDa (Jonsson et al, 1987), with three major forms with appareant Mr of 66, 63 
and 59 kDa, were detected in fibroblasts cell homogenates of patients presenting at 
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least one N370S mutated allele and the G377S and X mutant homozygotes. For these 
two last reported mutant enzymes (Amaral et al, 1996), the presence and the 
apparently normal amount of glucocerebrosidase molecular forms allows to expect that 
normal processing occurs of a mature enzyme (probably presenting reduced catalytic 
activity), instead of either a rapid lysosomal degradation, obstruction of transport or 
loss by secretion. Only the cell extracts of the L444P homozygote presented a 
significative reduction in the amount of glucocerebrosidase protein. 
Glucocerebrosidase residual activity was determined in peripheral blood total 
leukocytes and fibroblasts cell extracts of GD patients and since the detergent 
extraction (with Triton X-100) of this membrane associated enzyme results in its 
inactivation, taurocholate has been currently used for the in vitro enzyme reactivation. 
In these conditions glucocerebrosidase activity was found to be markedly reduced in 
patients cell extracts; however when the activity was determined in the absence of the 
bile salt taurocholate, patients presented an almost normal glucocerebrosidase activity 
in total leukocytes, as opposed to the clear deficiency found in fibroblasts. 
Genotyping revealed that this cell type specific residual glucocerebrosidase activity 
existed specifically for patients having at least one N370S mutated allele, being the 
glucocerebrosidase residual activity in total leukocytes higher than 69% of control 
mean. In contrast, in the remaining genotypes, the residual glucocerebrosidase activity 
in leukocytes ranged from 16-39% of control mean activity. Previous studies with 
purified mutant enzyme provided a simple explanation for the remarkable cell type 
dependency of the N370S glucocerebrosidase activity (Aerts et al, 1990b). The mutant 
enzyme in monomeric form exhibits a severely reduced activity either in the absence or 
in the presence of taurocholate. The activity of the mutant enzyme in reconstituted 
complexes of glucocerebrosidase with activator protein saposin C (SAP) and 
phosphatidylserine (PS) was, however, almost as high as in controls. Addition of 
taurocholate leaded to dissociation of the complex and reactivation of the monomeric 
form of glucocerebrosidase, but the reactivation is much greater in control 
glucocerebrosidase than in the mutant enzyme (Sá Miranda, 1992). 
Thus it was proposed that the cell-type specific differences of this mutated 
glucocerebrosidase activity were due to differences in the proportion of 
glucocerebrosidase extracted in aggregated, activated form (form II) from different cell 
types (Sá Miranda et al, 1990). The present study confirms and extends the findings of 
the early investigations since the results obtained in the form II quantification showed 
also that, when compared to controls, in the absence of taurocholate, form II enzyme 
contributes predominantly to the total glucocerebrosidase activity shown by extracts of 
total leukocytes of GD patients presenting at least one N370S mutated allele (from 21 
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to 100%). A similar finding was obtained for the G377S and to a lesser extend for the X 
homozygote. In contrast, the L444P homozygote presented only a low percentage of 
form II glucocerebrosidase. 
The different features of the mutant enzymes studied in this work are illustrated in 
Table 4-7. 
Table 4-7 
Features of mutant glucocerebrosidases extracted from cells of type 1 GD patients. 
Mutant enzymes 
Control N370S L444P G377S X 
enzyme 
Stability Normal Normal Reduced Near normal Near normal 
(based on GRIM) 
Activation state Intermediate High Low Intermediate Intermediate 
(based on form II) 
Taurochoiate effect 
(on form II activity) 
Marked 
activation 
Marked 
reduction 
Marked 
activation 
Slight 
reduction 
Not 
significantly 
affected 
Specific activity High Very low High Very low Low 
(with taurochoiate) 
Specific activity High High High High Low 
(with PS+SAP) 
Firstly, the activity of the N370S glucocerebrosidase aggregate form (form II) was 
decreased to about 10% of that measured without taurochoiate and only slightly 
reduced in the G377S homozygote; in contrast the activity of the X form II 
glucocerebrosidase was not significantly affected by taurochoiate but was markedly 
activated in the case of the L444P homozygotes. Secondly, the dependence of the 
mutated enzymes on the aggregated form was shown by the marked effect of the 
physiological activators PS and SAP on the specific activity (enzymatic activity per 
amount of cross-reactive glucocerebrosidase). For the N370S mutated enzyme the 
specific activity was found to be very low when measured in the presence of 
taurochoiate, and in general near normal when measured in the presence of the 
physiological activators PS and SAP. Similar findings were obtained for the G377S. In 
contrast there was only a low activation effect for the X and L444P homozygotes. In 
general for both the N370S compounds and the G377S homozygote this activation 
effect was higher at pH 4.5. It was also observed that although the L444P homozygote 
cell extracts have a low amount of glucocerebrosidase protein, this mutant enzyme was 
92 
Activity of glucocerebrosidase extract from cells of type 1 Gaucher disease patients with different genotypes 
found to present the highest specific activity (about 50% of control mean) when 
measured in the presence of taurocholate. 
Relatively high residual B-glucosidase activity in leukocytes from Gaucher patients had 
been observed previously (e.g. Beutler and Kuhl, 1970; Raghavan et al, 1980) and 
were explained by assuming the occurrence of non-specific p-glucosidases in the 
preparations. The findings obtained in this study raise the question of whether the 
residual capacity for glucocerebrosidase hydrolysis might be much higher in some 
blood cell types of GD patients (presenting at least one N370S mutated allele) than 
was generally assumed. 
Since the activity of the N370S mutated form seems to be highly dependent on the 
existence in the aggregated form, the results obtained with compound hétérozygotes of 
the N370S mutated allele, where the percentage of form II activity was found to range 
from 21 to 100% of total glucocerebrosidase, lead to the tentative search of correlation 
between the amount of the aggregated form and the clinical severity. Still no clear 
correlation was obtained but some observations can be made: 
The specific activity of the glucocerebrosidase monomeric form extracted from cells of 
the N370S homozygote patient 21 was very low when measured with taurocholate 
(T+), being however highly reactivated by the physiological activators PS+SAP at pH 
4.5 (18-fold the specific activity measured with taurocholate). This patient presented a 
mild to moderate clinical phenotype (SSI of 7) and all glucocerebrosidase activity was 
extracted from total leukocytes in the activated state, the aggregate form. 
In contrast to that observed for the N370S mutated enzyme, but similarly to that 
observed for the control enzyme, the specific activity of the glucocerebrosidase 
monomeric form extracted from cells of the L444P homozygote patient was very high 
when measured with taurocholate (T+), although the amount of CRIM was found to be 
very low; this patient presented a severe phenotype (SSI of 16) and the 
glucocerebrosidase activity extracted as aggregate form was almost absent (6.4%). 
Patient 36, the N370S/RecNcil compound hétérozygote, presents a severe clinical 
phenotype (SSI=19), and although the specific activity of the extracted monomeric form 
of glucocerebrosidase was found to be highly modulated by the physiological activators 
PS+SAP at pH 4.5 (reactivation related to T+ of 22-fold), a low amount of 
glucocerebrosidase was extracted in the activated aggregate form (23%). With respect 
to the N370S/RecTL patient 3, although all glucocerebrosidase was extracted as 
aggregate form (100%), and the specific activity of the extracted monomeric form of 
glucocerebrosidase was highly modulated by the PS+SAP at pH 4.5 (reactivation 
93 
Chapter 4 
related to T+ of 42-fold), this patient presents a less severe phenotype, but still a 
moderate score (SSI of 15). 
On the other hand, the large clinical heterogeneity observed in patients presenting the 
N370S/L444P genotype group (SSI ranging from 6 to 19) could be explained by the 
existence of variable proportions of the unstable L444P mutated enzyme, which 
presents high specific activity per amount of cross reacting material. This was 
suggested by the observation that from cells of patient 23 a low amount of 
glucocerebrosidase was extracted as aggregate form (21%), and accordingly the 
specific activity of the monomeric form was poorly modulated by the PS+SAP at pH 4.5 
(reactivation related to T+ of 2.4-fold). This data suggested the presence of higher 
proportion of L444P mutated enzyme and the patient presented a mild to moderate 
score of clinical severity (SSI of 6). However, patient 28 although presenting a similar 
score of clinical severity (SSI of 7), showed comparatively higher quantity of 
glucocerebrosidase extracted as aggregate form (77%) and the specific activity of the 
monomeric form of glucocerebrosidase was showed an higher reactivation by PS and 
SAP (reactivation related to T+ of 7.9-fold). 
It is likely that the G377S and X mutations resemble more the N370S mutation than the 
L444P. The G377S homozygote (patient 29) has a moderate to severe SSI of 14 and 
although an high amount of the glucocerebrosidase activity was extracted as aggregate 
form (76%), the specific activity of the glucocerebrosidase monomeric form was only 
moderately activated by the PS and SAP activators (reactivation related to T+ of 9.4-
fold). The X homozygote patient 37 presents a mild to moderate index of clinical 
severity (SSI of 6) and although the reactivation effect by PS and SAP on the specific 
activity of this mutated glucocerebrosidase monomeric form was relatively low 
(reactivation related to T+ of 4.4-fold) and a considerable amount of the 
glucocerebrosidase activity was extracted as aggregate form (27%). 
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Enzyme supplementation therapy in the study of 
underlying pathogenic mechanisms of Gaucher disease 
5.1 Introduction 
5.1.1 Secondary abnormalit ies in GD patients 
5.1.1.1 Glucosylceramide accumulat ion and other g lycol ip id 
abnormali t ies 
Glucosylceramide is an intermediate in the degradation of complex glycosphingolipids 
such as giobosides and gangliosides that are mainly present in cell membranes. In 
macrophages of GD patients due to the deficiency of glucocerebrosidase, the 
breakdown of glucosylceramide in the lysosome is impaired. The resulting Gaucher 
cells (lipid loaded macrophages) occur in almost every organ, but are especially 
present in the spleen, liver and bone marrow. Glucosylceramide was found to be 
increased in plasma of GD patients (Strasberg et al, 1983), being transported as a 
component of lipoprotein complexes (Dawson and Oh, 1977). The lipid level was 
reported as being about three times increased in type 3 Gaucher patients and twice in 
type 2 patients. In type 1 patients, glucosylceramide was described as being only 
slightly elevated, (Dawson et al, 1982), although the level has been found to rise after 
splenectomy (Nilsson et al, 1982; Svennerholm et al, 1982). The origin of the elevated 
plasma glucosylceramide is not precisely clear. It has been suggested that storage 
material might leak from lysed Gaucher cells into the extracellular space (Pennelli et al, 
1969; Hibbs et al, 1970). Concomitant with the increase in glucosylceramide, 
abnormalities have been reported in the levels of at least two other glycosphingolipids. 
Increased concentrations (5 fold) of the ganglioside GM3 have been found in tissues of 
patients with GD (Philippart and Menkes, 1964). In brain, the levels of lactosylceramide 
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and oligohexaosylceramides were found to be slightly raised as well as an increased 
proportion of GM2 and GM3 gangliosides (Nilsson and Svennerholm, 1982). Type 2 GD 
brain was characterized by a decreased galactocerebroside content in addition to the 
increased glucocerebroside content (Sudo, 1977; French et al, 1969). 
The neurotoxin lysosphingolipid glucosylsphingosine (a deacylated analogue of 
glucocerebrosidase also designated as psychosine) which is not detectable in normal 
human brain, is another compound that accumulates in brain from GD patients (Figure 
5-1). This substance is increased at least 100 to 1000 fold in the neuronophathic forms 
being the concentration higher in type 2 than in type 3, and higher in cerebellar than in 
cerebral cortex (Nilsson and Svennerholm, 1982). Glucosylsphingosine has been 
reported to inhibit protein kinase C (Hannun and Bell 1987), albeit at rather high 
concentrations. It has been suggested that the accumulation of this toxic substance is 
the basis for the extensive neuronal cell loss in the neuronopathic forms of GD. 
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Figure 5-1 
Proposed metabolic pathways for the degradation of sphingoiipids and lysosphingolipids. The 
pathways of sphingolipid catabolism are illustrated (thin arrows). Deficiency of enzymes in these pathways 
(solid bars) lead to the indicated diseases. It is proposed that the same enzymes also act on 
lysosphingolipids (double arrow), and therefore, both the parent sphingolipid and the lysosphingolipid 
would accumulate in enzyme deficient states. Sphingosine and lysosphingolipids differ from the parent 
sphingoiipids in their ability to strongly inhibit protein kinase C, thus interfering in the function of important 
pathways of signal transduction and cell regulation. Also the cytotoxicity of lysosphingolipids may 
ultimately lead to permanent tissue damage and cell death. (Adopted from Hannun and Bell, 1987). 
5.1.1.2 Activ i ty of lysosomal enzymes 
The clinical manifestation of GD is reported to be generally accompanied by 
abnormalities in plasma levels of the some lysosomal hydrolases (Ockerman and 
Kohlin, 1967; Hultberg et al, 1980). The cause of elevated serum activities of lysosomal 
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enzymes in Gaucher disease is not known, although Crocker and Landing (1960) 
suggested that spillage of lysosomal enzymes occurs from tissues rich in Gaucher 
cells. However, since the elevated levels of acid phosphatase and p-hexosaminidase 
activities were not accompanied by elevation of lactic dehydrogenase activity 
(Nagakawa et al, 1983), gross cellular injury appears not to be the cause of increased 
amounts of these enzymes. Furthermore, in vitro studies of murine macrophage 
cultures showed that the addition of glucocerebroside at concentrations that had no 
detectable effect on lactic dehydrogenase, resulted in release of substantial amounts of 
p-hexosaminidase into the medium (Gery et al, 1981). This suggests that the 
accumulation of glucocerebroside may stimulate exocytosis of large amounts of 
lysosomal hydrolases. 
5.1.1.2.1 Tartrate resistant acid phosphatase (TRAP) 
The acid phosphatase (EC 3.1.3.2.) is one of the six isoenzymes of acid phosphatase 
that in many tissues is a minor component of total acid phosphatase activity and in 
contrast to the major lysosomal acid phosphatases is not strongly inhibited by L-(+)-
tartrate. This tartrate-resistant acid phosphatase (TRAP) is produced in large quantities 
by osteoclasts and macrophages (Moss, 1992) being secreted during bone resorption 
(Chambers et al, 1987). Osteoclasts attach to the bone surface so as to form a sealed 
extracellular pocket, which is acidified by the action of a plasma membrane proton 
pump, thereby forming an acidic extracellular space into which lysosomal enzymes are 
secreted. TRAP of skeletal osteoclasts partially dephosphorylates the bone matrix 
phosphoproteins, osteopondin and bone sialoprotein and onCe dephosphorylated 
osteoclasts no longer bind to them (Ek-Rylander et al, 1994). This suggests that 
secretion of TRAP from osteoclasts into the resorption area could modulate attachment 
or motility of these cells on bone surface and affect the development of ruffled borders 
in bone tissue. 
TRAP has been mapped to the short arm of human chromosome 19 (Lord et al, 1990; 
Moss, 1992). The 5' flanking region of the TRAP gene contains an iron responsive 
element being the expression regulated by iron at the level of gene transcription 
(Alcantara et al, 1994). The mRNA is expressed at high levels in osteoclasts and in 
cells of monocyte/macrophage lineage. During in vivo osteoclast formation, it appears 
that TRAP expression first occurs in mononuclear cells near the bone surface prior to 
the appearance of osteoclasts. These mononuclear, TRAP-positive cells are 
considered to be osteoclast precursors (Lacey et al, 1994). The presence of iron in the 
TRAP active site is required for enzymatic activity (Lord et al, 1990). 
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Acid phosphatase increased activity in GD was known before the identification of (3-
glucosidase deficiency as the primary defect of the disease and was the most 
prominent secondary biochemical abnormality (Tuchman et al, 1956; Tuchman et al, 
1959; Chambers et al, 1977,1978; Robinson and Glew R, 1980). The serum activity of 
acid phosphatase was also found to be age dependent in controls and GD patients 
(Magalhães et al, 1984a). Although plasma TRAP activity in symptomatic GD patients 
can be about 10-fold increased, in asymptomatic patients this activity was found to be 
within the control range (e.g. Hollak et al, 1994). 
5.1.1.2.2 The (^-hexosaminidase activity 
Gaucher disease patients also have a two to three-fold elevation in plasma levels of p-
hexosaminidase (Moffitt et al, 1978). This activity is also known to increase markedly 
and progressively during pregnancy, as well as being moderately elevated in patients 
with diabetes mellitus (Bomback et al, 1976). Although the elevation of total p-
hexosaminidase activity in serum of patients with Gaucher disease and pregnant 
women is similar, the quantitative distribution of p-hexosaminidase isoenzymes is 
distinctly different. In control subjects p-hexosaminidase A is the major isoenzyme 
activity followed by p-hexosaminidase I and p-hexosaminidase B. All isoenzymic forms 
are elevated in pregnant women, but there is a characteristic increase of the I isozyme 
or p-hexosaminidase P (Stirling, 1972; Nagakawa et al, 1983). Patients with insulin-
dependent diabetes mellitus also have moderate elevation in all three isoenzymes 
(Bomback et al, 1976). 
In GD, although all hexosaminidase isoforms are elevated, when compared to control 
serum, p-hexosaminidase B activity was increased approximately 3 fold while p-
hexosaminidase A activity was increased nearly 2 fold (Moffitt et al, 1978). Spleen and 
liver from patients were found to contain a 5-fold increased in p-hexosaminidase 
activity (Ockerman and Kohlin, 1969; Moffitt et al, 1978). Separation of splenic p-
hexosaminidase A and B activities on DEAE-Sephadex chromatography showed that 
the activity of p-hexosaminidase B isoenzyme was increased 12 fold, whereas p-
hexosaminidase A activity was increased slightly more than 3 times relative to control 
spleen (Moffitt et al, 1978). 
5.1.1.2.3 Abnormalities in other lysosomal enzymes 
In GD it was observed a marked elevation in plasma levels of p-glucuronidase and 
nonspecific esterase activities (Moffitt et al, 1978). Spleen extracts contained increased 
activity in a-fucosidase (Ockerman and Kohlin, 1969), 10 fold increase in 
galactocerebrosidase activity (lactosylceramidase I) but not in GM1-ganglioside p-
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galactosidase (lactosylceramidase II), and a 2 fold increase in p-glucuronidase and 
nonspecific esterase activity (Ockerman and Kohlin, 1969; Moffitt et al, 1978). Similar 
increases were also observed in liver a-fucosidase. Only slight increases in brain a-
fucosidase have been observed (Ockerman and Kohlin, 1969). Levels of splenic 
alkaline phosphatase, arylsulfatase A and B, a-arabinosidase, sphingomyelinase, a-
mannosidase, and G|\/|-|-ganglioside (3-galactosidase activities were similar to those of 
control tissue (Moffitt et al, 1978; Aerts et al, 1990a). Arylsulfatase A activity was found 
to be markedly reduced (20% of control) in brain homogenates from a type 2 GD 
(Moffitt et al, 1978). 
5.1.1.2.4 Chitotriosidase activity 
A striking elevation of the activity of chitotriosidase, an endo-p-glucosaminidase, was 
described in plasma from Gaucher patients (Hollak et al, 1994). This activity in samples 
from type 1 (n=491), type 2 (n=4) and type 3 patients (n=11) was in average 1033, 199, 
and 650-foid respectively the median value of the control subjects (Aerts et al, 1995b). 
The same work reported that in asymptomatic Gaucher disease patients the elevation 
was only 4.5-9.7 fold. Besides the observation of only mild elevations in chitotriosidase 
levels in asymptomatic Gaucher patients, no correlation was found between this activity 
and the severity of clinical manifestations (as assessed by the use of the Zimran's 
severity score index, SSI), or with patients genotype (Hollak et al, 1994). 
Chitotriosidase activity was found to be absent in about 6% of the population due to a 
recessively inherited deficiency (Hollak et al, 1994). Recently a single mutation has 
been identified in homozygous form in chitotriosidase deficient individuals. The 
mutation, a duplication in the chitotriosidase gene, causes formation of mRNA that 
encodes for an enzymatically inactive chitotriosidase protein. The mutation has been 
detected with a high frequency in individuals from various ethnic groups, suggesting an 
ancient origin (Boot et al, 1995). Since Gaucher patients lacking chitotriosidase activity 
show the usual clinical symptoms, it is unlikely that chitotriosidase itself contributes to 
the clinical presentation of Gaucher disease (Hollak et al, 1994). 
Chitotriosidase activity was found to be about 12-fold increased in brain (Aerts et al, 
1995a) and 50-fold increased in spleen of a type 1 Gaucher patient as compared with 
control subjects. Two major isoforms of chitotriosidase with isoelectric points of 7.2 and 
8.0 and molecular masses of 50 and 39 KDa, respectively, were purified from spleen 
and the N-terminal amino acid sequence of the two forms proved to be identical 
(Renkema et al, 1995a). Isoelectric focusing revealed minor forms of pi 5.5-6.0 and pi 
about 6.5. In plasma, the apparent isoelectric point of chitotriosidase was 
predominantly 7.2 with minor amounts of 6.0 and 8.0, being comparable to that 
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observed in controls (Renkema et al, 1995a). An antiserum raised against the purified 
39-KDa chitotriosidase precipitated all isoenzymes and 98% of the activity in the 
Gaucher spleen extract. 
Both the N-terminal sequence and an internal sequence of chitotriosidase proved to be 
homologous to sequences in proteins that are members of the chitinase family (Hakala 
et al, 1993). This family consists of proteins from various organisms, with strong 
homology in several domains including the region that is involved in the catalysis of 
chitin (a polymer of (3-1,4-linked N-acetylglucosamine moieties) and the artificial 
substrate 4-MU-chitotrioside (Watanabe et al, 1993). The human chitotriosidase 
showed chitinolytic activity toward artificial substrates as well as chitin (Renkema et al, 
1995a) and may therefore be considered to be a chitinase that shares homology with 
chitinases from non-mammalian organisms, e.g. the nematode Brugia malayi (Fuhrman 
et al, 1992) or the fungus Aphanocladium album (Blaiseau and Lafay, 1992). 
The biological function and the relationship between the several hundred-fold 
increased plasma levels of chitotriosidase and the pathophysiology of Gaucher disease 
is however unknown. It was described that during monocyte morphological 
differentiation into macrophage, cells begin to produce and secrete increasing amounts 
of chitotriosidase (Hollak et al, 1994) as well as acid phosphatase (Moss, 1992). 
Northern blot analysis showed that the remarkably strong expression of chitotriosidase 
mRNA occurred only at a late stage of differentiation of monocytes to activated 
macrophages in culture (Boot et al, 1995). 
The finding that chitotriosidase was a chitinase was found to be very important since 
the human body is still believed to contain no chitin (Raghavan et al, 1994). The 
chitotriosidase isolated from Gaucher spleen clearly differed from the other mammalian 
members of the chitinase protein family which have been found to be devoid of 
chitinolytic activity; thus it appeared to be more closely related to the chitinases of non-
mammalian organisms. The unexpected occurrence of a human chitinase lead to the 
search of other proteins produced by macrophages that could interact with chitin. 
Renkema and co-workers found that macrophages synthesise large amounts of a chitin 
binding protein, that was early described as the human chondrocyte glycoprotein (HC 
gp-39) (Hakala et al, 1993). This protein has a high degree of similarity with the 
chitinase protein family. HC gp-39, in contrast to chitotriosidase, was not able to 
degrade the natural or the artificial chitinase substracts (Hakala et al, 1993). A 
comparison between the amino acid sequences of chitotriosidase and HC GP-39 
showed that the presumed catalytic center of chitotriosidase is almost completely 
conserved in HC gp-39, but two critical acidic amino acids, required for the hydrolytic 
activity, were found to be substituted, probably leading to the chitin lectin properties of 
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this protein (Renkema et al, 1995b). So human macrophages were found to synthesise 
a functional chitinase, a highly conserved enzyme with a strongly regulated expression. 
This human chitotriosidase is thought to be involved in defence against and in 
degradation of chitin-containing pathogens such as fungi, nematodes and insects, and 
can be used as a marker for specific disease states (Boot et al, 1995). 
5.1.1.3 Iron distr ibut ion 
In adult type 1 Gaucher patients, the accumulation of glucocerebroside in 
reticuloendothelial cells is in most cases accompanied by a varying degree of iron 
accumulation (Lorber, 1960; Lorber, 1965; Lorber and Nemes 1967; Lee et al, 1967). 
The existence of abundant iron was demonstrated histochemically (Lorber, 1960; 
Lorber and Nemes 1967), by electron microscopy (Lorber and Nemes 1967; Lee et al, 
1967), immunochemical procedures (Lorber and Nemes, 1967), chemical analysis 
(Lorber and Deren, 1968), and by abnormal iron kinetics (Lorber, 1965; Lee et al, 
1967). The presence of iron in the Gaucher cells may suggest a derivation of iron and 
lipid following the phagocytosis of erythrocytes (Pick, 1933). However, the observation 
that lipid and iron accumulation do not necessarily parallel each other, and that cells of 
infants with the disorder do not present iron accumulation (Pick, 1933) indicates that 
this is not basic to the disorder and that it only occurs after prolonged time. The water 
soluble non-heme iron is present associated with the ferritin protein (Rothen, 1944). 
Large aggregates of cross-linked ferritin molecules that comprise the water-insoluble 
non-heme iron particles are usually termed hemosiderin (Nixon and Olson, 1968). In 
Gaucher cells such aggregates are rare. The general cytoplasmic dispersion of ferritin 
molecules is not unique for Gaucher cells but has also been noted in normal 
macrophages (Karrer, 1958) and in hemochromatosis (Bessis and Caroli, 1959). In 
spleen of adult Gaucher patients, splenic parenchyma total iron (heme iron, ferritin and 
hemosiderin) is elevated between 3 and 28 times the normal level; heme iron is usually 
increased and the ferritin:hemosiderin partition varies from 35:65 to 60:40. In children, 
despite splenomegaly, total iron and ferritin:hemosiderin ratio is normal (Lorber and 
Deren, 1968). 
A dynamic equilibrium has been described between plasma iron and ferritin iron 
(Bessis, 1962). In normal subjects, much of the plasma iron enters the 
reticuloendothelial system and the hepatic parenchyma (Granick and Hahn, 1944; 
Fineberg and Greenberg, 1953). In Gaucher cells an appreciable number of ferritin 
micelles occurs in the periphery of the cytoplasm, particularly in and near the numerous 
pseudopods that at times form the external surface of the cell. This, together with the 
rapid disappearance of plasma radioiron, might indicate that iron in the Gaucher cells 
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was derived not only from ingested red blood cells (Lorber and Nemes, 1967; Lee et al, 
1967), but also from the surrounding plasma or interstitial fluid which normally contains 
a significant labile iron pool (Wasserman et al, 1964; Wasserman et al, 1965). 
The presence of iron in Gaucher cells is another example of iron accumulation in 
tissues with lipid accumulation, as for example also in xanthomata. It is unlikely that 
iron accumulation in Gaucher cells is only caused by the phagocytic nature of these 
cells, since although granular hemosiderin may be present in the trabeculae, sinus 
walls and Gaucher cells of the spleen, the Kupffer cells of the liver usually appeared to 
be normal despite their phagocytic function (Popper and Schaffner, 1957). In addition, 
many or most Niemann-Pick cells (Bloom, 1925) may develop from reticuloendothelial 
cells, yet appear to be devoid of iron. 
5.1.1.3.1 Cell-mediated immunity and iron metabolism 
Maintenance of cellular iron homeostasis is not only a general prerequisite for growth 
and proliferation of all cells but it also is of central importance for the regulation of the 
immune system. Both iron deficiency and iron overload can exert subtle effects on 
immune status by altering the proliferation of T and B cells (reviewed in De Sousa et al, 
1991; Brock, 1994). This is partially due to the central role of iron as a cofactor for 
critical enzymes, such as mitochondrial aconitase and ribonucleotide reductase. 
Furthermore, the availability of cellular iron may even have a specific influence on the 
proliferation of T helper 1 (Th1) and Th2 subsets, thus modulating the activities of 
different lymphocyte subpopulations and their subsequent effector mechanisms. In 
addition, iron plays a critical role in macrophage-mediated cytotoxicity by contributing to 
the production of several reactive oxygen species. As a consequence of all this, 
imbalances of iron metabolism seem to strongly affect immune effector function 
(reviewed in Weiss et al, 1995). 
There are several literature reports that indicate the very complex relationships 
between monocytes, macrophages, T lymphocytes, cytokines and cellular iron 
homeostasis. For example, the macrophage-derived cytokines interleukin 1(IL-1) and 
TNF-a are known to induce hypoferraemia by increasing iron uptake into 
monocytes/macrophages. Additionally, the Th1-type cytokines IFN-y and IL-2 were 
shown to enhance strongly the expression of transferrin receptor, the essential protein 
for iron uptake in macrophages. IL-6 may also increase ferritin synthesis, thus 
contributing to efficient storage of the acquired iron (reviewed in Weiss et al, 1995). 
The impact of iron on cell-mediated immunity was further substantiated by reports 
demonstrating that iron-loaded macrophages lose their ability to kill intracellular 
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pathogens by IFN-y-mediated pathways. However, the diversion of iron traffic by 
increased uptake and incorporation of iron into ferritin by macrophages is thought to 
cause growth limitation of microorganisms and tumor cells by restricting iron 
availability. Furthermore, it is thought that enhances the production/release of cytokines 
such as IFN-y orTNF-a by monocytes/macrophages, promoting host defence capacity. 
Finally, activated macrophages are able to synthesize transferrin, which then promotes 
and enhances lymphocyte proliferation in a paracrine manner, thus overcoming the 
depressive effects of hypoferraemia (reviewed in Weiss et al, 1995). 
T lymphocytes migrate to places of either physiological or pathological iron overload 
(De Sousa, 1978, 1981); it was postulated that immunological system cells may 
actively participate in the protection of potential iron toxicity (De Sousa, 1981; Nishiya 
et al, 1980). Porto (1993) demonstrated, for the first time in man, a remarkable stability 
of the total numbers and relative proportions of T lymphocytes in peripheral blood, and 
a correlation between the relative expantion of the CD4+ (helper) and CD8+ (killer) 
populations and iron metabolism. 
5.1.1.4 Osteoclastic activity and T lymphocytes 
The occurrence of the lipid loaded macrophages (Gaucher cells) in tissues and organs, 
underlies the GD most common signs of pancytopenia, organomegaly and skeletal 
deterioration (reviewed in Cox and Schofield, 1997). Infiltration of normal bone marrow 
by lipid-laden Gaucher cells results in apparently progressive displacement of the fat-
rich marrow proper with a consequent shift in haematopoietic activity from proximal to 
more distal sites (Rosenthal, 1995). The pathophysiology is however not clearly 
understood. In particular, the balance between the impact of altered numbers and 
increased activity of osteoclasts (whose progenitors in the marrow are of 
haematopoietic lineage), the possibly suppressed osteoblast activity (Siffert and Piatt, 
1982) as well as the mechanism of bone infarction (caused by impaired collateral bone 
micro- and macrovascular supply). Enzyme supplementation therapy (Barton et al, 
1991a), which has as its principal aim the correction and/or prevention of ongoing 
formation of the lipid loaded macrophages, has proven to be safe and effective in 
improving the haematological parameters and reducing the organomegaly in GD 
patients. However, the general experience is that the skeletal response to therapy lags 
behind all other symptoms (Elstein et al 1996). The relatively slow skeletal response to 
enzyme therapy does not necessarily imply poor delivery of enzyme to the skeleton. 
Tissue distribution studies with tracer doses of radio-iodinated mannose-terminated 
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enzyme showed avid uptake in the marrow, in proportion to the putative cellular pool of 
macrophages in this organ (Mistry et al, 1996). 
Recent reports of studies in vitro point to the involvement of T lymphocytes in bone 
homeostasis via the regulation of osteoclast differentiation (John et al, 1996; Horwood 
et al, 1998). Decreased CD8+ T lymphocyte numbers in diseases associated with 
increased bone resorption have been previously reported (e.g. Consolini et al, 1987; 
Nagasawa et al, 1995). In addition in vitro studies showed that depletion of cells 
expressing the CD8 antigen, from bone marrow cell populations that contain 
osteoclast-precursor cells, significantly increased the number of osteoclasts generated 
in vitro (John et al, 1996). More recently (Horwood et al, 1998), a mechanism was 
proposed for the osteoclastogenesis inhibition, in which IL-18 (produced by stromal 
cells or other cells of the bone microenvironment) act on T cells (either CD8+ or CD4+ 
subsets) via an unidentified receptor, to increase GM-CSF production, which ultimately 
inhibits osteoclastogenesis. However, this newly inhibitory pathway where IL-18 acts as 
a local inhibitory agent, may be able to be compensated for by other mechanisms, 
since GM-CSF-/- and GM-CSF R-/- deficient mice lack major skeletal abnormalities. 
5.1.1.5 Immunoglobul in abnormali t ies 
Nearly half of the tested patients presented hypergammaglobulinemia (Schoenfeld et 
al, 1980), possibly due to chronic stimulation of the immune system, which may also 
infer a connection to the relatively high incidence of multiple myeloma reported in 
Gaucher disease (Zimran et al, 1995a). The subset of patients at risk for these 
abnormalities is not known. 
5.1.1.6 Cytokines 
The functional consequences of the massive accumulation of glucocerebroside in 
tissue macrophages is not completely known, but the addition of glucosylceramide to 
cultured normal circulating monocytes was shown to stimulate lymphokine interleukin-1 
release, and augmented lipopolysacharide-induced interleukin-1 release by cells (Gery 
et al, 1981). In patients, the cytokine macrophage colony stimulating factor (M-CSF), 
the soluble form of CD14 (sCD14) and IL-8 were reported to be elevated (respectively 
2-8 fold, 2-5 fold and 2-20 fold) (Hollak 1996). CD14 is a monocyte/macrophage 
differentiation antigen and has been reported to be a receptor for LPS-LBP complex. 
Although the biological role of the soluble form of this receptor (sCD14) remains to be 
clarified, elevated levels might be associated with an increased number or activation of 
cells from the monocyte/macrophage lineage. Concentrations of IL-6 and IL-10 (which 
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are important regulators of lymphocyte growth and differentiation) were also found to 
be significantly elevated in sera from patients with GD (respectively 2 and 8-fold that of 
controls), lnterleukin-1 p was not detectable in sera obtained from patients and no 
difference from controls was observed in the concentrations of TNF-a. lnterleukin-6 
concentration in the serum of patients showing monoclonal or biclonal gammopathy 
has also been found significantly elevated. Since IL-6 has been implicated in the 
development of localized osteolysis in multiple myeloma and osteoporosis, enhanced 
release of these cytokines provides a functional link between GD and its associated 
lymphoproliferative and skeletal manifestations (Cox et al, 1997). The increased 
secretion of cytokines by stimulated macrophages as a response to extensive storage 
may thus contribute to the pathogenesis of the disease (Moffitt et al, 1978; Gery et al, 
1981). 
5.1.1.7 Monocyte dysfunct ion 
A significant monocyte dysfunction (but not in granulocytes) was most consistently 
expressed by markedly glucocerebroside dose-dependent suppressed superoxide 
generation. Consequently, NBT (nitroblue tetrazolium test) reduction and 
Staphylococcal killing were considerably reduced in monocytes (and normal in 
granulocytes) (Liel et al, 1994). This abnormality was observed in a large majority of 
GD patients, regardless of the clinical severity of the disease (Liel et al, 1994). 
Superoxide generation, or respiratory burts is produced by an enzymatic complex, the 
NADPH oxidase, in response to various microbial pathogens and by soluble inducers 
(Babior, 1984; Rossi, 1986). It constitutes the principal mechanism responsible for the 
killing of invading microbial pathogens. Available evidence implies an important role for 
the activation and translocation from the cytosol to the cell membrane of protein kinase 
C (PKC) in the process of phosphorylation of the p47 component and stimulation of the 
NADPH oxidase complex (Okamura et al, 1988, Rotrosen et al, 1990). Since 
granulocytes and monocytes from GD patients display normal activity of the NADPH 
oxidase system, it is unlikely that components of the NADPH oxidase system are 
inherently, quantitatively or qualitatively abnormal in GD. It is most likely that 
glucocerebrosidase interferes with the signal transduction at, or distal to PKC. The 
precise mechanism remains to be defined (Liel et al, 1994). 
Phagocytosis, which is unrelated to superoxide production, was also described as 
being decreased in monocytes but normal in granulocytes of GD patients (Liel et al, 
1994). Chemotaxis (monocyte motility) was also found to be impaired in 50% of the 
patients (Liel et al, 1994). Although the neutrophil is not classically considered to be a 
site of sphingolipid storage, a neutrophil chemotactic defect was also reported to 
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occurs in 29% of GD patients (Aker et al, 1993; Liei et al, 1994). However this could be 
the result of secretory products of mononuclear phagocytes, eg, tumor necrosis factor 
and interleukin-2 (Zimran et al, 1994a). 
Bacterial infections have a prominent role by ocurring repeatedly and being life-
threatening in patients with severe GD (Zimran et al, 1994a). Pyogenic infections are 
recognized as one of the three major causes of death in GD patients (Beutler, 1991), 
especially in the pediatric population (Zimran et al, 1994a). Osteomyelitis in GD 
patients, particularly by anaerobic pathogens (Finkelstein et al, 1992) could represent 
specific local failure of the reticuloendothelial system to eliminate invading pathogens. 
Susceptibility toward systemic infections is probably less likely due to the relative 
integrity of granulocytes function (Liel et al, 1994). Zimran and coworkers claim to have 
found a direct relationship between the phenotypic expression of early age of onset, 
severity score index, and tendency to bacterial infections and the chemotaxis defect 
(Zimran et al, 1994a). 
5.1.2 Aims and approach of the study 
Many questions remain unsolved with respect to the pathophysiology of GD. Factors 
influencing the clinical expression are unknown and a clear correlation between 
phenotype, genotype and residual activity of the enzyme is lacking. Analysis of 
secondary plasma abnormalities may help to increase insight into the complicated 
pathophysiology of the disease and could also provide useful disease markers. Some 
of these abnormalities are probably directly due to the mechanisms via which lipid-
loaded Gaucher cells affect their surroundings, e.g. hydrolases release and abnormal 
cytokine production. A number of hydrolases that might originate from macrophages 
(e.g. TRAP, p-hexosaminidase and chitotriosidase) are usually found to be elevated in 
plasma of symptomatic Gaucher patients. If the lipid-loaden macrophages are indeed 
involved in the release of those enzymes, their plasma levels may serve as quantitative 
markers for the amount of storage cells. The observation that administration of 
corticosteroids to patients with sarcoidosis (disease in which the macrophage is also 
involved in the pathology) leads to a rapid reduction in plasma chitotriosidase activity, 
seems to indicate that the synthesis and release of this enzyme is also highly 
dependent on the macrophage state of activation (Hollak, 1996). 
It is conceivable that both the amount of storage cells as well as their degree of 
activation contributes to the (intehndividually different) clinical expression of the 
disease. In order to get further insights in the amount of Gaucher cells and/or their 
activation state, the following studies were performed: 
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• Glucosylceramide concentration was determined in plasma of Portuguese GD 
patients presenting different genotypes and level of clinical severity. Plasma 
concentration of other membrane lipids (GM3 ganglioside and ceramide) was also 
studied in order to determine if the storage of glucosylceramide affects the 
metabolism of these compounds. 
• Serum ferritin, the activity of TRAP, p-hexosaminidase and chitotriosidase was 
determined in plasma of GD patients, in an attempt to find any correlation with the 
severity of clinical manifestations or genotype. 
• The T lymphocyte major subsets were also studied in GD patients in order to verify 
if abnormalities in the immune system could also be associated to the clinical 
expression of the disease. 
• Finally, this work reports the assessment of all these abnormalities in patients 
submitted to the enzyme supplementation therapy in order to get further insight in 
the pathophysiology of the disease. 
5.2 Materials and methods 
5.2.1 Materials 
5.2.1.1 Samples 
Blood and tissues were obtained from Portuguese GD patients (both under treatment 
and untreated) and control subjects. Separated plasmas were stored frozen at -70°C. 
Control spleens were collected from surgery of organ transplantation donors. Spleens 
from Portuguese patients with type 1 GD were collected after therapeutic splenectomy. 
All tissues were kept frozen at -70°C. Tissues requiring transportation were shipped in 
solid carbon dioxide. 
5.2.1.2 Reagents 
4-methylumbelliferone (4-MU), 4-Methylumbelliferylphosphate, 4-MU-p-D-N,N',N"-
triacetylchitotriosidase and 4-MU-N-acetylglucosamine (4 MU-GlcNac) were purchased 
from Sigma. The 4-MU-GlcNac sulphatide derivative (4-MU-glcNacS) was obtained 
from Moscerdam (The Netherlands). 
Standards of cholesterol, ceramide, non-hydroxylated and hydroxylated 
galactosylceramide, phosphatidylethanolamine, lactosylceramide, phosphatidylcholine, 
phosphatidylserine, phosphatidylinositol, sphingomyelin and ganglioside III were all 
from Sigma and of bovine origin. 
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Glucosylceramide standard was from Sigma and of Gaucher spleen origin. C18 Bond 
Elut columns (2.8ml column volume and 500mg sorbent mass) were from Analytichem 
International. 10x1 Ocm and 10x20cm HPTLC plates precoated with silica gel 60 
(0.25mm), were from Merck. 
All the others chemicals and solvents were from Merck. 
5.2.2 Methods 
5.2.2.1 Lipid analysis 
Extraction: Sphingolipids and phosphoglycerides are of amphipatic nature and were 
extracted from their biological sources with chloroform/methanol mixtures (Folch et al, 
1957). 
Total lipid extract was obtained by 2 cycles of vortexing 1 minute the sample with 6 
volumes of chloroform/methanol (1:2, v/v). The total volume of solvent extraction was 
evaporated to dryness and the dryed lipid content was further dissolved in 
chloroform/methanol/water (2:8:4). 
Fractionation: Prepacked reversed-phase C18 columns were used to remove non-lipid 
contaminants (Kirklund, 1987) and to separate by polarity differences into acidic and 
neutral lipids. The column bounded lipids were fractionated into acidic (eluted with 
methanol/water, 12:1) and neutral (eluted with chloroform/methanol, 1:2); water-soluble 
lipids namely gangliosides were recovered in the acidic fraction (Kirkund, 1987). The 
procedure was carried out at room temperature. Both fractions were evaporated to 
dryness at 40°C under a stream of nitrogen. 
Alkaline hydrolysis: To half of the neutral fraction, a mild hydrolysis was done as an 
additional purification step which allows the elimination of some contaminating 
phosphoglycerides that interfere in thin layer chromatography (TLC) with sphingolipids 
by presenting similar Rfs (Esselman et al, 1974)). The ceramide moiety is made of 
sphingosine, a long chain amino alcool, and an amide linked fatty acid (being human 
sphingosine essentially of C18 nature). Phosphoglycerides have O-linked fatty acids 
which do not occur in sphingolipids. A way to distinguish between these two types of 
lipids is performing alkaline hydrolysis. This treatment affects only lipids containing 
esterified fatty acids (Vance and Sweeley, 1967). 
After being redissolved by chloroform/methanol (1:2, v/v) one half of the neutral lipid 
fraction was subjected to mild alkaline hydrolysis in methanolic sodium hydroxide at 37 
°C during 30 minutes (Vance and Sweeley, 1967). Gangliosides being rather 
hydrophilic due to their content of glycosides are lost in the aqueous phase during 
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alkaline hydrolysis procedure (see flow scheme of the previously described lipid 
analysis procedure in Figure 5-2). 
PLASMA SAMPLE 
CH3COOH/CHCI3 extraction 
LIPID FRACTION 
Lipid fractionation 
ACIDIC FRACTION 
Alkaline hydrolysis 
Hydrolysed NEUTRAL FRACTION 
Figure 5-2 
Flow scheme of the lipid analysis procedure. 
Thin layer chromatography (TLC): Phosphoglycerides, sphingolipids and sterols were 
then fractionated by TLC and visualized with specific staining reagents. 
Dried fractions were redissolved in chloroform/methanol (1:2, v:v) and immediatly 
applied to HPTLC plates previously activated at 100°C for 1 hour before use. An 
equivalent to 100 uJ of plasma and appropriate amounts of lipid standards (0.25-2 u,g) 
were applied to the plates. Several developing solvent mixtures were used for lipid 
separation; The monohexoside fraction was separated into glucosylceramide and 
galactosylceramide on TLC plates previously impregnated with a 1% Na2B4Û7 
solution (Kean, 1966) before sample application and the development was performed 
with chloroform/methanol/water (70:30:5). To separate phosphatidylserine from 
phosphatidylinositol the plate was firstly developed with a mixture of 
chloroform/methanol/acetic acid/formic acid/water (35:15:6:2:1) to 4.5cm from the 
application point in the plate. The plate was then redeveloped with a mixture of n-
hexano/diisopropilic ether/acetic acid (65:35:2) in the same direction and to 6.0cm from 
the application point of the plate (Macala et al, 1983). The 
chloroform/methanol/15mmol/l CaCl2 (55:45:10) system was used for the resolution of 
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gangliosides and chloroform/methanol/NH3 25% (95:5:0.8) for the resolution of non-
polar lipids such as free ceramide and esterified cholesterol. 
After development plates were dried under air stream and the lipids were visualised 
with 0.4% anisaldehyde and 2% (v/v) sulphuric acid in acetic acid, followed by 30 
minutes at 100°C in the oven. Gangliosides were visualised with 0.3% resorcinol, 80% 
(v/v) sulphuric acid and 0.25 mmol/l cupric sulphate. 
The doublet observed in some of the sphingoiipid spots was caused by the diferential 
migration of the lipid molecules. This is due to either the content of hydroxy fatty acids 
in the ceramide moiety (being the lower band due to the hydroxylated one), or to 
differences in fatty acid lenghts in the ceramide moiety (Merrill and Jones, 1990). 
Quantification: The optical density of each band was scanned with a Transidyne 
General Corporation Densitometer, model 2500, in the transmittance mode, at 500nm 
wavelenght, and the area of each peak was determined by integration. Lane widths 
were kept constant within each comparison set. The quantification of the lipid band was 
made by comparing with the area of the respective standard applied on the same plate 
with a known concentration. The recovery of the sphingoiipid following the complete 
procedure ranged from 72 to 81%. With respect to sensitivity, the smallest amount of 
sphingoiipid that could be detected by TLC was 250ng and the maximal amount 
quantitatively detected was 2000ng. 
5.2.2.2 Plasma separation 
Plasma was obtained from heparinised peripheral blood, by centrifugation at 310 rpm 
during 10 minutes (Skoog and Beck, 1956). 
5.2.2.3 Preparation of t issue homogenates 
Tissues (4ml/g of tissue) were homogenised in 10 mmol/l Tris-HCI buffer ph 7.0 
containing 0.1% (v/v) Triton X-100, 1 mmol/l EDTA, 0.287 mmol/l PMSF and 0.004 
mmol/l leupeptin, by 6 cycles of 30 seconds at 4 000 rpm (Polytron homogeniser). Cells 
were disrupted by sonication with 30 cicies of 0.6 second, «50 watts, with pauses of 0.4 
second (Weat Systems W 375). The crude homogenates were then subjected to 
centrifugation at 100 000 xg for 1 h (Sorvai centrifuge). The entire procedure was 
performed at4°C. The resulting supernatant, referred to as homogenate, served as the 
source of enzyme in all assays. 
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5.2.2.4 Enzyme assays 
Fluorometric assays were performed using 4-methylumbelliferyl (4-MU) derivatized 
artificial substrates, essentially according to procedures described by Galjaard (1980). 
All assays were carried out at 37°C. Reactions were stopped by the addition of 1 mol/l 
sodium glycinate buffer, pH 10.0. The released fluorescence was compared with that of 
standards, using an excitation and emission wavelenght of 365 and 445nm, 
respectively (fluorescence read on an Aminco SPR spectrofluorometer). Standards 
used for the calibration curve were prepared from a solution of 10mmol/l 4-MU in 
cloroform/methanol (2:1). Results of each series of measurements were algebrically 
calculated by using the linear regression parameters corresponding to the calibration 
curve. 
Chitotriosidase activity: The assay was carried out by incubating during 15 minutes the 
previously acidified plasma or cell/tissue extract with 0.0260 mmol/l 4-MU-p-D-
N,N',N"-triacetylchitotriose substrate, prepared in 0.1/0.2 mol/l citrate/phosphate 
buffer, pH 5.2. 
Total ^-hexosaminidase activity: The assay was carried out by incubating during 15 
minutes the previously acidified plasma or cell/tissue extract with 1.7 mmol/l 4-MU-N-
acetyl-p-D-glucosaminide substrate, prepared in 0.1/0.2 mol/l citrate/phosphate buffer, 
pH 4.4. 
(3-hexosaminidase A activity: The assay was carried out by incubating during 60 
minutes the previously acidified plasma or cell/tissue extract with 1 mmol/l 4-MU-6-
sulpho-p-D-glucopyranoside substrate, prepared in 0.1/0.2 mol/l citrate/phosphate 
buffer pH 4.0. 
Tartrate resistant acid phosphatase (TRAP) activity: assay was carried out by 
incubating during 15 minutes the previously acidified plasma or cell/tissue extract with 
5mmol/l 4-MU-phosphate substrate prepared in 0.1 mol/l sodium citrate/citric acid 
buffer, pH 6.0, and 0.057 mol/l tartaric acid. 
5.2.2.5 Protein determination 
Protein was measured according to a modification (Herbert et al, 1974) of the Lowry's 
method (Lowry et al, 1951). Bovine serum albumin was used as a standard. 
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5.2.2.6 Cellulose acetate electrophoresis of p-hexosaminidase 
isoenzymes 
Samples were applied with an LRE applicator on cellulose acetate strips 
5.7cmX14.0cm (Cellogel) previously equilibrated in 40mmol/l potassium phosphate, pH 
6.0, electrophoresis buffer. The strips were placed in the electrophoretic tank (EP-166 
Medizin Technik) and a constant voltage of 200 V was applied for 1.5 hours, at 4°C. 
Strips were incubated at 37°C, for 0.25 hours, with 5mmol/l 4-MU-N-acetyl-p-D-
glucosaminide, in 0.1/0.2 mol/l citrate/phosphate buffer, pH 4.75. The reaction was 
stopped with 1 mol/l sodium glycinate buffer, pH 10.0. The fluorescent bands of (3-
hexosaminidase activity were visualized at 366nm and photographed with a type 667 
Polaroid film (Poenaru and Dreyfus, 1973; Ribeiro et al, 1995). 
5.2.2.7 Ion exchange chromatography of p-hexosaminidase 
Columns (0.5x5.0cm) of DEAE-Sephadex were prepared by equilibrating the resin in 
0.1 mol/l sodium phosphate buffer, pH 6.0, and next in 0.01 mol/l sodium phosphate 
buffer, pH 6.0. To the above columns, 0.2 ml of homogenate containing 0.1-0.5 mg of 
protein was applied. p-Hexosaminidase B activity was eluted in the first fractions of the 
equilibrating buffer wash with a flow rate of 0.2-0.3 ml/minute. Following elution of the B 
isoenzyme activity, p-hexosaminidase A activity was eluted with 0.01 mol/l sodium 
phosphate buffer, pH 6.0, containing a gradient of 0-0.3 mol/l NaCI. The enzymatic 
activity of 600 JLX! fractions was measured with 4-MU-GlcNAc substrate as previously 
described. The identity of the resolved isoenzyme activities was confirmed as being 
hexosaminidase A and B, respectively, either by the heat denaturation procedure of 
incubation at 0°C and 50°C prior to the enzyme activity measurement, as well as by 
cellulose acetate electrophoresis. The thermo-resistant activity was expressed as 
percentage of the total activity (Nagakawa et al, 1977). 
5.2.2.8 Statistical analysis 
Data were analyzed using the SPSS (Statistical Program for the Social Sciences). All 
testing was performed at the level of significance of 0.05. Correlation coefficients 
(Spearman rank correlation) were calculated to infer the possible association between 
the variables under study. The statistical analysis focused on the demonstration of 
significant differences found between group means was analysed by student t-test or 
by a non-parametric test (Kruskal-Wallis test) when data do not showed a normal 
distribution. 
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It was performed non-linear trend analyses to detect changes in the mean number of T 
lymphocyte cells in those patients treated with alglucerase/imiglucerase enzime 
supplementation therapy for at least 24 months. For the analyses from a single patient, 
multiple regression models were formed in a hierarchical steps-down fashion. The 
response variable was percent of initial activity for CD4+ (or CD8+) cells and indicator 
variables represented whether a change did, or did not, occur during each specified 
month of therapy. All possible subsets of indicator variables (i.e. months) were 
considered using themethod known as Leaps and Bounds (Furnival et al, 1974). Thus, 
models with one or more change(s) in the mean response were compared to that of the 
null model (no change in the mean response during therapy). A minimum risk criteria 
was applied for model selection (Eubanks, 1988). Specialized programs for these trend 
analyses were written using the statistical programming language S-PLUS 4.5 
(MathSoft, Inc., Seattle, Washington). This analyses was perfomed by CE McLaren 
from the Division of Epidemiology, Department of Medicine, University of California. 
5.2.2.9 Iron metabol ism and T lymphocyte analysis 
The hematological and biochemical parameters of iron metabolism were performed by 
the Department of Hematology, at the St. Antonio General Hospital, in Porto. The 
CD4+ and CD8+ T cell analysis was performed by the Department of Molecular 
Immunology and Pathology of the Abel Salazar Institute for Biomedical Sciences, of 
Porto University. 
5.3 Results 
5.3.1 Plasma l ipid analysis 
The neutral lipid fraction is mainly constituted of glucosylceramide, galactosylceramide, 
lactosylceramide, ceramide, sphingomyelin, free and esterified cholesterol and the 
phospholipids phosphatidylethanolamine and phosphatidylcholine. The separation of 
the glucosylceramide using the chloroform/methanol/water (70:30:5) system showed 
an increased concentration of this lipid in the majority of the GD patients; with respect 
to the remaining separated lipids (galactosylceramide, lactosylceramide, 
trihexosylceramide and sphingomyelin) no significant differences were found between 
patients and controls (Figure 5-3). 
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Figure 5-3 
TLC profile of glucosyiceramide extracted from plasma of type 1 GD patients. The neutral lipid 
fraction of plasma samples was submited to alkaline hidrolysis and the plates were developed with the 
chloroform/methanol/water (70:30:5) system. Applied standards (std) are glucosyiceramide (GluCer) 
hydroxilated and non hydroxilated, galactosylceramide (GalCer) hydroxilated and non hydroxilated, 
lactosylceramide (Lac), trihexosylceramide (Cer3) and sphingomyelin (Sph) C, control plasma sample. 
Statistical analysis showed that plasma glucosyiceramide concentration was 
significantly different (p<0.01) between controls (mean=0.843±0.292 mg/100 ml 
plasma, n=17) and GD patients (mean=2.21 ±0.966 mg/100ml plasma, n=29). Although 
plasma glucosyiceramide concentration could be 6-fold the control mean value, there is 
an overlap between the concentration range of patients (1.08-5.00 mg/ml of plasma) 
and controls (0.32-1.19mg/ml of plasma) (Table 5-1). 
No significantly difference (p=0.981) was observed in glucosyiceramide concentration 
between splenectomised and non-splenectomised GD patients. 
%.S-Y 
GD patients 
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Table 5-1 
Plasma glucosylceramide concentration (mg/100 ml plasma) of type 1 GD patients. The genotype, 
clinical severity score (SSI) and the spleen status (patients subjected to splenectomy) are also indicated. 
Genotype Patient SSI Splenectomy Glucosylceramide 
(mg/100ml plasma) 
N370S/N370S 5 5 - 1.28 
6 4 - 1.78 
9 4 - 1.49 
18 7 + 1.25 
21 7 - 2.32 
32 7 - 1.81 
Mean 1.66 
Range 1.25-2.32 
N370S/L444P 10 11 - 3.30 
11 11 - 2.68 
23 6 - 1.40 
28 7 - 1.58 
33 19 - 3.18 
34 11 - 2.33 
Mean 2.43 
Range 1.40-3.30 
N370S/R463C 1 15 - 4.98 
N370S/IVS2+1 7 14 + 2.17 
8 14 + 2.45 
15 5 - 1.14 
Mean 1.92 
Range 1.14-2.45 
N370S/? 19 10 - 1.13 
22 8 - 2.65 
24 10 + 2.78 
30 9 + 2.12 
31 14 + 1.81 
35 9 - 1.17 
39 12 - 3.62 
47 9 + 1.08 
Mean 1.82 
Range 1.08-2.78 
N370S/Rec TL 12 15 + 3.82 
N370S/Rec Neil 36 19 + 3.35 
L444P/L444P 41 16 + 1.71 
G377S/G377S 29 14 + 2.43 
XIX 37 6 - 1.81 
Glucosylceramide Patients Controls P 
n 29 17 
mean+std 2.21+0.966 0.843+0.292 <0.01 
Range 1.08-5.00 0.32-1.19 
Student't test was used to 
considered non-significant (n 
study differences between patients and 
.s.). 
controls. Probability (p) values above 0.05 are 
No statistically significant difference was also observed in plasma glucosylceramide 
concentration between the different genotype group of patients (Figure 5-4). 
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Figure 5-4 
Plasma glucosylceramide concentration (mg/100 ml of plasma) of genotyped type 1 GD patients 
(splenectomized and non-splenectomized). 
As it can be observed in Figure 5-5, a signif icant posit ive correlat ion ( r=0.60) was 
observed between plasma glucosy lceramide concentrat ion and clinical sever i ty score 
(SSI) of GD patients (Figure 5-5). As presented in the previous tab le, within the s a m e 
genotype group, clinically more severe patients (showing higher SSI) had higher 
plasma glucosylceramide concentrat ion (Table 5-1). More specif ical ly, pat ient 15 
(N370S/IVS2+1) presented a relatively mild clinical phenotype (SSI of 5) and w a s 
clinically asymptomat ic until very recently. In contrast, patient 7 and 8 showed about 
twice the concentrat ion of plasma glucosy lceramide and are comparat ive ly clinically 
more severe (both had an early onset and present a SSI of 14). Patient 12, 36 and 29 
present a relatively moderate plasmat ic glucosy lceramide accumula t ion and have a 
moderate to severe SSI (15, 19 and 14 respect ively) . Within the N370S/L444P 
genotype, patients 10, 1 1 , 33 and 34 present a higher level of circulat ing 
glucosylceramide than patients 23 and 28. Accord ing ly these two last patients present 
a moderate clinical phenotype (SSI of respect ively 6 and 7) whi le pat ient 10, 1 1 , 33 and 
34 have a more severe clinical phenotype (SSI of respect ively 1 1 , 1 1 , 19 and 11) 
(Table 5-1). 
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Correlation: r=0.62, p<0.05 
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Figure 5-5 
Plasma glucosylceramide concentration (mg/100 ml of plasma) and clinical severity (SSI) of type 1 
GD patients. 
In order to quantify plasma ceramide concentration, the TLC analysis was performed 
using the chloroform/methanol/NH3 25% (95:5:0.8) development system (Figure 5-6). 
No significant difference (p>0.05) was observed in ceramide concentration between 
controls (1.42±1.30, range 0.394-4.95 mg/100ml of plasma, n=12) and GD patients 
(1.95±1.45, range 0.212-4.68 mg/100ml of plasma, n=20). 
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Figure 5-6 
TLC profile of ceramide extracted from plasma of type 1 GD patients. To separate cholesterol and 
ceramide from the neutral lipid fraction of plasma samples the plate was developed with a mixture of 
chloroform/methanol/NH3 25% (95:5:0.8). Applied standards (std) are colesterol esters (CE), colesterol 
(CO) and 4 \ig of ceramide (CerO). Triglycerides (TG) migrate with CE. C, control plasma sample. 
In order to quantify plasma gangliosides concentration, the TLC analysis was 
performed using the chloroform/methanol/15mM calcium chloride (55:45:10) 
development system (Figure 5-7). No significant difference (p>0.05) was observed in 
GM3 ganglioside concentration between controls (1.19±0.38, range 0.870-1.91 
mg/100ml of plasma, n=6) and GD patients (1.48+0.502 range 0.650-2.90 mg/100ml of 
plasma, n=20). 
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Figure 5-7 
TLC profiles of GM3 ganglioside extracted from plasma of type 1 GD patients. To separate different 
gangliosides from the acidic lipid fraction of plasma samples plates were developed with the 
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chloroform/methanol/15 mmol/l calcium cloride (55:45:10) system. Applied standards (std) are 
monosialoganglioside GM3 (GM3), monosialoganglioside GM2 (GM2), monosialoganglioside GM1 (GM1), 
disialoganglioside GD1a (GD1a), disialoganglioside GD1b (GD1b) and trisialoganglioside GT1b (GT1b). 
The lipid band that migrates above GM3 ganglioside representes a mixture of acid phosphoglicerides. C, 
control plasma sample. 
5.3.2 Plasma tartrate résistante acid phosphatase (TRAP) act ivi ty 
Plasma TRAP activity is significantly different (p<0.01) between adult and infantile 
population. A statistically significant difference (p<0.01) was observed between the 
activity of TRAP in adult controls (mean=371.4±170.8 nmol/h/ml of plasma, n=68) and 
GD patients (mean=2459±1727 nmol/h/ml of plasma, n=24). Although the TRAP 
activity of patients could be increased 22-fold the control mean value, there was an 
overlap between the range activity from patients (507-7781 nmol/h/ml of plasma) and 
controls (54.1-968 nmol/h/ml of plasma). There is no overlap between plasma TRAP 
activity from the 2 infantile patients and the corresponding age matched control range 
(37.1-1591 nmol/h/ml of plasma) (Table 5-2). 
Table 5-2 
Plasma tartrate resistant acid phosphatase (TRAP) activity (nmol/h/ml of plasma) of type 1 GD 
patients. 
Plasma tartrate resistant acid phosphatase activity (nmol/h/ml) 
Adults (age >12 years) Infants (age <12 years) 
Patients Controls Patients Controls 
n 26 68 2 76 
Mean+std 2367+1697 371.4±170.8 2586±21.21 636.5±316.0 
Range 507-7781 54.1-968 2571-2601 37.1-1591 
P <0.01 <0.01 
Student't test was used to study differences between patients and controls. Probability (p) values above 0.05 are 
considered non-significant (n.s.). 
The analysis of plasma TRAP activity for each genotype group showed that the activity 
presented by the N370S homozygote group (1121+486.3, n=7) (being all of them 
adults) is significantly lower (p<0.05) than that presented by the remaining adults 
patients (2886+1759, n=19). Moreover, the overlap between plasma TRAP activity of 
GD patients and the control range was specially observed for the N370S homozygotes 
(Figure 5-8). 
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Figure 5-8 
Plasma tartrate resistant acid phosphatase (TRAP) activity (nmol/h/ml of plasma) of genotyped 
type 1 GD patients. 
No significant correlation (r=0.28) was obtained between plasma TRAP activity and 
clinical severity score (SSI) of adult GD patients (Figure 5-9). However normal activity 
values were observed in patients without skeletal disease (patients 18, 21, 32, 38). 
Exceptions were patients 30 and 49, who present abnormal TRAP activity values 
without imagiological (by Rx and RMN) signs of bone disease. 
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Figure 5-9 
Plasma tartrate résistent acid phosphatase (TRAP) activity (nmol/h/ml of plasma) and clinical 
severity (SSI) of type 1 GD patients. 
5.3.3 The ^-Hexosaminidase activity 
5.3.3.1 The p-hexosaminidase activity in plasma 
A statistically significant difference (p<0.01) was observed between total (3-
hexosaminidase activity in controls (657±250 nmol/h/ml of plasma, n=821) and GD 
patients (1819+1411 nmol/h/ml of plasma, n=36). Although p-hexosaminidase activity 
of patients could be increased 9-fold the control mean value, there was an overlap 
between the activity range from patients (187-7102 nmol/h/ml of plasma) and controls 
(140-1434 nmol/h/ml of plasma) (Table 5-3). 
Similar results were observed with respect to p-hexosaminidase A isoenzyme activity. 
Although the activity of patients could be increased 2-fold the control mean value, there 
was an overlap between the activity range from patients (78.0-610 nmol/h/ml of 
plasma) and controls (28.45-351 nmol/h/ml of plasma) (Table 5-3). 
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Table 5-3 
Plasma total p-hexosaminidase and p-hexosaminidase A activity (nmol/h/ml of plasma) of type 1 
GD patients. 
Plasma p-hexosaminidase activity (nmol/h/ml) 
Total p-hexosaminidase p-hexosaminidase A 
Patients Controls Patients Controls 
n 36 821 31 394 
mean+std 1819±1411 657.1±250.3 244.1+132.9 111.3±57.79 
range 187-7102 140.4-1434 78.0-610 28.45-351 
P <0.01 < 0.01 
Student't test was used to study differences between patients and controls. Probability (p) values above 0.05 are 
considered non-significant (n.s.). 
No statistically significant difference was observed in plasma p-hexosaminidase activity 
between the different genotype groups. The overlap between plasma p-
hexosaminidase activity of GD patients and the control range was observed for several 
genotype groups (Figure 5-10). 
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Figure 5-10 
Plasma total p-hexosaminidase activity of genotyped type 1 GD patients. 
No significant correlation (r=0.005) was obtained between plasma total p-
hexosaminidase activity and clinical severity score (SSI) of GD patients (Figure 5-11). 
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Figure 5-11 
Plasma total p-hexosaminidase activity (nmol/h/ml of plasma) and clinical severity (SSI) of type 1 
GD patients. 
5.3.3.2 The ^-Hexosaminidase activity in spleen 
In spleen extracts from patients presenting different types of GD, the activity of total (3-
hexosaminidase was found to be increased 3-17 fold (Table 5-4). In addition to the 
deficiency in glucocerebrosidase activity, in all types of GD it can also be observed a 2 
to 4-fold increase in p-glucuronidase, a-fucosidase and acid phosphatase. The activity 
of sphingomyelinase and a-mannosidase is however slightly decreased. 
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Table 5-4 
Total p-hexosaminidase and other lysosomal enzymes activity (nmol/h/mmg of protein) from 
spleen of GD patients. Studied spleens were from two type 1 GD patients (being one of them from 
Ashkenazi Jewish ancestry, A) a type 2 and a type 3 GD patient. Glucocerebrosidase was measured in 
the presence of sodium taurocholate, at pH 5.2. 
Patient's spleens Control's spleens 
Activity (nmol/h/mg of protein) % of control mean 
Activity (nmol/h/mg 
of protein) 
Enzyme 1 1(A) 2 3 1 1(A) 2 3 Mean 
(n=2) 
Range 
Total B-
Hexosaminidase 
18 480 31 248 10 004 54 677 563 963 305 1 667 3 280 1 781-4 780 
Glucocerebrosidase 1.68 0.57 1.17 1.77 8.4 2.8 5.8 8.8 20.0 18.6-21.4 
p-Glucuronidase 557 373 518 590 366 245 341 388 152 114-190 
a-Fucosidase 830 597 376 596 449 323 203 322 185 159-212 
p-Galactosidase 172 67.9 113 156 73 29 48 67 234 223-246 
a-Galactosidase 40.2 22.3 44.4 43.3 93 52 103 100 43.3 33.9-52.7 
Acid phosphatase 9 982 7 124 3 916 12 596 192 137 75.5 243 5 185 3 713-6 657 
Sphingomyelinase 14 7.7 7.5 8.1 93 51 50 54 17.5 15-20 
a-Mannosidase 101 56.5 103 94.1 71 39 72 66 143 127-159 
Cellulose acetate gel electrophoresis of p-hexosaminidase activity extracted from 
spleen showed that in contrast to controls, GD patients present a major form of p-
hexosaminidase B activity (Figure 5-12). 
a B c d e F 
Figure 5-12 
Cellulose-acetate gel electrophoretic pattern of total p-hexosaminidase activity extracted from 
spleen of GD patients. Studied spleens were from patients presenting different clinical types. Lane a, 
type 1 GD patient (N370S/?); lane b, type 1 GD Ashkenazi patient (N370S/84GG); lane c, type 2 GD 
patient (L444P/?); lane d, type 3 GD patient (L444P/?); lane e, and f controls. All samples contained 10ng 
of protein. 
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The quantification of p-hexosaminidase isoenzymes was done after isoenzymes 
separation by ion exchange DEAE-cellulose chromatography (Figure 5-13). Recovered 
fractions were identified by termostabiiity test at 50°C (Table 5-5) and migration pattern 
on cellulose acetate electrophoresis. p-Hexosaminidase activity contained in the low 
salt eluate was heat-resistant (and migrates as p-hexosaminidase B of the total applied 
extract) whereas that in the high salt was heat-labile (and migrates as p-
hexosaminidase A of total extract). The recovery of total hexosaminidase activity from 
the ion exchange column was greater than 90% and the ratio of the p-hexosaminidase 
A to that of the p-hexosaminidase B in control spleen was on average 3. Similar 
chromatographic elution patterns were obtained with spleen from GD patients, with the 
exception that a larger proportion of the total hexosaminidase activity appeared in 
fractions corresponding to hexosaminidase B (Figure 5-13). 
1 4 7 10 13 16 19 22 25 28 31 34 37 40 
Fraction 
-♦—infantile control —»—adult control —«—type 1 -«—type lAshkenazi - *— type 2 -ár-type 3 
Figure 5-13 
Ion-exchange chromatographic profile of p-hexosaminidase activity from spleens of controls, type 
1, type 1 Ashkenazi, type 2 and type 3 Gaucher disease patients. 
The p-hexosaminidase A/B ratio extracted from spleens of GD patients was on average 
0.38 (range 0.28-0.47). In GD patients, p-hexosaminidase B activity was found to be 
increased 5 to 24-fold whereas hexosaminidase A activity was only 2 times increased 
(only in the type 3 and type 1 Ashkenazi patient) (Table 5-5). 
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Table 5-5 
The p-hexosaminidase A and B isoenzymes activity and the percentage of termostable activity 
extracted from spleens of type 1, 2 and 3 GD patients. 
((-Hexosaminidase 
% Termostable activity at 50 "C 
Isoenzyme A Isoenzymes 
Activity (nmol/h/mg protein) 
Isoenzyme A Isoenzyme B Spleens A/B 
Control 11 91 4690 1566 3.0 
type 1 patient 1.5 75 3813 8039 0.47 
type 1 Ashk. 35 85 8666 22582 0.38 
type 2 18 87 4298 11074 0.39 
type 3 14 89 10434 37243 0.28 
5.3.4 Plasma chitotr iosidase activity 
Chitotriosidase activity was studied in a total of 345 individuals, including subjects 
without a diagnosis for any of the tested lysosomal storage diseases, type 1 GD 
patients, GD obligate carriers, GD putative carriers for unkown mutations, patients 
presenting other lysosomal storage diseases than GD and finally patients presenting 
Idiopathic Hemochromatosis. 
Subjects without diagnosis (n=229) presented a plasma chitotriosidase activity in the 
range of 1.00-413 nmol/h/ml (median=34.5 nmol/h/ml). Type 1 GD patients (n=29) 
presented a marked elevation of plasma chitotriosidase activity but ranged from 1.50 to 
68 394 nmol/h/ml (median=13 169 nmol/h/ml). GD obligate carriers (n=6) presented a 
plasma chitotriosidase activity in the range of 2.59-79.1 nmol/h/ml (median=43.8 
nmol/h/ml); similarly GD putative carriers for unidentified mutations (n=11) had an 
activity in the range of 19.00-149.2 nmol/h/ml (median=58.10 nmol/h/ml). Idiopathic 
Hemochromatosis patients (n=23) presented a plasma chitotriosidase activity in the 
range of 1.128-569.8 nmol/h/ml (median=70.26 nmol/h/ml) (Table 5-6). 
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Table 5-6 
Plasma chitotriosidase activity of patients with and without lysosomal storage disorders. 
Chitotriosidase activity (nmol/h/mnl 
plasma) 
Median Range n 
Subjects without diagnosis 34.5 1.00-413 229 
Type 1 GD patients 13 169 1.50-68 394 29 
GD obligate carriers 43.8 2.59-79.1 6 
GD putative carriers for unknown 58.10 19.00-149.2 11 
mutations 
Patients with a lysosomal storage 53.34 11.43-1216 23 
disorder 
Idiopathic Hemochromatosis patients 70.26 1.128-569.8 23 
The logarithm (log 10) of chitotriosidase activity value was used instead of the 
observed values, since the distribution of the values after this transformation is 
approximately normal (Kolmogorov-Smirnov test, p=0.66), allowing to analyse 
interferences regarding extreme values and outliers. The histogram of log 10 of 
chitotriosidase activity of all cases allows the perception of extreme values, on both 
tails of the distribution. GD patients distribute above de 3.00 class of log 10 of 
chitotriosidase activity (Figure 5-14). 
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Chitotriosidase activity (Log 10) 
Figure 5-14 
Histogram of plasma chitotriosidase activity (log 10) of type 1 GD patients, obligate and putative 
carriers (relatives) of GD families, and controls. The X axis shows the logarithm (base 10) of 
chitotriosidase activity. 
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The calculated mean and standard deviation for all the 229 control cases (individuals 
without diagnosis) was respectively 1.516±0.352. In Figure 5-15 it can be observed that 
there is also no overlap in plasma chitotriosidase activity between GD patients, GD 
carriers, putative carriers and controls (individuals without diagnosis). 
6-]  
5-
4> 
3-
1 • 
N = 29 6 11 229 
GD patient Putative carriers 
Obligate carriers Controls 
Figure 5-15 
Plasma chitotriosidase activity (log 10) of type 1 GD patients, obligate carriers, putative carriers of 
affected GD families. The Y axis represents the logarithm (base 10) of chitotriosidase activity. For each 
status median values are plotted within boxes limited by the 1st and 3rd quartil. Smallest and greatest 
values are also indicated outside boxes. Outlier values are indicated by symbols. 
One possible way to deal with the extreme values is to consider them as outliers, i.e., 
values that occur so far, without a biological explanation and that lay far away from the 
centre of the distribution. The criteria was to exclude all cases that lie away from the 
mean three standard deviations, i.e., cases below 0.462 and above 2.571; according to 
this criteria 9 cases were discarded. Independently of these outlyer values, GD patients 
are clearly distinguished from other lysosomal or non-lysosomal diseases by 
presenting a marked elevation of plasma chitotriosidase activity without overlap (Figure 
5-16). 
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N= 29 1 1 4 1 1 1 2 2 1 2 5 1 3 1 23 229 
GAU GM2/T GM2/J MLD NPD/C MTL SIA MPS Controls 
GM1 GM2/B1 ASP NPD MLP/II SAN/B ICX HEM 
Figure 5-16 
Plasma chitotriosidase activity (log 10) of patients with hemochromatosis (HEM), X-iinked ictiosis 
(ICX) and different lysosomal storage diseases. Gaucher disease (GAU), GM1 Gangliosidosis (GM1), 
Tay-Sachs disease (GM2/T), B1 variant of GM2 Gangliosidosis (GM2/B1), juvenile form of GM2 
Gangliosidosis (GM2/J), Aspartylglucosaminure (ASP), Metachromatic leucodistrophy (MLD), Niemman-
Pick (type A and B), Niemman-Pick type C (NPD/C), mucolipidosis type 2 (MLP/II), Maroteaux-Lamy 
(MTL), Sanphilippo type B (SAN/B), Sialidosis (SIA), and mucopolysacharidosis (MPS). The Y axis 
represents the logarithm (base 10) of chitotriosidase activity. For each status median values are plotted 
within boxes limited by the 1st and 3rd quartile. Smallest and greatest values are also indicated outside 
boxes. Outlier values are indicated by symbols. 
The new calculated logarithm mean and standard deviation were 1.534+0.300, and the 
95% confidence limits of 0.947-2.122, allow the conclusion that approximately 3% of 
the cases do lie outside these limits (being 2% below limits). All together, 
independently of status with respect to GD or any other studied disease, according to 
that reported (Hollak et al, 1994), cases that lie below the limits seem to present the 
inherited deficient of chitotriosidase activity. In fact, patient 33 was found to present this 
inherited chitotriosidase deficiency (chitotriosidase genotype analysis performed by the 
laboratory of Prof. J. Aerts). The non-logarithm mean, standard deviation and range 
calculated without the chitotriosidase deficient is presented in Table 5-7. 
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Table 5-7 
Plasma chitotriosidase activity of type 1 GD patients. 
N 
mean+std 
Range 
Plasma chitotriosidase activity (nmol/h/ml) 
Patients Controls 
40 
15 815116 439 
* 1 336-68 394 
818 
52.83±67.39 
* 8.85-132 
* Chitotriosidase deficient individuals were excluded. 
The analysis of chitotriosidase activity for each genotype group showed that the activity 
presented by the N370S homozygotes patients (3 751±2 807, n=11) is significantly 
lower (p<0.01) than that presented by the remaining patients (21 507+18 208, n=29) 
(Figure 5-17). Patient 33 did not have chitotriosidase activity and presented the 
inherited deficiency in the chitotriosidase gene (personal communication of J. Aerts). 
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Figure 5-17 
Chitotriosidase activity of genotyped type 1 GD patients. Considered control range (8.85-132 
nmol/h/ml of plasma) is not presented in the graph. 
No significant correlation (r=0.15) was observed between plasma chitotriosidase 
activity and clinical severity score (SSI) (Figure 5-18). 
130 
Enzyme supplementation therapy in the study of underlying pathogenic mechanisms of Gaucher disease 
n.s. 
24 
20 
~ 16 
C/3 
W 
CD > CD 
8 
12 
0 
-10000 
36 
O 
41 
O40 
31 O 8 
O O 
39 
1 O 
) 492419 
O O O 
7 
O 
29 
O 
3411 
O O 
3218,21 14 
O O 420 
5 16015 
0 6 0 O 
O r-
38,43 
O 
35 47 30 
O O O 
37 23 
OO 
■12 
O 
-20-
O 
22 
- O " 
- 1 -
O 
28 
O 
10 
o 
25 
~o~ 
10000 20000 30000 40000 50000 60000 
Chitotriosidase activity (nmol/h/ml plasma) 
70000 80000 
Figure 5-18 
Plasma chitotriosidase activity (nmol/h/ml of plasma) and clinical severity (SSI) of type 1 GD 
patients. 
5.3.5 Serum ferrit in 
When compared to the sex and age matched control range, 25 out of the 30 studied 
GD patients presented serum ferritin values abnormally high (7-fold maximum). 
Decreased serum iron and transferrin saturation were observed in 7 patients, 4 of them 
in association to the abnormal serum ferritin. Two of these were infantile patients, one 
of them (patient 19) presenting also abnormal serum ferritin (Table 5-8). 
131 
Chapter 5 
Table 5-8 
Serum ferritin (ng/ml), transferrin saturation, TS, (%) and serum iron ((ig/dl) presented by type 1 
GD patients. 
Patient Sex Age Genotype SSI Splenectomy Iron 
mm 
TS 
J%1_ 
Serum 
ferritin 
29 
49 
M 
M 
43 
49 
G377S/G377S 
G377S/G377S 
14 
10 
+1962 113 
136 
37 
45 
503 
1609 
41 M 17 L444P/L444P 16 +1993 106 35 441 
19 
24 
30 
31 
35 
46 a) 
47 
34 
23 
40 
10 c) 
11 c) 
33 
F 
M 
M 
F 
F 
F 
F 
F 
M 
M 
F 
M 
F 
10 
23 
36 
45 
27 
23 
29 
N370S/? 
N370S/? 
N370S/? 
N370S/? 
N370S/? 
N370S/? 
N370S/? 
10 
10 
9 
14 
9 
10 
9 
+ 
+1994 
+1994 
+1982 
59 
111 
96 
84 
83 
48 
123 
32 
30 
45 
13 
17 
25 
N370S/L444P 
N370S/L444P 
N370S/L444P 
N370S/L444P 
N370S/L444P 
N370S/L444P 
11 
6 
15 
11 
11 
19 
104 
81 
91 
40 
69 
76 
18 
44 
36 
25 
41 
15 
44 
39 
27 
30 
14 
25 
28 
319 
835 
2714 e) 
682 
445 e) 
117 
950 
7 b) F 21 N370S/IVS2+1 14 +1981 49 14 238 
8 b) F 44 N370S/IVS2+1 14 +1969 97 29 1163 
14 b) F 37 N370S/IVS2+1 7 - 50 18 359 
321 e) 
647 
637 
95 a)e) 
89 a)e) 
387 
38 
39 
32 d) 
18 
21 d) 
5 
43 
F 
M 
M 
F 
F 
F 
F 
31 
18 
54 
51 
52 
53 
30 
N370S/N370S 
N370S/N370S 
N370S/N370S 
N370S/N370S 
N370S/N370S 
N370S/N370S 
N370S/N370S 
2 
12 
7 
7 
7 
5 
2 
+1993 
116 
70 
57 
149 
79 
16 
65 
47 
23 
19 
61 
44 
5 
25 
1888 
710 
340 
261 
761 
485 
899 
1 M 23 N370S/R463C 15 . 93 28 1892 
36 M 32 N370S/recNcil 19 +1977 78 NA 1389 
12 F 58 N370S/recTL 15 +1939 70 25 1273 
20 F 26 N370S/X 5 . 92 26 579 
37 F 37 X/X 6 - 78 35 262 
Control Maie 50-181 19-62% e) 
range 
Female 44-160 15-59% 
Abnormal values were presented at bold. 
a, b, c) and d) indicate related patients from different families. 
e) For these patients there were not available serum ferritin values before therapy. 
f) Serum ferritin is sex and age dependent (Porto et al 1992) and considered reference values for the Portuguese 
population were presented in appendix section. 
No statistically significant difference was observed in serum ferritin between the 
different genotype groups (Figure 5-19). Patients without abnormal serum ferritin were 
representative of the 3 major genotype groups, being namely 1 N370S/? juvenile 
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patient (patient 46), 2 N370S/L444P infantile patients (patient 10 and 11) and 2 N370S 
homozygous adult unrelated patients (patients 31 and 32) (Figure 5-19). 
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Figure 5-19 
Serum ferritin of genotyped type 1 GD patients. 
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Figure 5-20 
Serum ferritin (ng/ml of serum) and clinical severity (SSI) of type 1 GD patients. 
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No significant correlation was also observed between serum ferritin level and clinical 
severity (SSI) of GD patients (Figure 5-20). 
5.3.6 Peripheral blood CD4+ and CD8+ T lymphocyte subsets 
The study of the peripheral blood T lymphocytes showed that GD patients presented 
significantly (p<0.05) decreased percentage of the CD4+ T lymphocyte subset (%CD4+) 
and %CD47%CD8+ T cell ratio (Table 5-9). 
Table 5-9 
Peripheral blood %CD4+ and %CD8+ T lymphocyte subsets of type 1 GD patients. 
Patients mean+std (n) Controls mean±std (n) 
%CD4+ 
%CD8+ 
%CD4+/%CD8+ 
39.64±9.05 (28) 
26.80+7.10(28) 
1.58±0.533(28) 
45.15±7.40(67) 
24.58±7.25(71) 
2.01±0.834 (67) 
0.02 
n.s. 
0.01 
Values represent the mean±sd of the percentage of each population gated on total lymphocytes. The number of 
analysed individuals is indicated between brackets. Student't test was used to study differences between patients and 
controls. Probability (p) values above 0.05 are considered non-significant (n.s.). 
The analysis of T lymphocyte %CD47%CD8+ ratio by genotype showed that when 
compared to the other patients, the N370S homozygotes present relatively higher ratio 
(Figure 5-21). 
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Figure 5-21 
Peripheral blood T lymphocyte %CD4+ and %CD8+ subsets ratio of genotyped type 1 GD patients. 
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There was no significant correlation (r=-0.29) between the %CD47%CD8+ ratio and the 
clinicai severity (SSI) of patients (Figure 5-22). 
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Figure 5-22 
Ratio of peripheral blood %CD4+ and %CD8+ T lymphocyte subsets and clinical severity (SSI) of 
type 1 GD patients. 
Statistical analysis showed that the %CD4+ and %CD8+ T lymphocyte subsets in the 
N370S homozygous patients were not significantly different from controls (Table 5-10). 
The statistically significant decreased %CD4+ T lymphocytes was observed in patients 
presenting the remaining genotypes. 
Table 5-10 
Peripheral blood %CD4+ and %CD8+ T lymphocyte subsets of N370S homozygous type 1 GD 
patients. 
N370S homozygotes Controls Other genotypes than 
Mean!std (n) P Meanlstd (n) P N370S homozygotes 
Mean±std (n) 
%CD4+ 44.8818.29 (8) n.s. 45.1517.40(67) <0.01 37.5418.65 (20) 
%CD8+ 24.3816.07 (8) n.s. 24.58±7.25(71) n.s 27.76±7.39 (20) 
%CD47%CD8+ 1.94±0.543(8) n.s. 2.01±0.834 (67) <0.01 1.4310.464(20) 
Values represent the meanlsd of the percentage of each population gated on total lymphocytes. The number of 
analysed individuals is indicated between brackets. Student't test was used to study differences between patients and 
controls. Probability (p) values above 0.05 are considered non-significant (n.s.). 
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The analysis of results considering two groups of patients, the splenectomized and 
non-splenectomized, showed that the %CD4+ T lymphocytes was significantly 
decreased in splenectomized patients. In the non-splenectomized patients the low 
CD47CD8* was due to the increased circulating population of the CD8 "P cells (Table 
5-11). 
Table 5-11 
Peripheral blood %CD4+ and %CD8+ T lymphocyte subsets in splenectomised and non-
splenectomised type 1 GD patients. 
Non-splenectomised Controls Splenectomised 
Mean+std (n) P Mean±std (n) P Mean±std (n) 
%CD4+ 41.80±7.59(16) n.s. 45.15±7.40 (67) <0.01 33.40±7.12 (11) 
%CD8* 29.33+8.01 (16) p<0.05 24.58+7.25(71) n.s. 23.4014.22(11) 
%CD4+/%CD8+ 1.56±0.573(16) p<0.05 2.01 ±0.834 (67) a) n.s. 1.47±0.423(11) 
a) Almost significant. 
Values represent the mean±std of the percentage of each population gated on total lymphocytes. The number of 
analysed individuals is indicated between brackets. Student't test was used to study differences between patients and 
controls. Probability (p) values above 0.05 are considered non-significant (n.s.). 
The study of the peripheral blood total leukocytes showed that the large majority of 
non-splenectomized GD patients presented leukopenia (3 995 ± 1 721 cells x106/l, 
n=20) whereas the splenectomized ones presented in general leukocytosis (13 240 ± 4 
901,n=10,p<0.01). 
Non-splenectomised patients where analysed separately and no statistically significant 
differences were observed in the CD4+ and CD8+ T lymphocytes (cells x106/l) between 
the different genotype groups of the non-splenectomized GD patients (Figure 5-23). 
However, a significant negative correlation (r=-0.64) was observed between the CD4+ T 
lymphocytes (cells x106/l) and the clinical severity (SSI) of the these patients (Figure 
5-24). 
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Figure 5-23 
Peripheral blood CD4+ and CD8* T lymphocyte subsets (cells x106/l) of genotyped non-
splenectomized type 1 GD patients. 
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Correlation: r—0.64, p<0.05 
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Figure 5-24 
Peripheral blood CD4+ and CD8+ T lymphocyte subsets (cells x106/l) and clinical severity (SSI) of 
non-splenectomized type 1 GD patients. 
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Moreover, when compared with controls, with one exception all GD patients presented 
decreased numbers of CD4+ T lymphocytes. However, although the number of GD 
patients without bone involvement is relatively low, the CD8+ T lymphocytes tended to 
be distinct on the basis of the presence or absence of bone disease (Figure 5-25). 
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Figure 5-25 
Peripheral blood CD4 and CD8 T lymphocyte subsets (cells x106/l) in non-splenectomised type 1 
GD patients with and without bone involvement. 
The statistical analysis was done in order to test whether the differences in the 
numbers of T cell subsets were significantly different between GD patients and 
controls. A significant (p<0.05) difference between the number of both CD4+ 
(483.1 ±173.4) and CD8+ (333.9±156.0) T lymphocyte subsets (cells x106/l) was 
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observed in non-splenectomised patients presenting bone involvement (n=16), as 
compared to controls (respectively 941.2±289.6 and 435.0+136.1, n=56) (Table 5-12). 
The available number of GD patients without bone disease (the non-splenectomised 
patients 21, 32, 38 and 49) was however not sufficient to substantiate the differences in 
T cell numbers between patients with and without bone involvement. 
Table 5-12 
Peripheral blood CD4+ and CD8+ T lymphocyte subsets (cells x106/l) of non-splenectomised type 1 
GD patients. 
GD patients with p Controls 
bone involvement 
CD4+T lymphocytes 
CD8+ T lymphocytes 
483.1 ±173.4(16) p<0.01 941.2 ± 289.6 (56) 
333.91156.0(16) p<0.05 435.0 ± 136.1 (56) 
Values represent the mean±SD of each population gated on total lymphocytes. The number of analyzed individuals is 
indicated between brackets. Probability (p) values above 0.05 are considered significant. 
5.3.7 Relationship between secondary abnormali t ies 
5.3.7.1 Peripheral b lood T lymphocyte CD4+ and CD8+ subpopulat ions 
and plasma tartrate résistante acid phosphatase (TRAP) 
activity 
To study whether T lymphocyte numbers could be associated with osteoclastic activity, 
plasma TRAP enzymatic activity was measured in these patients, and the correlation 
coeficient was calculated by the Spearman rank correlation. As shown in Figure 5-26, 
in non-splenectomised GD patients with bone involvement, a significant negative 
correlation was observed between TRAP activity and CD8+ T lymphocyte cell numbers 
(unilateral test r=-0.508, p<0.05, and for the CD4+ T lymphocyte subset r=-0.279, being 
non-significant). Different linear regression models (e.g. linear, cubic, exponential) were 
tried but further data is needed in order to elucidate the poor fitness encountered. 
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Figure 5-26 
Peripheral blood CD4+ and CD8* T lymphocyte subsets (cells X106/l) and plasma tartrate résistante 
acid phosphatase, TRAP, activity (nmol/h/ml ) of non-splenectomfsed tye 1 GD patients. 
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5.3.7.2 Correlation between the increase in plasma glucosylceramide 
concentration and lysosomal enzyme activities 
To study whether plasma glucosylceramide concentration could be associated with the 
increased activity of plasma lysosomal enzimes the correlation coefficient was 
calculated between these parameters. 
As shown in Figure 5-27 a significant positive correlation was observed between 
plasma glucosylceramide concentration (mg/100ml of plasma) and chitotriosidase 
activity (nmol/h/ml of plasma) (r=0.65, p<0.05). 
Correlation: r=0.65, p<0.05 
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Figure 5-27 
Plasma glucosylceramide concentration (mg/100 ml of plasma) and chitotriosidase activity 
(nmol/h/ml of plasma) of type 1GD patients 
A significant positive correlation was also observed between plasma glucosylceramide 
concentration (mg/100ml of plasma) and TRAP activity of adult GD patients (nmol/h/ml 
of plasma) (r=0.50, p<0.05) (Figure 5-28). 
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Figure 5-28 
Plasma glucosy lceramide concent ra t ion (mg/100 ml of plasma) and TRAP act iv i ty (nmol /h/ml of 
plasma) of type 1 GD patients 
Plasma total p-hexosaminidase activity was only found to be significantly correlated 
with TRAP activity of adult GD patients (r=0.70, p<0.05) (Figure 5-29). 
Correlation: r=0.70, p<0.05 
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Figure 5-29 
Plasma total (3-hexosaminidase act iv i ty (nmol/h/ml of plasma) and TRAP act iv i ty (nmol /h/ml of 
plasma) of type 1 GD pat ients 
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Plasma TRAP activity of GD patients was also found to be significantly correlated with 
between the activity of chitotriosidase (r=0.71, p<0.05) (Figure 5-30). 
Correlation: r=0.71, p<0.05 
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Figure 5-30 
Plasma TRAP activity and chitotriosidase activity of type 1 GD patients. 
5.3.8 Enzyme supplementation therapy 
5.3.8.1 Plasma glucosylceramide concentration of GD patients 
submitted to the enzyme supplementation therapy 
For the large majority of the patients, after 12 months of treatment, plasma 
glucosylceramide concentration decreased to the control range (Figure 5-31). 
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Figure 5-31 
Plasma glucosylceramide concentration (mg/100ml of plasma) of type 1 GD patients submitted to 
the enzyme supplementation therapy. 
5.3.8.2 Plasma chitotr iosidase activity of GD patients submit ted to the 
enzyme supplementat ion therapy 
The decrease in plasma chitotriosidase activity was depicted as percentage of the 
initial value since Plasma chitotriosidase activity was found to decline rapidly during 
therapy, starting already within the first month. In contrast, patients that started 
treatment with the low dose/high frequency regimen showed a comparatively slower 
reduction in chitotriosidase activity. Since these patients were not showing clinical 
improvement (e.g. with respect to hematological parameters) the administrated 
regimen was changed to the high dose/low frequency of 60U/kg/2w (Figure 5-32). 
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Figure 5-32 
Plasma chitotriosidase activity (expressed in percentage of the initial value) of type 1 GD patients 
submitted to the enzyme supplementation therapy. 
For the generality of the patients, the maximal decrease of chitotriosidase activity was 
observed in about 12 months of treatment. In this period, complete normalization of 
chitotriosidase levels was almost achieved for patients presenting less abnormal initial 
values. In contrast, plasma chitotriosidase activity of the patient receiving therapy for 
the longest period of time decreased to about 10% of the initial value, which still 
accounted for about 40-fold the maximal value of the control range (not shown). 
5.3.8.3 Plasma TRAP activity of GD patients submitted to the enzyme 
supplementat ion therapy 
Plasma TRAP activity showed a slow and irregular tendency to decrease, and for the 
majority the patients this activity remained borderline of the maximal values of control 
range. Patients that presented normal TRAP activity before treatment revealed 
sustained activity within control range (Figure 5-33). 
Some observations were made for some patients: Patient 1 (which presented the 
highest TRAP activity level) decreased till 25% of the initial value after 15 months of 
treatment, but at 31 months returned to the initial activity value, without interruption of 
treatment. The patient submitted to the larger period of therapy (patient 10) decreased 
only till 35% of baseline, showing an irregular decreasing tendency. Patient 29 
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interrupted treatment and after 6 months an increase of TRAP from 56% to 238% of 
the initial activity (Figure 5-33). 
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Figure 5-33 
Plasma tartrate résistante acid phosphatase (TRAP) activity (nmol/h/ml of plasma) of type 1 GD 
patients submitted to the enzyme supplementation therapy. 
5.3.8.4 Plasma p-hexosaminidase activity of GD patients submitted to 
the enzyme supplementation therapy 
With the exception of patient 1, all patients that presented abnormally high total (3-
hexosaminidase activity before treatment showed a decreased to control range in 3 to 
6 months of enzyme supplementation therapy (Figure 5-34). 
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Figure 5-34 
Plasma total p-hexosaminidase activity (nmol/h/ml of plasma) of type 1 GD patients submitted to 
the enzyme supplementation therapy. 
5.3.8.5 Serum ferritin of GD patients submitted to the enzyme 
supplementation therapy 
With the exception of the case that presented the most abnormal serum ferritin, the 
remaining patients that presented abnormally high serum ferritin before treatment 
showed a decreased to control range in 6 to 12 months of enzyme supplementation 
therapy (Figure 5-35). 
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Figure 5-35 
Serum ferritin (ng/ml) of type 1 GD patients submitted to enzyme supplementation therapy. 
5.3.8.6 Peripheral blood CD4+ and CD8+ T lymphocyte subsets of GD 
patients submitted to the enzyme supplementation therapy 
No significant changes were observed in the relative proportions of T lymphocyte major 
subsets (Figure 5-36). The coefficients of variation (CV) of %CD4+ and %CD8+ T cells 
were constantly lower than 20% in patients subjected to the enzyme supplementation 
therapy (being exceptions patients 31 and 11 with a covariance of respectively 25% 
and 36% for CD8+ determinations). 
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Figure 5-36 
Peripheral blood T lymphocyte %CD4+ and %CD8+ subsets of type 1 GD patients submitted to the 
enzyme supplementation therapy. 
To address the question whether the abnormally low T cell numbers presented by 
patients with bone involvement reflected disease activity, the peripheral blood T 
lymphocyte subset numbers were followed in 5 patients undergoing enzyme 
supplementation therapy for at least 24 months. As shown in Figure 5-37, for 4 of 5 
patients, non-linear trend analysis showed that statistically significant changes in T 
lymphocyte cells occurred only after 12 months of therapy. The coefficient of 
determination for these 4 individual analysis varied from 79% to 100% for CD4+ and 
from 88% to 100% for CD8+ indicating a good fit of trend models to the data. Using this 
trend analysis, the change in T cells of patient 19, observed at the 3rd month of therapy 
was not significant. In contrast, with exception of patient 33 (who presents the inherited 
deficiency in chitotriosidase activity), therapy has the effect of progressively lowering 
chitotriosidase activity of these patients to a sustained level. With respect to TRAP 
activity, some of these patients presented a comparatively slower and irregular 
decrease (patients 41, 1 and 19), observation that agrees to the unclear evolution of 
bone disease in these patients. Clinically it must be stated that after about 24 months 
of treatment, patient 33 showed imagiological signs of improvement (e.g. closed 
pathological fracture) whereas patient 1 started to present vertebral compression. 
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Figure 5-37 
Peripheral blood CD4+ and CD8+ T lymphocyte subsets (% of initial number of cells), plasma 
chitotriosidase and TRAP activity (% of initial activity) of type 1 GD patients submitted to the 
enzyme supplementation therapy. Arrows indicated the occurrence of significant changes of peripheral 
blood T lymphocytes. 
5.4 Conclusions 
The main conclusions of this work are presented in Table 5-13. 
Plasma glucosylceramide which is thought to be originated from lysed lipid loaded 
macrophages was measured in type 1 GD patients presenting different genotypes and 
clinical severity. In contrast to the reported slight elevation for type 1 GD patients 
(Dawson et al, 1982), plasma glucosylceramide concentration of the studied type 1 GD 
patients was found to be higher (2.7-fold the control mean) and similar to that reported 
for neuronophatic forms of the disease. However since the studied patients presenting 
the N370S/N370S, N370S/IVS2+1 and N370S/? genotypes had on average only 
slightly increased levels of plasma glucosylceramide concentration, it is possible that 
some genotypes were over-represented in the few type 1 GD patients reported in the 
literature. Importantly, in the studied type 1 GD patients a significant correlation was 
observed between plasma glucosylceramide concentration and clinical severity, as 
assessed by the severity score index (SSI). Also in disagreement to that previously 
reported (Nilsson et al, 1982; Svennerholm et al, 1982), plasma glucosylceramide 
153 
Chapter 5 
concentration of non-splenectomized patients was not significantly different from that 
presented by the splenectomized patients. 
Although it has been reported a 5-fold increased GM3 concentration in spleen and 
brain of GD patients, in this study no significant changes were demonstrated in plasma 
of patients. 
With respect to the previously reported increased activity of plasma chitotriosidase, a 
human chitinase and a putative marker of macrophage activation (Hollak et al, 1994), 
which may reflect the overall Gaucher cell accumulation in the body (reviewed in Aerts 
and Hollak, 1997), and the tartrate resistant acid phosphatase (TRAP) activity (Ek-
Rylander et al, 1991), which may constitute a marker of osteoclastic activity (Ek-
Rylander et al, 1994), the results of the studies described in this chapter confirmed and 
extended the information about these secondary abnormalities in type 1 GD patients: 
Firstly, although on average GD patients presented significantly increased plasma 
TRAP activity (6.6-fold the control mean), some overlap was observed between 
controls and the N370S homozygous GD patients. TRAP activity was statistical! 
significantly lower in GD patients presenting the N370S/N370S genotype, but no 
significant correlation was observed between TRAP activity and the clinical severity 
(SSI) of all GD patients. In spleen extracts from type 1 GD patients TRAP activity was 
however only 1.4 to 2.4-fold increased. TRAP activity was also analyzed as a marker of 
bone involvement and with two exceptions, normal activity values were observed in 
patients without skeletal disease. The hypothesis can be raised that the occurrence of 
abnormal TRAP activity in plasma of these two patients without imagiological signs 
probably constitutes an earlier marker of developing bone disease. This will need future 
confirmation. 
In contrast to TRAP, p-hexosaminidase activity was significantly increased in spleen (a 
tissue rich in Gaucher cells) and as reported mainly due to the p-hexosaminidase B 
isoenzyme (5 to 24-fold elevation). In plasma, where p-hexosaminidase was only 
increased 2.8-fold the control mean, a large number of patients presented activity 
values within control range and no significant correlation was observed between total 
p-hexosaminidase activity and genotype or clinical severity score. 
Plasma chitotriosidase activity of GD patients was found to be on average 300-fold the 
mean control value, being the only secondary abnormality in GD that does not overlap 
with control range. In accordance to that reported by others (Guo et al, 1995) no 
overlap was also observed between chitotriosidase activity of type 1 GD patients and 
the activity of patients affected by other lysosomal or non-lysosomal diseases. 
Importantly, in the present study chitotriosidase activity was found to be significantly 
154 
Enzyme supplementation therapy in the study of underlying pathogenic mechanisms of Gaucher disease 
lower in GD patients presenting the N370S/N370S genotype. No significant correlation 
was observed between this activity and the disease clinical severity score, but since 
2% of the control population was found to be deficient in chitotriosidase activity, the 
carrier status of GD patients for this deficiency needs to be established. 
The majority of the studied GD patients presented the previously described abnormally 
increased serum ferritin and no significant correlation was observed between this 
abnormality and the patients genotype or severity score index. 
This study contributed to further characterisation of GD with respect to novel secondary 
abnormalities: 
Leukopenia is one of the haematological abnormalities that can be associated with GD, 
and the study of the peripheral blood T cell major subsets showed that a subgroup of 
GD patients presented abnormal CD47CD8+ T lymphocytes ratio. No significant 
abnormalities were observed in the N370S homozygotes. In splenectomized patients 
the number of leukocytes, including T lymphocytes was increased but the %CD4+ T cell 
subset was decreased. In contrast, non-splenectomised GD patients presented 
significantly lower number of the two major T lymphocyte subsets. Importantly, lower 
numbers of CD8+ T cells appeared associated with the subgroup of patients showing 
bone involvement. Although few patients were classified without bone involvement, this 
was specially observed in GD patients homozygous for the N370S glucocerebrosidase 
gene mutation (4 out of 6). 
Factors influencing the clinical expression are unknown and a clear correlation 
between the disease severity and patient's genotype is lacking. In summary, the 
findings obtained in the study of the disease secondary markers showed that with 
respect to genotype/marker correlation, the clinically milder N370S homozygous 
patients were characterized by the absence of significant abnormalities in CD4+/CD8+ T 
lymphocyte ratio. When compared to the other GD patients the N370S homozygotes 
presented also significantly less abnormal TRAP and chitotriosidase activity. With 
respect to the phenotype/marker correlation, plasma glucosylceramide concentration of 
GD patients was significantly correlated with clinical severity score. Moreover, in non-
splenectomised GD patients it was observed an association between TRAP activity, 
the number of peripheral blood CD8+ T lymphocytes and the presence of clinical signs 
of bone disease. The association between bone pathology and statistically significant 
abnormalities in the CD8+ T lymphocyte subset, was further substantiated by the 
existence of a significant correlation between the peripheral number of these cells and 
TRAP enzymatic activity, the putative marker of osteoclastic activity. The analysis of 
these secondary plasma abnormalities may thus provide useful disease markers and 
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contribute to obtain more insights into the complicated pathophysiology of the disease. 
A significant correlation was observed between TRAP, chitotriosidase activity and 
glucosylceramide concentration. The presence of these abnormalities in plasma may 
thus be directly due to the mechanisms via which the lipid-loaded Gaucher cell 
releases plasma glucosylceramide. If the lipid-loaded macrophages are indeed 
involved in the release of the hydrolases that were elevated in plasma of symptomatic 
GD patients, their plasma levels may serve as quantitative markers for the amount of 
storage cells. Follow-up studies of patients submitted to the enzyme supplementation 
therapy showed that plasma p-hexosaminidase activity normalized within 3 to 6 months 
of therapy and glucosylceramide decreased to normal level in about 12 months of 
treatment. This probably reflects the absence of lysed lipid loaded macrophages. In 
contrast, TRAP activity showed a slow and irregular tendency to decrease and for the 
large majority of patients becoming borderline with the control range. The persistence 
of abnormal TRAP activity level in treated patients probably reflects the slower 
reversion of the bone disease. In this trial, chitotriosidase activity level was from all 
tested parameters, both the most abnormal prior to the therapy as well as the most 
responding to the alglucerase/imiglucerase supplementation. This response was 
specially observed for patients submitted to the high dose/low frequency regimen. 
Although there was a decrease in serum ferritin, no effect was however observed in the 
relative percentage of CD4+ and CD8+ T lymphocytes. With respect to the absolute 
numbers of these cells statistically significant changes occurred however after 12 
months of treatment. In the corresponding time period, the irregular decrease of TRAP 
activity agrees with the observed unclear and/or slower evolution of bone pathology in 
these patients. 
The results obtained with the enzyme suplementation therapy allow to conclude that 
the lipid-loaded macrophages are indeed involved in the release of chitotriosidase and 
total p-hexosaminidase activities; their plasma levels may thus serve as quantitative 
markers for the amount and/or activation of storage cells. The less clear reduction of 
TRAP activity seems to indicate that the release of this enzyme is probably more 
restricted to a specific location of slower correction and/or prevention of ongoing 
formation of the lipid laden GD cells. 
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Chapter 6 
Discussion and future prospects 
At the start of the investigation described in this thesis the molecular nature of the 
defects underlying glucocerebrosidase deficiency in Gaucher disease (GD) patients 
was still very poorly understood. It had became clear from enzymatic and 
immunological studies that many of the Portuguese non-neuronopathic (type 1) 
patients showed a considerable amount of residual glucocerebrosidase protein with 
abnormal kinetic properties (Sá Miranda, 1992), and this fact was related with the 
presence of the N370S mutated glucocerebrosidase in these individuals. This mutation 
was considered to be characteristic of Ashkenazi Jewish Gaucher patients. In the 
Portuguese type 1 GD patients the N370S glucocerebrosidase mutation accounted for 
63% of the mutated alleles (Amaral et al, 1993). This frequency was remarkably high 
since for non-Jewish type 1 GD patients it had been reported to be 22-46% (Beutler et 
al, 1991; Choy et al, 1991; Levy et al, 1991; Sidransky et al, 1992), in sharp contrast to 
the value of 77% observed in Ashkenazi Jewish populations studied (Beutler et al, 
1992). 
By ascertaining the N370S carrier frequency in the Portuguese population (0.0043), the 
incidence of the homozygosity for the most common causal mutation of GD was in this 
population calculated to be of 1 in 55 000 births. Considerably higher frequency of this 
mutation was meanwhile also determined in the Ashkenazi Jewish population; two 
studies encompassing 2121 presumably normal Ashkenazi Jewish subjects showed a 
gene frequency of 0.032 for the N370S mutation, and expected incidences of 1.03 
N370S homozygous per 1000 births in this population (Zimran et al, 1991; Beutler et al, 
1993). The existence of hot spots in specific restricted areas of Portugal, with high 
frequency of carriers that could have been maintained due to a certain amount of 
inbreeding, might have escaped this survey, in which a randomly selected sample 
representative of the general Portuguese population was used. However, among the 
new-borns in the restricted area of Azores islands the frequency of the N370S mutated 
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allele was found to be of 0.0053, value that was not significantly different from the 
general population (0.0043). The frequency determined for the Belmonte population 
(including the closed small community of individuals of Sephardic Jewish ancestry) was 
found to be of 0.0091, which was higher but not statistically different from that obtained 
for the general Portuguese population. This result would be interesting if a Sephardic 
Jewish ancestry could have been ascribed to the identified carriers. 
In the study of the origin of the N370S mutated allele in the Portuguese population, 
linkage analysis between this mutation and the previously described intragenic Pvull 
polymorphism showed that as observed for other patients, Portuguese GD patients 
presented complete linkage disequilibrium between the N370S mutated allele and the 
Pv1.1" haplotype. One possible explanation for this finding is that the N370S mutation 
has more than once been introduced, in the context of a Pv1.1" allele, the most 
common haplotype in most different racial groups (Sorge et al, 1985) as well as in the 
general Portuguese population. Another possible explanation would be that the 
mutation was only once introduced in this haplotype. At present it is not possible to 
exclude one of the two possibilities. A common origin for this mutation in the 
Portuguese and the Ashkenazim, could be raised due to the Jewish ancestry of the 
Portuguese; it is known that in XVI century Sephardic Jews living in Portugal were 
obliged to mix with the remaining catholic population. At present, in the Portuguese, 
Spanish and Dutch patients (with nonestabhlished Jewish ancestry), it is the most 
frequent mutation that is always associated with type 1 GD. However, according to 
Beutler (Beutler, 1992) the N370S mutated glucocerebrosidase allele has a recente 
Ashkenazi Jewish origin due to the strict linkage between the N370S mutation and the 
Pvl.T allele. In his view, it would be likely that when the mutation would be ancient, no 
perfect linkage between the N370S mutation and the Pvu II polymorphism would be 
expected due to the occurrence of crossovers in the glucocerebrosidase gene. Not 
favouring this hypothesis is the fact that the N370S mutated glucocerebrosidase allele 
has been observed (at relative high frequency) in the remaining Caucasian patients. 
Moreover, when considering the hypothesis of being ancient, it is not known whether 
crossovers affecting the N370S codon and the Pvu II polymorphic site occurred with 
the expected general statistic frequency; it has been observed that the 
glucocerebrosidase allele is continuous with other essential genes (Long et al, 1996) 
which might restrict the propagation of alleles with specific crossovers. Thus it seems 
more likely that the relative high frequency among Ashkenazim is caused by a common 
founder effect and limited mixing of this ethnic group with other populations. In 
conclusion, since at present the precise origin of the frequent N370S 
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glucocerebrosidase allele is unclear, further studies are necessary in order to ascertain 
the origin of the N370S mutation; in addition to standard restriction site polymorphisms, 
RFLPs derived from minisatellite probes (variable number of tandem repeats, or 
VNRTs) are much more sensitive and possibly the question may finally be answered 
with a reasonable degree of precision. Nevertheless, when comparing the frequency of 
other sphingolipidosis in the Portuguese and Ashkenazim populations there are clear 
differences in relative frequencies, apparently suggesting differences in general genetic 
background. Gaucher disease, B1 variant of GM2 gangliosidosis, metachromatic 
leukodystrophy and type C Niemann-Pick disease, are in this order the most frequent 
in the Portuguese; in the Ashkenazim the more frequent ones are also Gaucher 
disease, but followed by Tay-Sachs and Niemann-Pick type A diseases (Bach et al, 
1992), although an high frequency of metachromatic leukodystrophy was also 
described but in Habbanite Jews (Zlogotora et al, 1980). Additionally the two more 
frequent mutations present in Tay-Sachs patients of Askenazi Jewish origin are rare in 
Portuguese GM2 gangliosidosis patients and the most frequent B1 Variant mutation in 
the Portuguese patients has not been described in Ashkenazi patients. 
Since about 15% of mutated alleles in Portuguese type 1 Gaucher patients remain still 
unidentified (Amaral et al, 1996), being most probably private mutations, the 
determination of the urinary glucocerebrosidase activity per amount of cross reacting 
material showed that obligate carriers for known and as well as unknown mutated 
alleles could be detected in patients families. Although a combination of the enzymatic 
assay and DNA analysis had still to be used to ascertain those individuals whose 
values were falling in the cut-off range of high probability of misclassification, this 
enzyme based assay (EBA) may be particularly useful to screen carriers in non-
Ashkenazi populations, where a large number of mutations can be associated with GD. 
The identification of as yet unidentified glucocerebrosidase mutations in the 
Portuguese population will enable the revision of the EBA cut-off range proposed and 
lead to a better insight on its sensitivity and specificity, when mutations other than 
N370S or L444P are considered. 
In this study an exceptionally large number of N370S carriers were identified within the 
control population from where GD patients were originated (4 in 83, frequency of 
0.024), pointing to a geographically restricted N370S allele frequency similar to the 
reported in the Ashkenazi Jewish community (0.032). A similar study was also carried 
out in the Netherlands and allowed the detection of most obligate carriers, but no 
carriers were found in the tested control sample (n=86). Although the frequency of the 
N370S mutation has not been determined, the results obtained with this study suggests 
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a comparably lower frequency of N370S mutated allele in Dutch population (Aerts et al, 
1991). More recently, the study of the relative incidence of glucocerebrosidase 
mutations in Dutch GD patients confirms that results by showing that the N370S 
mutation was present in only 41% of the patients mutated alleles who belong to 
families that have lived in The Netherlands for at least several generations (Boot et al, 
1996). 
The application of the urinary EBA allowed the identification of subclinical cases of GD 
in the study of affected GD families, i.e. individuals with markedly impaired 
glucocerebrosidase activity but without clear clinical symptoms. The determination of 
the N370S mutated allele frequency in the Portuguese population gave an insight on 
the incidence of N370S glucocerebrosidase homozygosity and its association with 
actual disease manifestation. On the basis of the obtained N370S gene frequency, the 
difference between the predicted number of homozygotes and that identified until now 
in the Portuguese population supported the idea that a large number of the GD patients 
with this genotype developed only mild symptoms or no symptoms at all. However, the 
clinical presentation of the N370S homozygous Portuguese patients ranged from mild 
to moderately severe forms of GD. Thus, accurate prediction of these patient's clinical 
course is not feasible on the basis of the N370S homoallelic glucocerebrosidase 
genotype, but till now the homo or heteroallelic presence of the N370S mutated 
glucocerebrosidase is linked with a non-neuronopathic course of the disease. Thus, 
detailed studies on the residual activity modulation of this mutant glucocerebrosidase 
are of great importance to understand the factors that prevent the pathological features 
ofGD. 
In this thesis work, immunoprecipitation of the glucocerebrosidase residual activity from 
peripheral blood total leukocytes and skin fibroblasts, showed that comparatively more 
glucocerebrosidase was extracted from leukocytes than from fibroblasts in the 
aggregate form (complexes of glucocerebrosidase monomers, saposin C and lipids) 
from patients presenting at least one N370S mutated allele. This could not be attributed 
to the existence of an higher amount of intralysosomal activator protein in these cells, 
since comparative studies between lymphoblasts and fibroblasts (Van Weely, 1992) 
reported that the ratio of cross-reactive activator protein related to cross-reactive 
glucocerebrosidase varied considerably between individual lysosomes, but not 
significantly different between lymphoblasts and fibroblasts of either controls or 
patients. Comparable post-translation modifications of the glucocerebrosidase 
oligosaccharide moieties, predominant localisation in compartments with high density 
characteristic of lysosomes, and a similar degree of interaction with membranes was 
162 
Discussion and future prospects 
also observed between these cell types (van Weely, 1992). Further analysis are 
needed on the physical-chemical properties of the N370S glucocerebrosidase 
aggregate/complex form by either activity modulaters or conformational changes 
introduced by mutations. In situ radiation activation experiments in which the molecular 
mass of the complexe of catalitically active glucocerebrosidase was determined, 
showed that glucocerebrosidase in this physiological aggregated state is probably 
present as a dimer (Choy et al, 1986). It is dificult to predict which properties of 
glucocerebrosidase will be presented by dimers of different mutant proteins, hampering 
the prediction of the outcome of particular combinations of mutations in genetic 
compounds. In this regard the present study did not evidence conformational influence 
on the aggregation of the enzyme in N370S compound hétérozygotes. In particular, the 
observation of similar glucocerebrosidase specific activity of N370S homozygotes and 
the N370S/IVS2+1 or N370S/L444P compound hétérozygotes was not surprising since 
it can be expected that in these compound hétérozygotes the measured enzymatic 
activity is almost exclusively contributed by the N370S mutated enzyme, given that the 
L444P allele encodes an unstable glucocerebrosidase (Ohashi et al, 1991) and the 
IVS2+1 splice mutation directs synthesis of low levels of aberrant mRNAs, not resulting 
in synthesis of active enzyme. No significant differences were also observed between 
the molecular activity presented by N370S homozygotes and compounds for the 
N370S mutation and RecTL, RecNcil or R463C, being necessary to study these 
proteins by mutant expression since no homoallelic patients were identified till now for 
those mutations. However, with respect to the L444P mutated enzyme the findings 
obtained in patients cell extracts differed from the reports on features of the mutant 
enzyme obtained in the overexpression systems. Cells of the L444P homozygote 
patient showed little enzyme with almost normal properties (high specific activity per 
amount of cross reactive molecule in the presence of taurocholate), whereas the 
L444P mutant enzyme obtained by mutant expression in human HeLa cells was 
reported to be normally stable and catalitically abnormal, with an activity ranging 
between 13-25% of the control (Pasmanik-Chor et al, 1995). So far it is unclear why 
these differences exist. It should be considered that the overexpression system 
markedly influences the properties of the enzyme. In contrast to the normal situation, in 
a overexpression system there is a less efficient control of the quality of the newly 
formed enzyme (correct folding). Furthermore, it is known that in overexpression 
systems a large proportion of protein molecules differ in conformation, a post-
translational modification from the regularly produced proteins. Interestingly, the 
predictive value of this mutated allele for patients phenotype has also been limited; 
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usually Caucasian L444P homozygotes have been developing neuronopathic type 2 or 
type 3 forms of GD, but in contrast Japanese L444P homozygotes do not develop 
neurological disease. The Portuguese L444P homozygote (patient 41) has not showed 
so far characteristic neurologic symptoms of Gaucher disease, although suffering from 
behaviour abnormalities. 
The study of patients presenting different genotypes allowed to conclude that the 
glucocerebrosidase molecular activity extracted from cells of patients presenting at 
least one N370S mutated allele was found to be considerably higher when measured in 
the presence of the physiological activators phosphatydilserine and saposin C, being 
this effect markedly pH dependent. Previous studies on the purified spleen N370S 
mutated enzyme had already showed that the activity of this mutated enzyme in the 
presence of activator protein and phospholipids, had a very sharp pH-optimum (in 
contrast with the control enzyme) (Aerts, 1988; Sá Miranda, 1992). Other studies had 
also reported that at higher pH values this mutated enzyme was dramatically less 
sensitive to CBE inactivation (reflecting a decrease of the substrate affinity) (van 
Weely, 1992). According to these findings, it is conceivable that the degree of 
activation of the glucosylceramide-loaden macrophage (Gaucher cell) determine 
intralysosomal conditions and thus modulate differently the highly pH dependent 
catalytic activity of the N370S mutated enzyme. Thus it can be speculated that the 
variability in intralysosomal pH may underlie the heterogeneity in severity of the clinical 
expression of Gaucher disease in individuals presenting the N370S mutated 
glucocerebrosidase. 
Given that the increased secretion of lysosomal hydrolases by stimulated macrophages 
seems to be a response to extensive storage (Moffitt et al, 1978; Gery et al, 1981), the 
hypothesis was raised that they may also represent a measure for the total body 
burden and activation of lipid loaded macrophages. In fact, chitotriosidase activity was 
recently demonstrated in isolated Gaucher cells and in situ hybridisation experiments 
with a specific probe for chitotriosidase RNA revealed unequivocally that the storage 
cells massively synthesised the enzyme (Boot, 1997). In this thesis work, plasma 
chitotriosidase activity was found to be significantly less abnormally increased in 
patients presenting the N370S/N370S genotype. The results otained in the 
measurement of plasma hydrolases activity levels were not found to reflect the overall 
patient clinical severity score but may represent a measure of the lipid loaded 
macrophages of unknown specific sources. In fact, the clinical manifestation of GD is 
heterogeneous and has a multi-systemic nature due to the presence of pathological 
storage cells in different body locations. In accordance, some of the splenectomized 
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patients showed similar plasma chitotriosidase activity level as patients presenting 
splenomegaly. It therefore seems likely that in splenectomized patients, the presence 
of Gaucher cells take place in other different body locations, like liver and bone marrow 
compartments. The currently used quantification of the extent of GD clinical 
presentation is based upon standard laboratory measurements, radiographs and 
physical examination, being thus mainly compiled by the extent of cytopenia, 
organomegaly and both subjective and objective bone abnormalities. However, the 
degree of liver and spleen enlargement is not an ideal measure for the local amount of 
storage cells since the presence of fibrosis and altered vascularization also adds to the 
increase in volume. Although the accumulation of glucosylceramide occurs specially 
within lysosomes of macrophages, in this study a significant correlation was observed 
between plasma glucosylceramide and patients clinical severity (as assessed by the 
severity score index, SSI), suggesting that plasma glucosylceramide may reflect the 
overall Gaucher cells accumulation. 
Alglucerase supplementation therapy further substantiated that plasma hydrolases are 
directly released by lipid-laden Gaucher cells and most likely that they are originated 
from storage cells in different tissues. Whereas patient's total p-hexosaminidase 
activity decreased to normal range in about 3 to 9 months of treatment, TRAP activity 
showed a slowly and irregular tendency to decrease, and in the large majority of 
patients did not achieved control range. According to these results, TRAP activity which 
has been suggested to reflect osteoclastic activity, would thus probably correlate better 
with bone involvement and constitute a marker for the slow and unclear evolution of 
bone disease. Hollak however claims to have found a better correlation between this 
enzymatic activity and the degree of organomegaly, in particular liver pathology 
(Hollak, 1996). Chitotriosidase activity was found to decrease in a dose dependent 
manner since patients submitted to the low dose/high frequency regimen showed a 
delayed response. Based on this observation it may be speculated that plasma 
chitotriosidase levels do not reflect the severity of one specific clinical sign but the 
overall severity as expressed in the total body burden of lipid loaded cells. According to 
our findings this may be the best secondary marker of the total Gaucher cells, and thus 
constitute a useful and convenient marker to monitor the efficacy of alglucerase 
therapy with respect to the overall correction and/or prevention of storage cells. In 
conclusion, if TRAP activity level could be correlated with bone disease, whereas p-
hexosaminidase and chitotriosidase activity levels with a combination of organomegaly 
and bone disease, this would greatly help in the evaluation of the response of the 
different compartments to alglucerase treatment. 
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The study of peripheral blood T cell major sub-sets showed that when compared with 
controls, non-splenectomised GD patients presented significantly lower number of the 
two major T lymphocyte subsets. The mechanisms via which Gaucher cells affect their 
surroundings, e.g. locally abnormal cytokine production, may contribute to the 
abnormal ratio of the T lymphocyte CD4+ and CD8+ sub-populations observed in the 
great majority of GD patients. However, no correlation was observed between the level 
of chitotriosidase activity, which seems to reflect the degree of macrophage activation, 
and patients CD4+ and CD8+ T lymphocyte abnormalities. In IH patients the relative 
proportion of CD8+ cells were correlated with the degree of iron overload (patients with 
high CD47CD8+ ratios have higher iron store than patients with normal or low ratios). 
Such correlation was not observed in GD patients. 
Evidence as been reported that GM1-CD4 interaction triggers dissociation of p56lck 
from CD4 as well as CD4 internalization and degradation. Concomitant with the 
increase in glucosylceramide, a five-fold increase in GM3 ganglioside has also been 
reported in the GD tissues (Philipart and Menkes, 1964). Since CD4 expression may 
be regulated by other sialyated gangliosides (Grassi et al, 1990) it may be expected 
that the abnormal presence, proportion and redistribution of these compounds on the 
surface of Gaucher cells may also change the expression of CD4 in T cells of these 
patients. Importantly, lower numbers of CD8+ T cells appeared associated with the 
subgroup of patients with bone involvement. Although few patients were classified 
without bone involvement, the association between bone pathology and the number of 
CD8+ T lymphocytes was further substantiated by the existence of a significant 
correlation between the number of these cells and TRAP activity, the putative marker of 
osteoclastic activity. In vitro models may be limited by a series of factors like: species 
and anatomical site specificity, the absence of intermediary or accessory cells, the 
absence of normal marrow spatial organization and cellular interactions with the 
extracellular matrix. The present study of GD may constitute an ideal system to obtain 
additional important insights and to test the validity of conclusions reached in vitro. On 
the basis of the proposed mechanism for T cells involvement on osteoclastic 
proliferation/differentiation (Horwood et al, 1998), the presence of lower number of T 
lymphocytes in GD patients presenting bone involvement would result in increased 
osteoclastic activity. The resultant higher resorptive activity would finally lead to the 
loss of balance between bone modeling and remodeling homeostasis. Further studies 
are however necessary to clarify the possible regulatory interactions between these T-
cell subsets and the pathophysiology of Gaucher disease. In patients submitted to the 
alglucerase supplementation therapy, follow-up studies for an about 2 year period 
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showed that the individual %CD4+/%CD8+ ratio imbalances persisted over time, 
confirming the existence of a strict homeostatic regulation of the relative numbers of 
the two major peripheral T lymphocytes sub-populations. 
In virtue of these results further studies are necessary in order to establish if the T 
lymphocytes imbalances may also contribute to the pathogenesis of the disease. The 
presence of abnormal T lymphocyte major subsets of patients other than the N370S 
homozygotes may however suggest the involvement of these cells the pathophysiology 
of GD in the more severely affected patients and thus constitute a new additional 
hallmark associated with the mild clinical expression and progression of the disease of 
the N370S homozygous genotype. 
Based on the results of the presented investigations a number of follow-up studies 
should next be undertaken. 
The N370S glucocerebrosidase activity seems to be highly dependent on the 
lysosomal environment, therefore in vitro assays do not truly reflect the in vivo activity. 
This finding is likely to account for the lack of correlation between the clinical 
phenotype and the residual glucocerebrosidase activity. A better insight of the effect of 
the intralysosomal environment on glucocerebrosidase activity, especially the pH and 
saposin C concentration, seems to be crucial for the understanding of the 
pathophysiology of Gaucher disease. It would also be important to establish whether 
such a correlation exist if the activity is measured in extracts of purified 
monocytes/macrophages, since it is these cells specially which are involved in the 
pathology of type 1 Gaucher disease. Moreover, it has been proposed that the 
hydrolysis of other endogenous substrates than glucocerebroside (e.g. p-xyloside) may 
also as well be impaired (Aerts, 1995) and it would be of interest to study the extent to 
which this contributes further to the clinical presentation. 
The apparent lack of correlation between clinical GD phenotype and 
glucocerebrosidase genotype and properties of residual enzyme strongly suggest that 
epigenetic factors might modulate the outcome of a glucocerebrosidase deficiency. 
These factors have to be established in the future. Furthermore, attention has to be 
paid to the role of macrophage-derived factors (cytokines and/or hydrolases) in the 
pathology of Gaucher disease. For this purpose, the availability of a good animal model 
of GD or of cultured lipid-loaden macrophages (Gaucher cells) will be essential. 
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Given the gross abnormality in plasma chitotriosidase in GD patients it is of interest to 
determine the physiological role of this enzyme to have some insight in the possible 
consequences of its marked elevation. This will be crucial to the identification of 
possible effects of the relative common deficiency in enzyme activity in man and to 
identify the cause and consequences of the strong increase in plasma levels of 
chitotriosidase in clinically affected Gaucher patients. 
Due to the expensive nature of the enzyme supplementation therapy it would be of 
interest to assess further the feasibility of substrate deprivation as a strategy for the 
treatment of Gaucher disease. The administration of inhibitors of the enzyme 
UDPglucose:ceramide glucosyltransferase, the enzyme that catalyses the first step in 
the glycosphingolipid biosynthesis, has been found to result in extensive 
glycosphingolipid depletion in cells treated in vitro, without causing toxicity. In normal 
mice fed via the diet for several weeks, glycolipid levels were reduced 50-70% in all 
tissues examined without resulting pathology (Piatt and Butters, 1997). Preliminary 
results obtained with these inhibitors in the mouse model of another human 
glycosphingolipidoses, the Tay-Sachs disease, showed that the accumulation of GM2 
ganglioside in the brain was prevented by reduction of the number of storage neurones 
and the quantity of ganglioside per cell (Piatt et al, 1997). 
Gene therapy of Gaucher disease is also under study (Barranger et al, 1997). One 
approach involves ex vivo retroviral transduction of human CD34 cells. In this FDA 
approved study, no myeloablation was used and multiple transplants of genetically 
corrected cells were employed. The results to date revealed the presence of the 
glucocerebrosidase transgene in peripheral blood leukocytes in three subjects and 
measurable gene expression. Studies are in progress to determine whether 
engraftment and persistence of transduced cells can be accomplished in patients. A 
second approach involves gene transfer and transplantation of retrovirally transduced 
myoblasts in mice, resulting in engraftment of transduced muscle cells as well as 
persistent in vivo secretion of glucocerebrosidase in the circulation. The secreted 
enzyme was found to be taken up by resident macrophages in the liver of transplanted 
animals, showing that transplanted myoblasts may be useful in producing enzyme to 
correct the deficiency of glucocerebrosidase in tissue macrophages. 
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APPENDIX 
Reference values for serum iron level, transferrin saturation (%) and ferritin in the 
Portuguese population (Porto et al, 1994). 
Reference values males females 
mean range mean range 
Serum iron (ng/dl) 107 50-181 95 44-160 
Transferrin saturation (%)^  39 19-62 34 15-59 
Serum ferritin (ng/ml) depending 
on age (years) 
10 32 8-123 32 7-134 
20 59 16-218 32 7-134 
30 108 29-401 32 7-134 
40 155 30-483 38 7-196 
50 155 30-483 47 9-242 
60 155 30-483 60 12-304 
70 155 30-483 75 15-387 
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